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Abstract 
 
This  thesis  describes  the  need  for  imaging  the  tumour  pathophysiological 
microenvironment in order to understand response to treatment. Specifically looking at 
tumour  vascularisation  in  in  vivo  murine  xenograft  models  of  disease,  response  to 
treatment with vascular disruption is assessed via photoacoustic tomography (PAT) and 
magnetic resonance imaging (MRI). 
Photoacoustic imaging is a novel imaging modality based on the detection of ultrasound 
waves  created  by  the  absorption  of  nano-second  pulsed  laser  energy  within  tissue 
chromophores. It has the spectral specificity of optical techniques whilst also achieving the 
high resolution of ultrasound. Haemoglobin is the main chromophore found in biological 
tissue and this modality is therefore ideally suited to imaging tumour vascularisation. Using 
a Fabry-Perot interferometer this thesis demonstrates for the first time the feasibility of 
using  PAT  for  pre-clinical  research  and  the  characterisation  of  typical  tumour  vascular 
features in a non-invasive non-ionising manner. Response to different concentrations of a 
vascular  disrupting  drug  is  then  demonstrated,  with  novel  insights  in  to  how  tumours 
recover from vascular damage observed.  
MRI of response to vascular disruption is also presented. As MRI is widely used in the clinic 
it can serve as a translational tool of novel imaging biomarkers, and serves to further 
understand  the  differences  in  response  of  pathologically  vascularised  of  tumours.  This 
thesis  looks  at  markers  associated  with  disruption  of  haemodynamics,  using  apparent 
diffusion (ADC) to elucidate onset of necrosis, increase in haemoglobin concentration (R2*) 
as indication of impaired flow, and arterial spin labelling (ASL) as a marker of tumour blood 
perfusion.  This  is  shown  in  both  subcutaneous  and  clinically  relevant  liver  metastasis 
models. 
Taken as whole, the results from this thesis indicate that whilst understanding the response 
of  the  tumour  vasculature  to  pharmacological  intervention  is  complex,  novel  imaging 
techniques  can  provide  invaluable  translational  information  on  the  pathophysiology  of 
tumours. 
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Chapter 1 Introduction 
1.1 Introduction and scope of this thesis 
Cancer  is  often  described  in  terms  of  a  genetic  disease  (1,  2),  although  it  is  better 
considered  as  a  group  of  inherently  associated  diseases  that  share  a  characteristic 
phenotype: uncontrolled cell growth and proliferation (3). Once a cell attains a cancerous 
pre-disposition the progression of the disease will be to spread to other parts of the body, a 
process known as metastasis, and develop into further solid tumour deposits. The major 
sites of metastasis are lung, liver, and bone, although there are many different metastatic 
locations, with primary tumours generally predisposed to form metastasis in certain target 
tissues  (4); once cancer spreads  to  these organs  it  reduces their  function  by  replacing 
functional  cells  with  tumour  tissue.  Metastatic  spread  of  disease  is  the  main  cause  of 
mortality in patients with cancer, causing 90% of human cancer-related deaths (5). The 
latest global figures, for 2012, show that there were 14.1 million new cases of cancer 
diagnosed, 8.2 million cancer deaths, and 32.6 million people living with cancer that had 
been diagnosed within the previous 5 years (6). It is therefore an important clinical need 
and a highly active area of research, with much emphasis on development of new therapies 
with  which  to  treat  patients,  and  methods  capable  of  assessing  response  of  these 
therapies. Given the wide range of different types of cancer that can arise – each individual 
cell type in the human body can become cancerous – and the myriad of possible underlying 
genetic mutations than can give rise to a cancerous state, a common feature amongst 
tumours is often sought for targeting therapeutically. This is possible, as all cancers will 
possess  certain  characteristic  pathological  features,  allowing  treatment  in  relation  to 
cancer biology without involving the specific genetic cause or cell origin. This thesis aims to 
demonstrate the therapeutic response to targeting one of these pathological characteristic 
features of cancer cells, namely angiogenesis and the vascular network in tumours. In order 
to  do  this  the  novel  imaging  modality  ‘Photo-Acoustic  Tomography’,  and  new  vascular 
associated  Magnetic  Resonance  Imaging  scanning  sequences,  will  be  employed  in  pre-
clinical models of disease, and their potential translation to human use shown. Therapeutic 
response will be assessed following vascular disruption with the Vascular Disrupting Agent 
(VDA) OXi4503 (combretastatin A1 di-phosphate /CA1P). A review of the cancer biology 
and pathophysiological target, the novel drugs used to treat the disease, and the imaging 
techniques employed, will first be reviewed in this introduction, followed by the original 
research conducted in to this area of oncology.  17 
 
1.2 Cancer biology 
Cancer can be considered as an evolutionary accumulation of genetic changes; mutations in 
genes or epigenetic regulation of gene expression which confers a growth advantage to a 
cell  allow  it  to  out-compete  other  cells  and  expand  into  a  cancerous  neoplasm.  The 
causative genetic mutations can either be hereditary, known as germline mutations, or 
caused  directly  in  the  cells,  known  as  somatic  mutations,  by  carcinogens  (7).  The  first 
described carcinogen was noted in 1775 by the London surgeon Sir Percival Pott (8), with 
the association between soot and testicular cancer in chimney sweeps. The progression of 
a cancerous neoplasm has long been thought of as a multistep sequence of cellular events, 
with various mutations required for tumourigenesis. Evidence that this is the case can be 
found in the fact that tumours are monoclonal, as a result of clonal expansion of the 
neoplastic  cells  (9,  10).  Mutations  affecting  either  oncogenes,  genes  that  drive  cell 
proliferation  and  increase  the  possibility  of  errors  in  genetic  encoding,  or  tumour 
suppressor genes, genes that can halt the cellular cycle and cause apoptosis, will increase 
the  chance  of  acquiring  the  necessary  growth  advantages  needed  for  a  cancer  cell  to 
progress to a tumour (11, 12). This progressive accumulation of genetic alterations in cells 
thus enables tumour growth and possible metastatic dissemination. Although this provides 
an  underlying  genetic  profile  of  disease  progression  which  should  enable  precise 
individually-tailored  personalised  therapy,  the  exact  genetic  mutations  observed  vary 
enormously, even within similar tumour types, and may not follow a sequential pathway to 
tumourigenesis.  The  mutations  required  for  cancer  progression  can  however  also  be 
classed according to the acquired capabilities or survival advantages conveyed to the cell. 
These capabilities were described as characteristic hallmarks of cancer in the seminal paper 
be Hanahan and Weinberg (13); knowledge of specific genetic alterations is therefore not 
required as such, but assumed as causative of hallmark abilities conferred to the cell that 
are common across all tumours. These hallmark abilities as originally set out are: the ability 
to  sustain  proliferative  cellular  signalling,  evading  the  action  of  growth  suppressors, 
enabling replicative immortality, activation of local tissue invasion and distant metastatic 
spread, the induction of blood vessels to supply the growing tumour via angiogenesis to 
supply oxygen and nutrients to the nascent tumour, and resisting cell death signals. An 
update of the hallmarks of cancer in 2011 (14) added two further hallmark characteristics 
of  cancer  biology,  namely  the  avoidance  of  destruction  by  the  immune  system  and 
deregulation  of  cellular  energetics,  and  described  two  contributing  ‘enabling 
characteristics’  of  tumour  formation  in  genome  instability  and  tumour  promoting 
inflammation. Figure 1.1 shows an adaptation of the now iconic image of these ‘Hallmarks 18 
 
of cancer’ (14). These reviews give great insight in to the genetic mutations of different 
cancers  and  how  they  can  create  the  different  hallmarks,  showing  the  potential  of 
genetically defined personalised medicine; on the other hand it also provides a framework 
in which to target tumours based on the acquired capabilities as a whole without knowing 
the genetic cause. As this thesis is concerned with imaging pathophysiology and response 
to treatment in order to enhance current translation of novel cancer therapies, the genetic 
aspect of cancer development, whilst acknowledged here, is not further discussed. 
 
 
 
 
 
 
   
  
Figure 1.1 Hallmarks of cancer   
The acquired capabilities of cancerous cells are depicted by the arrows leaving the ‘Cancer cell’, with  
the two enabling characteristic named outside and contributing to the formation of the cancer cell.  
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1.3 Tumour microenvironment  
The acquired capabilities of cancerous cells alone cannot fully explain the complexity of the 
developing tumour; of the ≈10 trillion cells in the human body, many may have acquired 
genetic mutations from exposure to radiation, oxidative stress and successive replication, 
and may have formed pre-cancerous micro-lesions. The reason why some of these and not 
others  develop  into  tumours  and  advanced  stage  cancers  is  due,  in  large  part,  to  the 
microenvironment of the surrounding tissue and associated non-malignant cells (15). The 
tumour microenvironment is an evolving concept that defines the behaviour of cancer not 
by the genetics of the cancer cells alone, but by the surrounding milieu that the tumour 
cells need for survival, growth, proliferation and metastasis. This microenvironment of non-
cancerous cells can account for upwards of 50% of the total mass of primary and metastatic 
tumours.  These  can  be  divided  in  to  three  main  categories  of  stromal  cell  type:  1) 
infiltrating immune cells, consisting of macrophages, T and B lymphocytes, natural-killer NK 
and NKT cells, inflammatory monocytes, neutrophils, mast cells and platelets; 2) Cancer 
associated  fibroblastic  cells,  consisting  of  activated  fibroblasts,  cancer  associated 
adipocytes  and  mesenchymal  stem  cells;  3)  angiogenic  vascular  cells,  consisting  of 
endothelial cells and pericytes (16). Other microenvironment components present are the 
malignant cells themselves, endothelial cells associated with lymphatics, dendritic cells, red 
blood  cells,  and  the  extracellular  matrix  (16).  The  interaction  of  this  tumour 
microenvironment with the malignant cells influences the progression of the cancerous 
neoplasm, with often a tumour promoting effect due to growth factors such as platelet-
derived (PDGF), vascular-endothelial (VEGF), fibroblast (FGF) and epidermal (EGF) (17, 18).  
Traditional  chemotherapy  and  radiotherapy  will  affect  all  cells  within  the  tumour 
microenvironment, with reaction of the tumour-associated cells also affecting outcome of 
treatment (19, 20). Targeting of the tumour microenvironment as well as the hallmark 
characteristics of tumours is therefore an attractive option, which could increase the action 
of chemotherapy drugs (21). 
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1.4 Tumour angiogenesis 
Of the hallmarks of cancer as established by Hanahan and Weinberg, arguably the one of 
most clinical importance is angiogenesis. The angiogenic formation of new blood vessels is 
a normal biological process through which avascular tissues are supplied with blood flow. It 
has a physiological role in wound healing, foetal development and in the reproductive cycle 
(22). Angiogenesis can however be pathological in nature, and has been associated with 
psoriasis, endometriosis, ischemic heart disease, rheumatoid arthritis, hepatitis and solid 
tumour development. It has long been known that for solid tumours to develop beyond a 
size of ≈1mm
3 new blood vessels must supply nutrients and oxygen to the cancerous cells 
(23).  The  neo-vasculature  created  to  enable  tumour  growth  is  chaotically  formed  and 
pathologically different from normal vasculature (24), with resulting impaired flow of blood 
to the tumour that has implications for therapeutic intervention, such as re-oxygenation for 
radiotherapy and delivery of chemotherapeutics. As well as permitting tumour growth and 
affording a degree of resistance to therapy, the tumour vascular, crucially, gives tumour 
cells the ability to disseminate into the systemic circulation, allowing the metastatic spread 
which is the major cause of patient mortality. With regards to solid tumour development 
and progression, the relationship between tumour cells and the vascular network was first 
described in 1907 by Professor E Goldman (25). The invasion of malignant tumour cells into 
local  blood  vessels,  followed  by  the  development  of  metastases  at  distant  sites,  was 
described  via  histological  and  ex  vivo  techniques;  it  was  noted  that  tumour  cells 
disseminated through the vascular system by cell infiltration into nearby arterial vessels. 
How  these  cells  entered  the  vascular  system  was  put  down  to  a  general  vascular 
degeneration  at the  site of malignancy  and the  function of  the  lymphatic  system. The 
second point of note in this paper concerned the distribution of tumour blood vessels and 
the  general  conditions  of  circulation  within  tumours;  while  the  architecture  of  blood 
vessels within specific normal organs was known to be characteristically organised, the 
presence of a tumour leads to uncontrolled development and chaotic irregularity, with the 
growing tumour periphery developing extensive new blood vessels. The majority of the 
tumour does not receive a rich supply of blood; the peripheral vessels branch irregularly 
into small abnormal vessels, and blood supply to the core is diminished, leading to localised 
necrosis in many tumours.  The degree of vascularisation is also related to the tumour 
location;  the  level  of  pre-existing  vasculature  at  the  site  of  tumour  development 
determines how vascular that tumour will initially become. The one common feature of 
tumour  blood  vessels  observed  was  a  structural  one;  in  the  tumour  periphery,  and  in 
normal tissue surrounding the growing tumour, the vessels would coil around themselves 21 
 
in a spiral fashion and send capillary shoots towards tumour.  The appearance of the whole 
tumour  blood  vessel  network  was  also  found  to  differ  depending  upon  tumour  type; 
carcinoma tumours were found to be more vascular towards the periphery with fewer 
vessels  penetrating  into  the  tumour,  whilst  sarcomas  showed  an  even  distribution 
throughout  the  tumour.  Because  the  vascular  architecture  differed  between  tumours, 
though derived from the same endothelial cells, Goldman concluded that this was the 
result of host tissue remodelling, due to action of the tumour environment. These initial 
observations have been corroborated many times in subsequent years, notably by Judah 
Folkman  (23,  26,  27),  and  further  expanded  by  more  recent  work  demonstrating  the 
involvement of further stromal cell elements of the tumour microenvironment in relation 
to tumour neo-vasculature angiogenesis, all of which validates the targeting of the vascular 
microenvironment as a therapeutic approach (28, 29).  
1.5 Vascular targeted therapy  
Given the importance of the tumour vascular microenvironment, cancer therapies that 
target tumour blood vessels have been actively sought (30, 31). The two main classes of 
drug that have emerged in the vascular targeting area are angiogenesis-inhibiting agents 
(AIAs) and vascular disrupting agents (VDAs) (32, 33). AIAs aim to stop further growth of 
the tumour vasculature and thereby inhibit tumour progression. There are many molecular 
targets within the AIA group of drugs, with the major ones being the vascular-endothelial 
growth factor (VEGF) (34, 35) and its receptor (VEGFR) (36), receptor tyrosine kinases (37), 
angiopoietin/Tie-2 (38) and plasma membrane integrins  (39). Although promising novel 
therapeutics, AIAs have been largely ineffective at stopping tumour progression as single 
therapies (40-42). However an intriguing concept of ‘vascular normalisation’ has emerged 
(43); it has been noted that combination of AIAs with traditional cancer therapies such as 
chemotherapy (44-46) can show increased survival in patients when compared to stand-
alone treatment, the theory being that AIAs can normalise the aberrant pro-angiogenic 
signalling  in  the  tumour  microenvironment  and  create  a  vasculature  that  is  more 
susceptible to drug delivery and re-oxygenation for purposes of radiotherapy. 
VDAs on the other hand target established tumour vasculature with the aim of destroying 
it. VDAs cause direct apoptosis of vascular endothelial cells, thereby destroying tumour 
vasculature, and reduce the blood flow to tumours, causing ischaemia and subsequent 
central tumour necrosis (32). An additional anti-mitotic effect has also been noted with 
certain VDAs. There are two main classes of VDA, those that bind to tubulin and those that 22 
 
do not. VDAs that are independent of tubulin binding are part of the flavonoid class, with 
the  lead  compound  being  DMXAA  (5,6-dimethlxanthenone-4-acetic  acid,  ASA404, 
vadimezan).  Direct  and  indirect  anti-vascular  activity  is  caused  by  apoptosis of  tumour 
blood  vessel endothelial  cells  (47).  Tubulin  binding  VDAs  bind  at  the  colchicine  site  of 
tubulin  (48)  and  cause  depolymerisation  of  tubulin,  cytoskeleton  re-arrangement  and 
changes  to  cell  morphology  (49).  The  lead  compounds  in  this  category  are  the 
combretastatin family of drugs, including combretastatin A-4 phosphate (CA4P) (50) and 
combretastatin  A-1  phosphate  (CA1P,  OXi4503)  (51).  These  agents  selectively  target 
proliferating tumour endothelial cells, causing blebbing and rounding of endothelial cells, 
increased vessel permeability, Rho-mediated vasoconstriction and cessation of blood flow, 
and  ultimate  destruction  of  tumour  neo-vascularisation  (52,  53).  Reduction  in  tumour 
perfusion  following  VDA  treatment  can  be  observed  within  minutes,  with  a  dose                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
dependent response observed in functional tumour blood vessels, resulting in widespread 
central necrosis by 24-48 hours  (54). A characteristic rim of surviving tumour cells remains 
however following treatment (49, 52), which is thought to survive due to receiving oxygen 
and  nutrients  from  surrounding  normal  tissue  vasculature,  which  is  not  affected.  This 
frequently leads to repopulation of the tumour vasculature and viable cancer cells, and 
progression of the tumour. The use of VDAs therefore generally requires combination with 
radiotherapy or other chemotherapy for successful treatment of cancer. Many VDAs are 
still being developed, and the questions surrounding how they affect tumour vasculature, 
and how best to combine them with other therapies, remain. Monitoring of response, both 
in preclinical animal models and in patients, should help to answer these questions and 
increase the translational throughput of novel VDA treatment strategies (55). 
1.6 Colorectal cancer 
Colorectal carcinoma (CRC), the subject of this thesis, is one of the most prevalent forms of 
cancer in the world; in the region of 1.2 million patients are diagnosed with CRC worldwide 
each year, making it the 3
rd most common cancer globally (56). In Europe it is the third 
most common cause of cancer related death (56). The associated metastatic spread is high 
and  usually  to  the  liver,  with  14-20%  of  patients  at  diagnosis  already  with  hepatic 
metastases and a further third with localised disease which subsequently progresses to 
liver metastatic stage (57, 58). Using the ‘Tumour-Node-Metastasis’ or TNM system, the 7
th 
revision of which was recently published (59), patients with liver metastases are classed as 
stage IV disease, where survival at 5 years is only 6%, although if surgically resectable this 23 
 
increases  to  around  25%-40%  (60).  Management  of  this  CRC  with  synchronous  liver 
metastases  is  difficult  (61):  whether  the  metastases  are  resectable  or  not,  treatment 
usually  entails  surgical  removal  of  the  primary  colorectal  tumour  followed  by  interval 
chemotherapy, with liver resection performed at a later date if possible  (62, 63).  For 
patients where resection is not possible, either due to advanced stage liver burden or 
metastatic disease that has spread beyond the liver, guidelines for treatment are to use 
systemic  chemotherapy  either  to  reduce  the  size  of  liver  burden  for  potential  surgical 
resection, or as palliative treatment for symptoms of disease and increased quality of life 
(64).  Further  development  of  chemotherapy  strategies,  especially  vascular  targeted 
therapies  mentioned  previously,  are  therefore  of  great  need.  Preclinical  models  for 
investigating  therapy  of  colorectal  cancer  are  usually  one  of  two  types:  spontaneous, 
induced or transplanted mouse models (syngeneic models), or transplanted human tumour 
cells in immune deficient animals (xenograft models) (65). The use of vascular targeted 
therapy for CRC and advanced liver metastases in human xenograft studies has shown that 
OXi4503 causes vascular shutdown and massive central necrosis (66, 67); however, the 
monitoring of this response has been in an invasive manner that is not applicable to human 
use.  In  patients  with  liver  metastases  treated  with  OXi4503  limited  data  is  available, 
although the use of dynamic contrast magnetic resonance imaging (DCE-MRI) in a phase I 
clinical trial of OXi4503 has shown that non-invasive assessment of response is possible 
(68).  Further  elucidation of  the  mechanism  of  action  of  vascular  targeted  therapy  and 
response to treatment of individual tumours would therefore greatly enhance translational 
ability of novel drug treatments and biomarkers of response. 
1.7 Translational imaging 
Staging of the extent of cancer, and assessing the response of tumours to therapy, is an 
important part of clinical oncology. Assessment usually takes the form of a decrease in 
tumour  volume  or  progression  of  the  disease.  This  is  based  on  the  observation  that 
therapies that cause a regression of the tumour volume will generally demonstrate an 
increase  in  patient  survival  (69,  70);  standardisation  of  measurements  was  therefore 
needed,  and  resulted  in  the  publication  of  the  ‘Response  evaluation  criteria  in  solid 
tumours’  (RECIST)  (71)  for  accurately  measuring  response  to  treatment  based  upon 
differences  in  measured  size  of  tumours.  Volumetric  changes  in  tumours  following 
successful treatment may take weeks to become apparent, or in the case of cytostatic 
therapies  show  no  change  at  all,  meaning  lost  time,  unnecessary  side  effects  and 24 
 
unsuccessful  clinical  trials  in  the  former,  or  a  missed  opportunity  in  the  translation  of 
potentially  effective  new  therapeutic  strategies  in  the  latter.  Imaging  strategies  have 
evolved that are capable of providing functional markers of response for specific targeted 
drugs for this reason. Many reviews have been published describing these advances in 
oncology imaging (72-75); the following subsections of examples of imaging modalities for 
translational  imaging  that,  whilst  not  exhaustive,  describes  those  that  have  the  most 
relevance to imaging the response of the tumour vasculature microenvironment to therapy 
with the aim of clinical translation.  
1.7.1 Magnetic resonance imaging 
Magnetic resonance imaging (MRI) was developed in the 1970s by Paul Lauterbur and 
Peter Mansfield, for which they were awarded the Nobel prize in 2003 (76). The basic 
principles of MRI imaging are outlined below in section 1.8; the fundamental concept is 
that of detecting nuclear spin re-orientation in a magnetic field. As water is abundant in 
tissue and very sensitive to MR detection, imaging protocols are predominantly linked to 
imaging water (72). Anatomical images can therefore be generated with MRI, however the 
real strength is the ability to change imaging parameters in order to bias the detection 
towards  functional  differences  of  different  tissues.  The  main  techniques  developed  to 
image tumour vasculature are MR angiography (77) and dynamic contrast-enhanced MRI 
(DCE-MRI) (78). MR angiography is concerned primarily with imaging vessel structure, and 
is discussed at more length in the corresponding part of this thesis, chapter 4. DCE-MRI is a 
more common technique that is employed to assess density, integrity and leakiness of 
tissue vasculature based on exogenous contrast agent kinetics in tissue. It is commonly 
used in the clinic for the diagnosis and evaluation of cancer (79) with many contrast agents 
developed  for  use  in  patients.  A  quantitative  analysis  of  DCE  data  is  therefore  highly 
dependent  upon  the  distribution  and  elimination  of  the  contrast  agent  employed; 
gadolinium-based  compounds  for  example  have  a  distribution  half-live  of  around  90 
minutes in humans and 27 minutes in mice (80). DCE-MRI is therefore based on several 
assumptions,  the  main  being  that  the  contrast  agent  flows  freely  between  different 
compartments whose volumes do not change over the course of the scan. Differences in 
contrast agent used, success of injection, route and biodistribution of the compound, plus 
many other variables, make DCE-MRI difficult, although not impossible, to compare across 
studies. An inherent measure of the vascular components of tumours would therefore be 
highly preferable. 25 
 
1.7.1.1 Basic principles of MRI imaging 
There are many sources that describe in detail the fundamental concepts of MRI imaging 
for a comprehensive review (101-103). It is beyond the scope of this thesis to explain in 
depth the exhaustive information on this topic, but the basic principles will be established 
here,  with  more  detailed  information  in  the  relevant  chapters.  MRI  is  based  on  the 
principle  of  nuclear  spin;  certain  nuclei  spin  on  their  axis  creating  a  magnetic  dipole 
moment.  These  can  essentially  be  thought  of  as  small  magnets.  When  inside  a  strong 
magnetic field, denominated B0, the majority of these nuclei align with the direction of the 
major field, called the Z axis, and process around it. The frequency of process around the Z 
axis depends on the specific nuclei imaged and the microenvironment in which it is found. If 
the number of protons plus the number of neutrons is an odd number, then the spin is 
designated as ½; the spins will be either of lower energy and align with B0 or of higher 
energy  and  align  opposite  to  B0.  There  is  a  net magnetisation  along  the  Z  axis  as  the 
number of spins aligning with B0 is higher than those opposing it. By applying an oscillating 
magnetic field radiofrequency pulse perpendicular to B0, which is rotating at the resonant 
frequency of the nuclear spin around the Z axis, the net magnetisation ‘tips’ from the Z axis 
in to the X-Y plane. These three concepts are illustrated in figure 1.2. The receiver coil in 
MR  systems  detects  magnetisation  in  this  X-Y  plane  and  signal  is  produced.  Net 
magnetisation will initially be in phase in this transverse plane, but as the pulsed magnetic 
field is switched off the spins will dephase due to magnetic field inhomogeneities, and the 
net magnetisation will be restored to the B0 field. Characteristic times can be described 
based on the dephasing of these spins, and used to discern differences in tissue structure, 
as different tissues will possess different values (72). 
 T1 is the time taken for the longitudinal (Z axis) magnetisation to return to 63% [1-(1/e)] of 
its initial value after being tipped into the X-Y plane. It is known as spin-lattice, as the 
energy from the radiofrequency pulse is dissipated into the surrounding nuclear lattice in 
order to regain magnetisation. Water containing tissue will have long T1 times, of around 
400-1200ms, fluid even longer at around 1500-2000ms, and fat containing tissue shorter T1 
times,  at  around  100-150ms.  In  order  to  bias  MR  imaging  to  be  T1  weighted  images, 
parameters  can  be  set  by  creating  a  short  repetition  time  TR  for  repeat  of  the 
radiofrequency pulse and short echo time TE. 
T2 is the time taken for the transverse magnetisation in the X-Y plane to decay by 37% (1/e) 
of its initial value after the radiofrequency pulse. It is called spin-spin relaxation, as it occurs 
due to the loss of phase between nuclear spins. T2* is the same as T2 but with the added 26 
 
dephasing effect of field inhomogeneities. T2 is generally faster than T1. In biological tissue 
water-containing tissue has a T2 in the order of seconds, whilst fat-containing tissue is in 
the range of 10-100ms. To bias an MR scan for T2 weighting the TE is set long, which then 
allows imaging of tissues with long T2 times, such as water, that will appear bright on 
imaging. 
 
 
 
 
 
   
Figure 1.2 Nuclear magnetic spin in MRI   
Nuclei spin on their axis with an angular momentum ω, creating a magnetic dipole north and 
south (A). When placed in a strong magnetic field B0 the majority of nuclear spins line up with 
the field in the Z axis direction (B). In order to achieve an MR signal the magnetisation vector is 
flipped over on to the transverse X-Y plane by applying a radiofrequency pulse (C).  
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1.7.2 Contrast enhance computed tomography 
Computed tomography (CT) is an imaging modality that uses X-ray imaging to reconstruct 
three dimensional data based on differentiation of tissues due to high or low enhancement 
(81); x-rays pass through the tissue and are attenuated by absorption or scatter of photons. 
Low attenuation occurs in soft tissue, allowing most of the x-ray to pass through to the 
detector,  whilst  hard  structures  such  as  bone  possess  higher  attenuation  properties. 
Contrast enhancement can be used to observe how different structures handle the passage 
of the contrast agent. As exogenous contrast agents are required, as with DCE-MRI but 
using iodine based compounds, many of the same concepts of contrast agent kinetics can 
be applied (82, 83). One advantage of DCE-CT is that the signal intensity, measured in 
Hounsfield units, is linear over a large range, meaning that concentrations of contrast agent 
are proportional to the change observed in the signal intensity (84). Disadvantages include 
the use of ionising radiation and the need for repeated image acquisitions for dynamic 
screening  (85).  For  vascular  studies  micro-CT  can  provide  high  resolution  quantitative 
measures  of  vascular  volume,  density  and  branching  patterns  (86),  however  concerns 
remain  regarding  the  use  of  radiation  and  the  standardisation  of  exogenous  contrast 
administration. 
1.7.3 Ultrasound 
Ultrasound (US) is a low cost, sensitive and easy to use in vivo imaging technique (87). High 
frequency mechanical oscillations of sound in short pulses are transmitted into a tissue of 
interest, and an echo return detected via a transducer which creates electrical signals for 
processing into an image. The echo produced is dependent upon the different echogenicity 
within the tissue, allowing structural images to be produced. With regards to functional 
measurements of angiogenesis, power Doppler measurements can be used to assess blood 
flow (88) and micro-bubbles can be used as a contrast agent (89). These microbubbles are 
able to circulate within blood vessels and, due to their large acoustic impedance difference 
with biological tissue, can be used as a strong echogenic marker, forming the basis for 
contrast-enhanced US (CEUS) (90). CEUS has been used to measure blood perfusion and 
flow  rate  in  tumours  and  organs  (91)  and  has  been  targeted  at  tumour-induced 
angiogenesis through conjugation to a peptide targeting αvβ3 (92). However, molecular 
imaging is limited to the intravascular space due to compartmentalisation issues, with the 
aforementioned problems of exogenous contrast still problematic for CEUS. 28 
 
1.7.4 Optical imaging  
Optical techniques for imaging tumour pathophysiology are generally the preserve of pre-
clinical research, as human studies using optical imaging have been limited in ability. A few 
optical imaging systems have recently had an impact on patient imaging however, with the 
main  modality  being  fluorescence  imaging,  such  as  the  development  of  microscopic-
endoscope fluorescence imaging (93). However, the only fluorescent molecules approved 
for human use are indo-cyanine green, fluorescein, photofrin and 5-aminolevulinic acid 
(94), limiting the ability of research.  On the macroscopic level only intra-operative imaging 
has  been  achieved,  with  liver  metastases  from  CRC  accurately  identified  (95).  Non-
fluorescence  based  systems  such  as  optical  coherence  tomography  are  based  on  the 
scattering of photons, and can be used to image structures in vivo (96), however the field of 
view  is  small  and  data  acquisition  slow  (73).  A  novel  imaging  modality  combines  both 
optical and ultrasound imaging capabilities: photoacoustic imaging (PAI). This can either be 
in the form of microscopy (PAM) (97) or full tomographic mode (PAT) (98). Whilst PAM 
allows greater resolution of images, the area of interest is focussed on to one plane, and 
the imaging area therefore restricted. PAT, on the other hand, is able to image larger areas 
of tissue and does not focus onto a particular plane, but rather receives all data possible 
within  the  region  of  interest.  The  underlying  principle  of  both  PAM  and  PAT  is  the 
generation of sound from the absorption of light, known as the photoacoustic effect. This 
was first described by 1880 Alexander Graham Bell when he published his work on the 
invention of the ‘photophone’ in the American journal of science (99). Bell’s work in to the 
transmission of sound by modulation of sunlight effectively demonstrated the principle of 
information encoded onto light, and is the precursor to today’s medical imaging use of the 
photoacoustic effect (100). Modern biomedical imaging scanners are able to achieve spatial 
resolution  similar  to  ultrasound  imaging,  but  with  addition  of  the  high  specificity  and 
spectral ability of optical techniques. 
1.8 Hypothesis and aims of this thesis 
The hypothesis of this thesis is that non-invasive imaging of tumour pathophysiology will 
provide  novel  translational  imaging  biomarkers  for  vascular  targeted  therapy.  Having 
reviewed aspects of oncology related to the abnormal biology of cancer and assessment of 
response,  the  aims  of  this  thesis  are  to  further  the  translational  ability  of  preclinical 
research, and provide response markers for prognosis and clinical intervention. In order to 
achieve  this,  the  work  will  concentrate  on  one  of  the  hallmarks  of  cancer,  which  is 29 
 
applicable to many different disease situations. As the main cause of tumour growth and 
metastatic spread is the formation of neo-vasculature within the tumour, this thesis will 
look at vascular development and growth, and the therapeutic targeting of tumour blood 
vessels.  It  is  envisaged  that  this  will  provide  greater  understanding  of  the  underlying 
vascular pathophysiology, and provide markers of response to therapeutic intervention. 
The therapeutic approach to be used is that of vascular disruption, as this can be used for 
targeting solid tumour growth of both known and undetected micro-metastatic cancerous 
lesions. As OXi4503 is an advanced VDA in clinical use which causes a large degree of 
vascular  shutdown  in  preclinical  models,  which  should  aid  detection  of  response,  this 
compound has been selected for investigation. This thesis will concentrate on colorectal 
carcinoma, as this has important and direct clinical relevance, but it is envisaged that any 
findings will be applicable to all solid cancer types, as it is the tumour vasculature that is 
being assessed. For this study two distinct CRC cancers will be employed, SW1222 and 
LS174T, as they possess different vascular pathophysiologies when forming tumours in vivo. 
The models to be used are 1) subcutaneous, which is easy to use and interpret, and widely 
employed, therefore can be compared across preclinical studies, and 2) a model of liver 
metastatic disease which will be more relevant for clinical translation. The assessment of 
these models will be by non-invasive molecular imaging; whilst great advances have been 
made with various modalities this has mainly been through use of exogenous contrast 
agents. One of the aims of this thesis is to develop imaging biomarkers of vessel growth 
and assessment of response that are based on inherent tumour vascular characteristics. To 
this end the novel imaging modality of photoacoustic tomography will be employed to give 
greater insight into the structure of tumour vascular networks, and the response of these 
to treatment with OXi4503. Novel use of MRI sequences will also be used to demonstrate 
that  inherent  characteristics  of  the  tumour  vasculature  can  be  assessed  for  response 
criteria to vascular targeted therapy. The layout of this thesis includes a general Materials 
and Methods section (chapter 2) that applies to all subsequent research. The basic physical 
principles of PAT are then discussed, and its suitability for imaging tumours in vivo assessed 
(chapter 3) followed by PAT assessment of vascular disruption (chapter 4). Focus is then 
placed  on  the  development  of  MRI  imaging  sequences  capable  of  assessing  vascular 
function  without  exogenous  contrast  agents  (chapter  5),  and  assessment  of  the  liver 
metastatic  model  response  to  VDA  treatment  (chapter  6).  The overarching results  and 
implications  of  this  research,  coupled  with  future  work  that  would  improve  the 
translational ability of these concepts, is presented in the final section (chapter 7). 30 
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Chapter 2 General materials & 
methodology 
2.1 Introduction 
The approach and experimental set up of all research work is specified in detail in each 
chapter. The following paragraphs set out basic materials and methods used, and cover 
elements of equipment, techniques and models employed. All work was performed in the 
UCL Cancer Institute, the UCL Centre for Advanced Biomedical Imaging (UCL CABI), and the 
UCL Biological Services Unit (BSU).  
2.2 Tissue culture 
All cell tissue culture work, for both preliminary in vitro studies and preparation of cells for 
in  vivo  studies,  was  performed  under  sterile  technique.  Cell  lines  grown  in  vitro  were 
reanimated from a stock of frozen aliquots stored in liquid nitrogen. Cells were grown in 
ventilated  flasks  (Corning,  Sigma-Aldrich,  Gillingham,  UK)  under  simulated  physiological 
conditions of 37⁰C and 5% CO2.  
2.2.1 Equipment 
2.2.1.1 Haemocytometer & Countess cell counter 
In  order  to  ascertain  the  number  of  cells  within  a  given  volume  of  media  a  Countess 
automated  cell  counter  (Invitrogen,  Limited,  Paisley,  UK)  was  used.  A  cell 
suspension/trypan  blue  (Sigma-Aldrich,  Gillingham,  UK)  1:1  mixture  was  loaded  into  a 
Countess slide and inserted into the machine. Correct focus was defined and automated 
cell  count  sequence  selected.  Results  were  checked  to  ensure  correct  identification  of 
viable and non-viable cells via trypan blue exclusion, and results of total cells/ml and cell 
viability saved electronically. 
2.2.1.2 Centrifuge   
In order to concentrate cell densities, cell suspensions were pelleted by centrifugation at 
455g  for  5  minutes,  supernatant  removed  via  vacuum  aspiration,  and  cell  pellets 
resuspended at the desired concentration.  38 
 
2.2.2 Techniques 
2.2.2.1 Cell lines 
The human colorectal carcinoma cell lines SW1222 and LS174T were acquired from UCL 
Cancer Institute stocks at passages p2 and p5 respectively. Transduction of SW1222 and 
LS174T cell lines with the firefly luciferase gene had been performed (Dr Martin Pule, UCL 
Cancer Institute) and these were also acquired, at passages p5 and p8 respectively. All cell 
lines were shown to be negative for mycoplasma infection by an in house polymerase chain 
reaction (PCR) test before collection, and at subsequent checks. Growth conditions were 
checked with the American Type Cell Culture website (1). Medium used was D-Modified 
Eagles  Media  (DMEM,  Sigma-Aldrich,  Gillingham,  UK)  with  the  addition  of  10%  foetal 
bovine serum (FBS), 1% L-glutamine (100x) and 1% non-essential amino acids (100x, all 
from Invitrogen, Paisley, UK). Anti-bacterial infection agents, such as the commonly used 
antibiotics penicillin-strepomycin, were not used during tissue culture as these could mask 
possible infections and become a detriment to any subsequent in vivo studies in immune-
compromised  animals.  Instead,  any  flasks  thought  to  be  potentially  infected  were 
discarded. 
2.2.2.2 Cell sub-culture 
Cells  were  passaged  under  sterile  conditions  within  the  class  II  down-flow  ventilated 
biosafety cabinet (ESCO model no LP2-4S1, Hatboro PA, USA). At each passage cell flasks 
were checked under a brightfield microscope for signs of infection. Flask medium was also 
inspected for signs of potential infection, such as a cloudy or milky appearance. At any 
indication of possible infection cells were discarded immediately. Cell medium was changed 
every 2 to 3 days to maintain nutrient levels. To prevent contact-growth inhibition and 
ensure exponential growth, cells at ≈80% confluency were split as follows:  medium was 
removed via  aspiration  and  adherent cells rinsed with  phosphate  buffered saline  (PBS, 
Lonza, UK) to remove dead cell debris, growth factors and any remaining media. This PBS 
was then removed and 1ml of trypsin-EDTA (Source Bioscience UK ltd) added per ≈30cm
2 
surface area of flask. Flasks were placed in the incubator for 5-10 minutes until the cells 
had  detached  from  the  monolayer  of  the  flask  and  were  in  suspension.  The  action  of 
trypsin was then inhibited by the addition of an equal amount of FBS containing media as 
trypsin used, and as much of a single cell suspension as possible achieved by pipetting. 
Between 1:2 and 1:8 dilution, based on apparent confluency of the flask monolayer, was 39 
 
then  passaged  into  a  new  flask  and  returned  to  the  incubator.  A  complete  record  of 
passage number, date and dilution factor was kept every time cells were split. 
2.2.2.3 Frozen storage procedure 
In order to maintain a personal stock of cell lines a repository was created, with aliquots of 
each cell line frozen down for cryogenic storage. Briefly, healthy, exponentially growing 
cells were detached from a flask and a single cell suspension created. The suspension was 
pelleted by centrifugation, washed in PBS, re-pelleted, resuspended in a known volume of 
serum free medium and total cell number determined by Countess automated cell counter. 
The suspension was then centrifuged and the pellet re-suspended in freezing medium (10% 
dimethylsulphoxide (DMSO, ThermoFisher Scientific, Cambridge, UK) and 90% FBS) at a 
concentration of 2x10
6cells/ml. . This solution was then placed in 1ml aliquots in cryotube 
vials (Nalgene, SLS Ltd, UK) labelled with cell line, freeze date, concentration, and passage 
number. Aliquots were then frozen inside cryo-freezing containers to allow a slow gradual 
freezing process in a -80⁰C freezer (New Brunswick Scientific, Eppendorf, Enfield CT, USA), 
and subsequently stored in liquid nitrogen storage facility (UCL Cancer Institute). 
2.2.2.4 Preparation for in vivo work 
For  in  vivo  experimentation  the  number  of  required  cells  was  calculated  and  flasks 
expanded accordingly to provide sufficient total cells. An upper passage limit of 25 was 
used in case differential growth characteristics and/or tumour forming capability had been 
introduced due to excessive  in vitro handling and/or cell  adaptation after multiple cell 
divisions. Cells were detached, pelleted, washed in PBS, re-pelleted and counted. The cell 
suspension was then pelleted by centrifugation and resuspended in the desired volume of 
serum  free  media,  depending  upon  the  in  vivo  experimental  procedure.  The  final  cell 
suspension was used in vivo as soon as possible In order to preserve cell viability and limit 
any potential cell aggregations. 
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2.3 Animal experiments 
All in vivo experiments were performed in accordance with UK regulations and UK Home 
Office  Scientific  Procedures  act  (1986)  under  PIL  40/8141  and  PPL  70/7309  ‘Targeted 
Cancer Therapies’. For all animal experiments the Workman P et al (2) ‘Guidelines for the 
welfare and use of animals in cancer research’ were adhered to. Animals strains used were 
immune-deficient Nu/Nu mice lacking T-cells due to developmental absence of a thyroid 
gland. The background species of the mice were either MF1, procured from an in house 
breeding colony, or CD1 mice, procured from Charles River Laboratories, both species being 
ultimately outbred colonies of Swiss Webster stock (3). 
Animals were housed in barrier conditions within UCL BSU facilities in individual ventilated 
cages (IVC) with food and water ad libitum. Daytime conditions were simulated by a 12 
hour light/dark cycle. Animals for experimentation were females between the ages of 8-10 
weeks,  with  a  seven  day  acclimatisation  period  allowed  between  arrival  at  biological 
services facilities and experimental use.  
2.3.1 Animal handling 
All in vivo techniques were acquired through previous training and tuition at the royal 
veterinary college London, resulting in a home office licence for modules 1-4 (PIL 40:8141). 
Typical procedures performed included restraint via scruffing, injection of substances (cell 
suspensions, drug solutions, contrast agents, etc.) via subcutaneous (s.c.), intraperitoneal 
(i.p.)  and  intravenous  (i.v.)  routes  of  administration,  and  induction  of  anaesthesia  for 
routine imaging procedures. Animals were checked daily when under procedure and at no 
point  showed  signs  of  suffering  or  lasting  harm  due  to  experimental  procedures. 
Termination was carried out via cervical dislocation via a schedule 1 method. 
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2.3.2 Pre-clinical tumour models 
2.3.2.1 Subcutaneous tumour model 
Cell lines were prepared through tissue culture techniques to a concentration of 5x10
6 per 
100µl of serum free media.  A 100µl bolus of cells was injected subcutaneously into the 
right flank above the hind leg via a 1ml syringe with a 25 gauge x 16mm needle, within a 
sterile down-flow cabinet (Techniplast, UK). Animals were returned to IVCs and checked 
daily for tumour growth, with typical values being a growth to 0.1cm
3 in 14-16 days. 
A set of digital callipers were used to measure tumour volume; animals were restrained 
and  tumour  length,  breadth  and  height  measured.  To  calculate  volume  the  ellipsoid 
formula  from  three  distinct  measurements,  as  seen  below,  was  used  as  this  has  been 
shown to provide the most accurate estimate of relative and actual tumour mass (4). The 
maximum volume permissible was 1.5cm
3, after which the mice were killed by schedule 1 
cervical dislocation. 
𝑣 = 𝐿 𝑥 ? 𝑥 𝐻 𝑥(
𝜋
6
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2.3.2.2 Orthotopic liver metastases model 
Cell lines were prepared through tissue culture techniques to a concentration of 1x10
6 per 
100µl of serum free media. A surgery suite was prepared in advance by disinfecting all 
surfaces with Mikrozid AF spray (Schülke & Mayr, Meadowhall, UK). Sterile surgical drapes 
were placed over the operating table. All surgical instruments to be used were sterilised by 
autoclaving.  Sterile  surgical  gown,  mask  and  gloves  were  used  at  all  times  within  the 
surgical suite. Animals were taken individually in to the surgical suite and anaesthetised 
with 4% isoflurane (Abbott Laboratories, USA) in oxygen (BOC, UK) at a flow rate of 1L/min. 
Anaesthetised  mice  were  placed  on  the  operating  table  with  an  individual  nose  cone 
supplying 1-2% isoflurane in 0.5L/min O2 for maintenance of anaesthesia. The flank of the 
animal was swabbed with clorhexidine solution above the location of the spleen in order to 
sterilise  the  skin  before  operation.  Pre-operative  analgesia  was  provided  through 
subcutaneous injection of 0.1mg/kg buprenorphine (Vetergesic, Reckitt Benckiser, UK) just 
above the site of incision. Depth of anaesthesia was monitored by a paw-pinch response; 
surgery commenced when no pinch response was observed.  A set of surgical scissors and 
tweezers were used to make a ≈1cm incision through the skin above the spleen; these were 
then considered to be ‘outside’ instruments and therefore not used internally. A further set 42 
 
of ‘internal’ round-edged scissors and non-toothed tweezers were used to make an incision 
through the exposed muscle wall. The spleen was located and gently held in place in order 
to allow intrasplenic injection of cells; a fine gauge 27g needle was introduced into the 
spleen and 100µl of cell suspension injected. Care was taken to inject at a steady pressure, 
with correct injection noted by a paling of the spleen with no spillage of liquid into the 
opened cavity. Following injection cells were allowed to wash through to the liver for 2 
minutes, after which the splenic artery and vein were ligated with undyed, absorbable, 
coated vicryl sutures (Ethicon, Johnson & Johnson, UK) and splenectomy performed to 
prevent formation of an intrasplenic tumour. The muscle wall was then sutured with PC-5 
4-0 coated vicryl sutures (Ethicon, Johnson & Johnson, UK). The skin layer was securely 
closed using the Autoclip wound closure system (Harvard apparatus Ltd, UK), the area 
swabbed with clorhexadine, and mice returned to a recovery box. Full recovery of the 
animals was checked before returning the IVCs to the holding room and at 24 hours post 
operation. One week following surgery, when wounds had completely healed, the wound 
clips were removed. 
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2.4 In vivo imaging 
2.4.1 Magnetic Resonance Imaging 
All magnetic resonance imaging (MRI) experiments were performed on a dedicated small 
animal Agilent 9.4T MRI scanner (Agilent Technologies, Santa Clara, USA) located within the 
UCL  Centre  for  Advanced  Biomedical  Imaging  (UCL  CABI,).  Animals  were  taken  to  the 
preparation room adjacent to the MRI scanner room and, when ready for imaging, placed 
in an anaesthetic induction box with 4% isoflurane in 1L/min O2.  Once anaesthesia was 
achieved animals were transferred to the MRI cradle designed to fit into the bore of the 
MRI scanner magnet, with anaesthetic gas flow changed to the incorporated nose-cone 
face mask and reduced to 1-2% isoflurane in 0.5L/min O2. A rectal probe was inserted into 
the animals to monitor body temperature, and respiratory bellows placed immediately 
inferior  to  the  diaphragm  to  measure  respiration  rate.  In  order  to  maintain  animal 
temperature a heated fan set to 36.8⁰C using feedback measured from the rectal probe 
was used to blow warm air down the bore of the magnet. Both body temperature and 
respiration rate were monitored remotely via SAM PC software (SA Instruments, USA) in 
the MRI control room throughout all data acquisitions. Small bore MRI gradients were used 
with a 39mm birdcage coil (RAPID Biomed, Rimpar, Germany) to transmit radiofrequency 
pulses and receive MRI signals. If mice had subcutaneous tumours image motion artefacts 
produced  from  respiration  were  reduced  by  setting  the  tumour  within  silicone  rubber 
impression  paste  (CharmFlex,  Dentkist  Inc,  UK).  If  an  intravenous  or  intraperitoneal 
injection  was  required  a  primed  remote  line  was  set  up  before  image  acquisition  and 
secured in place with tape and/or rubber impression paste. This allowed administration of 
substances at a later timepoint after baseline data acquisition. Total scan time including 
experimental set up was limited to 3 hours anaesthesia per animal as stipulated in the 
project licence. Following MRI scans animals were placed in a recovery box and monitored 
for a minimum of 20min before returning to the IVC and holding facility.  
2.4.2 Photoacoustic Imaging 
All photoacoustic imaging (PAI) experiments were performed on the in-house system built 
by the UCL Department of Medical Physics and Bioengineering located within CABI. The 
system set up and specifications are discussed in greater depth in the relevant chapter. 
Animals  were  taken  in  IVCs  to  the  preparation  section  within  the  PAI  room,  with 
experimental  flow  designed  to  allow  one  animal  at  a  time  to  then  be  taken  to  the 
anaesthetic induction box. Animals were anaesthetised with 4% isoflurane in 1L/min O2.  44 
 
Once anaesthesia was achieved animals were placed on a cradle specifically designed to fit 
the PAI sensor, with a window 15x15mm permitting access to area to be imaged. The area 
of interest, either a subcutaneous tumour or physiologically normal mouse flank, was then 
wiped with a water based lubricant (Johnson&Johnson, USA) to enable acoustic coupling 
with the PAI sensor, and the cradle put in to place within the scanner.  When in position the 
animal received 1-2% isoflurane in 0.5L/min O2 via nose-cone face mask. A warm air blower 
coupled to a thermal chamber was used to maintain animal temperature, and respiration 
monitored visually through the Perspex wall of the chamber. Data acquisition was then 
performed  via  the  associated  computer  control  system.  Total  scan  time  including 
experimental set up was limited to 3 hours anaesthesia per animal as stipulated in the 
project licence, but was typically much less than this, with 1hr usually enough to acquire 
multiple  scans.  Following  PAI  scans  animals  were  left  within  the  heated  chamber,  and 
isoflurane switched off to allow breathing of O2 until recovery. Animals were then returned 
to IVCs and monitored for a minimum of 20min before returning to the holding facility.  
2.4.3 Bioluminescence Imaging 
An IVIS Lumina system (PerkinElmer, USA) was used to acquire bioluminescence images of 
firefly luciferase gene transfected cell lines. For whole body in vivo images animals were 
administered D-luciferin (Biosynth, USA) from a stock concentration of 30mg/ml prepared 
in sterile saline solution and injected intraperitoneally (i.p.) at 5ml/kg for a total dose of 
150mg/kg. The substrate was allowed to biodistribute for 15 minutes to allow a plateau of 
peak emission before image acquisition.  Animals were anaesthetised at 12 minutes post 
injection with inhalational isoflurane at 4% in O2 then placed within the imaging chamber 
with nose cone isoflurane supply reduced to 1.5% for maintenance. Imaging parameters 
were set for 1s, 30s and 60s exposure time with no binning. Photon count was calculated 
over a user defined region of interest (ROI) using VivoVision software (PerkinElmer, USA) 
with photon emitted per second per steradian (p/s/str) used to define total photon flux and 
average radiance. 
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2.5 Tissue collection 
In order to investigate ex vivo any changes in pathophysiology observed in vivo mice were 
sacrificed and biological tissue specimens were excised and kept for analysis as either fixed 
or frozen samples. 
2.5.1 Formalin fixation of samples 
Samples to be used for morphological immunohistochemistry were preserved via formalin 
fixation. Samples were placed in sterilin containers (ThermoFisher Scientific, Cambridge, 
UK) containing 10% neutral buffered formalin (Sigma-Aldrich, Gillingham, UK ) and left for a 
minimum of 48hrs before processing to allow full fixation. Samples were then processed at 
UCL Department of Histopathology by dehydration through a series of increasing ethanol 
solutions,  following  which  they  were  embedded  in  paraffin  blocks  and  sectioned  on  a 
microtome (model RM 2135, Leica, UK) at 5µm thickness, and transferred to a heated 
section-bath for around 5 minutes. Individual sections were then picked up onto polysine 
microscope slides (VWR international, Leicestershire, UK) and placed onto a hotplate for 
≈10min before placing into an oven set to 65⁰C for a minimum of 1 hour. Slides were then 
stored at room temperature until required for staining. 
2.5.2 Frozen storage of samples 
For fluorescence immunohistochemistry, samples were snap-frozen in order to preserve 
localisation of both tissue antigens and injected markers of perfusion and hypoxia. For this 
the sample was excised and placed in pre-cooled isopentane (Sigma-Aldrich, Gillingham, 
UK),  then  lowered  gradually  in  to  a  dewer  containing  liquid  nitrogen  (BOC,  UK).  Once 
frozen,  samples  were  transferred  to  labelled  sterilin  containers  and  stored  in  a  -80⁰C 
freezer (model U570 premium, New Brunswick Scientific) until sectioned. For sectioning, 
frozen  samples  were  mounted  in  OCT  embedding  matrix  (Lamb  RA,  ThermoFisher 
Scientific, Cambridge, UK) and cut on a cryostat (model CM3050 s, Leica, UK) at 10µm 
thickness and picked up via contact on to polysine microscope slides (VWR international, 
Leicestershire, UK). Slides were then stored at -80⁰C until required for histochemistry.  
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2.5.3 Haematoxylin and eosin staining 
For basic cell morphology and tissue structure haematoxylin and eosin (H&E) staining was 
performed. Below are the steps used for the H&E protocol staining: 
1)  Deparaffinise slides in histoclear for 10 minutes and rehydrate by 5 minutes each in 
100% IMS, 70% IMS, H2O.  
2)  Place slides in distilled H2O for 5 minutes. 
3)  Place slides in haematoxylin for 5-10 minutes. 
4)  Wash thoroughly in tap H2O. 
5)  Dip in acid/alcohol (1% HCL/70% IMS) for a 1 second.  
6)  Wash thoroughly in tap H2O. 
7)  Place slides in eosin for 30 seconds. 
8)  Wash thoroughly in tap H2O. 
9)  Dehydrate slides in 70% and 100% IMS 
10) Place slides in histoclear for 5-10 minutes. 
11) Mount coverslips on to slides with DPX. 
12) Visualise and capture microscopy image. 
2.5.4 Double fluorescence immunohistochemistry 
For  specific  CD31  antigen  marker  for  blood  vessels  and  hypoxia  via  anti-pimonidazole 
immunohistochemistry the following protocol was used: 
1)  Fix sections in acetone for 10 minutes. 
2)  Air dry sections for a few seconds and circle with wax pen. 
3)  Rehydrate sections in PBS. 
4)  Apply 3% normal goat serum/PBS for 20 minutes. 
5)  Tap off excess and apply Rat anti Mouse CD31 1:2 (Gift from Montevani lab) and Rabbit 
anti-pimonidazole (Hypoxyprobe, USA) 1:400. Leave for 1hr at room temperature. 
6)  Wash in PBS 3 Times (5 minutes each). 
7)  Apply Goat anti Rat 546 and Goat anti Rabbit 488 secondary antibodies (AlexaFluor, 
Invitrogen, Life Technologies, UK) both at 1:200. Leave for 1hr at room temperature. 
8)  Wash in PBS 3 Times (5 minutes each). 
9)  Visualise and capture microscopy image. 
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2.5.5 Injected biological markers 
2.5.5.1 Perfusion 
In order to visualise perfusion of a specific tissue of interest the fluorescent dye Hoechst 
33342, used to stain the DNA of perfused cells, (Cambridge Bioscience, UK) was injected i.v. 
60 seconds prior to schedule 1 killing  and tissue snap freezing. A stock concentration was 
made  up  at  6.25mg/ml,  covered  from  light  and  stored  at  4⁰C.  Animals  were  dosed  at 
2ml/kg  (e.g.  for  an  average  25g  mouse  50µl  would  be  injected)  for  a  final  dose  of 
12.5mg/kg. Tissue samples frozen with injected Hoechst 33342 were kept shielded from 
light at all times where possible. 
2.5.5.2 Hypoxia 
To visualise areas of hypoxia within the tissue of interest the small molecule pimonidazole 
(Hypoxyprobe, USA), shown to be strongly correlated with oxygen electrode measurements 
in mouse tumours (5), was injected  at least 30 minutes before schedule 1 of the animal. 
Stock concentration was prepared to 10mg/ml and animals dosed at 6ml/kg (e.g. for an 
average 25g mouse 150µl would be injected) for a final dose of 60mg/kg. 
2.6 Microscopy 
2.6.1 Brightfield 
For all brightfield microscopy, slides were visualised on a Zeiss Axioskop2 microscope (Carl 
Zeiss, UK) using 10x and 20x objectives, with images captured using an Axiocam (Carl Zeiss, 
UK) high resolution digital camera. For data acquisition Axiovision software v 4.8(Carl Zeiss, 
UK) was used. Composite images of whole tumour sections were acquired on an Axioskop 2 
microscope by stitching together a large number of individual tiles at high resolution.  
2.6.2 Fluorescence 
Slides were visualised on a Zeiss AxioImager microscope (Carl Zeiss, UK) using 10x and 20x 
objectives, with images captured using an Axiocam (Carl Zeiss, UK) high resolution digital 
camera.  For  data  acquisition  Axiovision  software  (Carl  Zeiss,  UK)  was  used.  Multi-
fluorescence high resolution composite tiled images of whole tumour sections were then 
acquired.  
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Chapter 3 In vivo photoacoustic 
imaging of tumour pathophysiology 
3.1 Introduction 
3.1.1 The applicability of photoacoustic tomography for in vivo 
imaging 
Photoacoustic tomography is ideally suited to assessing tumour pathophysiology in vivo; it 
is completely non-ionising and non-invasive, with no detrimental effects through its use. 
Using the high tissue-based contrast and spectroscopic capability of optical techniques and 
the spatial resolution of ultrasound, PA imaging can provide highly detailed structural and 
functional information on the tumour microenvironment (1). The imaging niche in which 
this fits is one of tens to hundreds of micron resolution and millimetre depth penetration 
(2), making it well placed to provide macro-environment changes at the tumour-localised 
level. Figure 3.1 shows the depth penetration and spatial resolution of PAI in comparison to 
other common biomedical imaging approaches (3). As can be seen PAI is well suited to 
imaging specific biological phenomena such as tumour angiogenesis and progression of 
disease. Previously published studies using PA systems have shown preliminary tumour 
imaging data (4-7); however the results of these studies were unsatisfactory in terms of 
imaging  depth,  which  was  limited  to  a  few  hundred  microns,  which  is  insufficient  to 
encompass whole growing tumours, and gives poor image quality. The vascular anatomy 
was  not  clearly  defined,  making  tumour  vasculature  differentiation  from  normal  tissue 
virtually impossible. These PA systems were based on detection of ultrasound waves using 
piezoelectric detectors, which limits image quality due to insufficient broadband detection 
of most clinical piezoelectric devices, and limited apertures of available arrays (8).  
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This  chapter  introduces  the  basic  physics  of  PAI  before  expanding  on  the  concept  of 
photoacoustic tomography (PAT) imaging through an all-optical, non-piezoelectric detector 
based  system  used  at  UCL.  Basic  in  vivo  experiments  then  demonstrate  the  increased 
suitability  of  the  PAT  system  over  other  optical  imaging  systems  for  imaging  tumour 
vascular pathophysiology in a longitudinal manner. 
3.1.2 Photoacoustic effect 
The photoacoustic effect is the production of sound following absorption of optical energy, 
first noted by Alexander Graham Bell in 1880 (9). In the realm of biomedical imaging this 
phenomenon is utilised to acquire images and functional information on the location of 
certain energy absorbers within tissue.  Significant advances in utilising the photoacoustic 
effect for scientific and technological research were only possible following the creation of 
the first laser in the 1960s (10). The reasons for this can be found in the fundamental 
characteristics of laser light and its interaction with biological tissue. These aspects central 
to PA imaging are described below.  
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Figure 3.1 Imaging modality depth penetration and spatial resolution comparison  
Imaging modalities are: Intra-vital Microscopy (IVM), Photoacoustic Imaging (PAI), Ultrasound 
(US), Magnetic Resonance Imaging (MRI), Computed tomography (CT) and Positron Emission 
Tomography (PET). Penetration through tissue can be seen on the Y axis, with MRI, CT and PET 
considered whole body imaging. Size of sphere relates to spatial resolution possible with each 
modality (IVM 1-2µm, PAT 5-500µm, US 500-1000µm, MRI 1000µm, CT 100µm, PET 1000µm). 
Colour of sphere denotes whether the modality is invasive or uses ionising radiation (Red) or 
non-invasive (Blue).  
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3.1.2.1  Laser principles  
The light used by Bell in 1880 was simply sunlight condensed and modulated through a 
series of mirrors. The problem with this light source is a lack of consistent power which is 
also  often  of  low  intensity,  a  multiple-wavelength  or  polychromatic  spectrum,  and  an 
incoherent  and  divergent  means  of  propagation.  Light  amplification  by  the  simulated 
emission of radiation, first proposed by Einstein in 1917 (11) and now commonly known by 
its acronym laser, overcomes these problems: laser light is produced when an electron, 
orbiting its atom in a high energy state, is struck by a photon. This leads to the electron 
returning to a resting state around the atom and emitting two photons with the same 
energy, frequency and direction (12). These emitted photons stimulate the emission of 
subsequent photons, leading to the light characteristics that make it ideal for PA imaging: 
  Spectral purity: all forms of energy that propagate through space as waves can be 
represented on the electromagnetic spectrum. ‘White light’ or sunlight is a mix of 
different wavelengths within the visible range. Laser light in contrast is emitted at a 
single wavelength. This can be in the hundreds of nanometre range for visible light 
(400-700nm)  through  to  infrared  (700nm-1mm).  This  spectral  purity  allows  PA 
excitation  systems  to  be  tuneable  and  to  interrogate  samples  at  different 
wavelengths with high specificity. 
  Coherence and collimation: light emitted through stimulated emission of radiation 
produces wavelengths that are in phase in both time and space. This creates a 
directionality of laser beam excitation. Laser beams are emitted in parallel and 
therefore have a defined beam diameter. No divergence from this beam occurs, 
allowing the energy to be identical over any distance, with no decrease in energy 
intensity until deposited within the tissue of interest (13). 
  High  intensity:  a  final  attribute  of  lasers  worth  noting  is  the  high  peak  power 
attainable. This allows high energy to be contained within each nanosecond pulse, 
thereby  achieving  higher  PA  wave  production  due  to  increased  signal  to  noise 
whilst staying within safety limits (14). 
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3.1.2.2  Interaction with tissue 
Laser light incident on biological tissue will result in a number of consequences. These are 
depicted in figure 3.2 and described below (13): 
  Reflection:  approximately  4-7%  of  laser  light  incident  on  skin  will  simply  be 
reflected back from the tissue (15). This depends on the angle at which it interacts 
with the skin surface, and affects how much energy is absorbed within the tissue. 
  Scattering: once in biological tissue, laser light is spread from its original beam 
through  refraction  in  different  tissue  areas,  mainly  through  striking  dermal 
collagen, which alters the path of the photons. This results in increased spatial 
distribution of the energy of the applied laser beam. The larger the beam diameter 
size the less scattering occurs and deeper penetration depths achieved. The laser 
light  is  also  scattered  less  with  increased wavelength,  as  scattering  is  inversely 
proportional to the incident light wavelength (16). 
  Absorption: the first law of photobiology, known as the Grotthus-Draper law, states 
that  only  absorption  of  incident  laser  light  will  produce  a  biological  effect. 
Reflection  and  scattering  will  affect  the  initial  distribution  of  the  absorbed 
deposited energy however, so should also be taken into consideration. Absorption 
occurs at particular molecules known as chromophores; biological chromophores 
are discussed below. 
  Transmission: any light from the laser that is not reflected, scattered or absorbed 
will pass through the tissue either to deeper lying structures or completely.   
 
 
   
Figure 3.2 Light interaction with biological tissue  
Light that is incident on biological tissue will have a combination of the effects shown above; it 
can be reflected from the surface of the tissue, photons that do penetrate the tissue will be 
scattered and either absorbed or transmitted through to the other side. For the purpose of PAT 
imaging absorption is the main effect required.  53 
 
3.1.2.3  Tissue chromophores 
Energy  from  the  deposited  laser  light  will  be  absorbed  by  specific  chromophores.  In 
biological tissue the most frequent chromophores are water, melanin, oxyhaemoglobin, 
deoxyhaemoglobin,  lipids,  collagen  and  elastin.  The  absorption  coefficient  for  these 
chromophores over a range of wavelengths can be seen in figure 3.3 (8). 
 
 
 
 
As can be seen from figure 3.3 the main tissue chromophores in the 600-900nm section of 
the  spectrum  are  oxyhaemoglobin,  deoxyhaemoglobin  and  melanin.  All  other  major 
chromophores are at least one order of magnitude lower than these three; this creates a 
biological imaging ‘window’ in which haemoglobin and melanin are the predominant PA 
signal-producing  chromophores.  These  images  will  therefore  reflect  the  deposition  of 
haemoglobin  within  the  vascular  network  of  the  tissue,  and  also  areas  of  melanin,  if 
present, in the form of pigmentation.  Absorbance of light energy by a chromophore can 
result in the following biological responses: 
  Photothermal: this is one result from the conversion of light energy to heat. It is 
dependent on the wavelength and pulse duration used, and therefore the fluence 
(J/cm
2)  or  energy  density  achieved.  Photothermal  effects  can  severely  damage 
tissue if the fluence is too great. Significant increases in temperature are therefore 
Figure 3.3 Absorption coefficient for tissue chromophores  
The  graph  shows  absorption  in  µa  (cm
-1)  for  a  range  of  tissue  chromophores,  at  excitation 
wavelengths  from  400nm  to  1800nm.  Chromophores  shown  are:  oxyhaemoglobin  (red), 
deoxyhaemoglobin (blue), melanin (dashed black), 80% water in tissue (black), 20% water in 
tissue (brown), elastin (yellow), collagen (green), and lipid (pink).  54 
 
not  desired  when  acquiring  PA  images,  and  are  kept  below  the  Maximum 
Permissible Exposure (17) through the use of pulsed laser excitation beams. 
  Photochemical:  certain  chromophores,  either  directly  or  following  a  change  in 
conformation upon absorbing energy, elicit chemical reactions within the tissue. 
Although not a common result of laser light absorption, this has been used for 
photodynamic  therapy,  through  the  use  of  photosensitizers  generating  reactive 
oxygen species (18). 
  Photomechanical: this response occurs when high energy and short pulse duration 
laser  excitation  is  used.  Thermal  expansion  of  the  chromophore  occurs  which 
creates  an  initial  pressure  distribution  and  waves  of  ultrasound  to  propagate 
outward through the tissue from the absorber. 
 
3.1.2.4  Physics of chromophore PA signal production 
Once  laser  energy  is  deposited  in  the  tissue  chromophores  it  produces  a  rapid 
photomechanical  response  with  a  temperature  increase  of  less  than  0.1K  due  to  the 
nanosecond  pulsed  nature  of  the  beam.  This  is  not  sufficient  to  cause  photothermal 
destruction of tissue, but does lead to a photomechanical induced distribution of pressure. 
This pressure is released in the form of acoustic waves in the tens of megahertz range with 
amplitudes of less than 10 kilo-pascals. These acoustic waves propagate back through the 
tissue  and  can  be  detected  by  various  ultrasound  sensor  systems.  The  physics  of 
photoacoustic signal production for a specific point  𝑟 can therefore be described as the 
initial pressure distribution 𝑝0, given by the thermodynamic conversion efficiency Γ of the 
absorbed optical energy at that point 𝐻(𝑟); 
𝑝0(𝑟) =  Γ𝐻(𝑟) 
The thermodynamic conversion efficiency Γ is known as the Grüneisen coefficient, and is 
a dimensionless constant that describes the degree of conversion of heat to pressure. It 
is formulated as; 
𝗤 = 
𝗽𝑐2
?𝑝
 
In this equation β is the volume of thermal expanse, c is the speed of sound within the 
tissue, and Cp is the specific heat capacity at constant pressure. These parameters account 55 
 
for  the  conversion  efficiency  of  the  deposited  energy.  However,  the  absorbed  optical 
energy 𝐻(𝑟)is also dependent upon a number of factors; 
𝐻(𝑟) = 𝜇𝑎(𝑟)𝜃(𝑟;𝜇𝑎,𝜇𝑠,𝑔) 
In this equation 𝜇𝑎(𝑟) is the local absorption coefficient of the chromophore and the 
remaining 𝜃(𝑟;𝜇𝑎,𝜇𝑠,𝑔) is the optical fluence of the applied laser beam, where 𝜇𝑎 is the 
absorption coefficient, 𝜇𝑠 is the scattering coefficient, and 𝑔 is the anisotropy factor.  
This shows that the initial pressure distribution  𝑝0 is dependent upon mechanical and 
thermodynamic properties of the tissue, and optical parameters of the applied laser beam. 
The greatest source of variance in PA imaging however can be found in the applied laser 
beam,  as  the  Grüneisen  coefficient  Γ  is  thought  to  change  minimally.  PA  imaging  is 
therefore often described as absorption based, as it is the spatial absorption of photons 
encoded onto acoustic waves that provides the PA signal for image reconstruction. It is not 
however a simple measure of the local absorption coefficient 𝜇𝑎, as this is dependent on 
the  fluence  𝜃  which  is  also  dependent  on  𝜇𝑎;  the  initial  pressure  distribution  𝑝0  is 
therefore a non-linear function of 𝜇𝑎. The assumption that the thermodynamic conversion 
efficiency (Grüneisen coefficient Γ) is non-variant within tissue is also of importance; whist 
it is true that PA images correspond primarily to optical absorption and photon scattering it 
is recognised that the Grüneisen coefficient may have a role in image contrast (8). This is 
therefore a major caveat to any attempt at estimation of quantitative spectroscopy using 
PA imaging (19). 
3.1.3 Advantages of PA tomography systems 
The  in-house  PA  system  developed  by  UCL  Medical  Physics  and  Bioengineering  (Prof 
Beard’s group (20)) is a tomography- mode PA scanner. It has many advantages over other 
PA imaging approaches; the laser incident upon the tissue sample is of large diameter 
which provides full field illumination, giving a larger tissue volume irradiated by diffuse 
light. This enables imaging of greater fields of view than PA systems that concentrate on 
microscopic imaging. PA microscopy leads to images with very high resolution, but the area 
of interest that it is possible to image is small. On the other hand, other tomographic PA 
systems that use standard ultrasound detectors are capable of imaging large areas but with 
limited resolution of detected ultrasound. 
Another advantage of the UCL PA scanner is that it is ‘backward mode’, so that the PA 
signal is detected in the opposite direction of the applied laser beam. This eliminates the 56 
 
need for complex ultrasound detection arrays, and allows the characterisation of the area 
of  interest  that  is  directly  in  front  of  the  sensor.  By  using  an  all  optical  Fabry-Perot 
interferometer the laser excitation light can be applied directly to this area of interest, 
making the UCL scanner suited to imaging superficial anatomy. It is the least restrictive of 
all current PA systems available, and therefore well suited to image the developing tumour 
vasculature over time. 
3.1.4 Why it should be used for tumour pathophysiology  
PA tomography through the system developed at UCL Medical Physics has the potential to 
provide detailed structural and functional information on living tissue in greater detail than 
systems already described. The major advantages are that it is a backward-mode system 
that facilitates illumination of the area of interest, and therefore gives superior imaging of 
superficial anatomical features, and in addition it is an all-optical system which provides 
better acoustic performance compared to piezoelectric receivers. 
The superficial vascular network of tissues can be readily imaged with this system, as has 
been previously demonstrated ex vivo (21); this should translate to imaging  whole tumours 
in vivo, with the abnormal pathophysiological and progression of these tumours evident 
over time. It is the aim of this chapter, therefore, to apply the PAT system to the study of 
subcutaneous tumours in vivo and establish what is possible using this approach. Through a 
series of experiments, the parameters affecting in vivo tumour visualisation will be tested, 
in  order  to  determine  what  structural  and  functional  information  can  be  obtained  in 
preclinical studies of tumour pathophysiology, with the ultimate aim of clinical translation.  
   57 
 
3.2 Methods 
3.2.1 System design 
The PA system in place at UCL has been previously described in the literature (20), and 
forms the basis for the following description. The main features, including backward-mode 
detection set-up and completely optically detected planar sensor, are described in detail 
(21). A schematic of this system set-up can be seen in figure 3.4. 
 
 
 
 
 
 
   
3.2.1.1 PC 
Controller 
3.2.1.4 Interrogation laser 
3.2.1.3 Planar 
detection system 
3.2.1.2 Laser 
excitation source 
Figure 3.4 Schematic of PAT Scanner set up 
The  main  parts  of  the  PAT  scanner  at  UCL  are  shown  above  and  described  in  the  following 
paragraphs;  PC  controller  (3.2.1.1),  Laser  excitation  source  (3.2.1.2),  Planar  detection  system 
(3.2.1.3), and Interrogation laser (3.2.1.4). 58 
 
3.2.1.1 PC controller 
All aspects of image acquisition were fully automated via PC control; the wavelength of 
laser  excitation  was  controlled  via  the  optical  parametric  oscillator  (OPO),  phase-bias 
optimisation of the interrogation laser and optical x-y scanner for detection of PA signal, 
and digital storage oscilloscope (DSO) for PA waveform raw data capture and storage, were 
all  fully  controlled  remotely  from  the  PC  via  LabVIEW  (National  Instruments,  US)  and 
Matlab (MathWorks, US) software. Reconstruction of raw data was performed in Matlab 
using established algorithms for correction of sound attenuation in tissue (22, 23). 
3.2.1.2 Laser excitation source 
The laser energy used to induce photoacoustic signals was created using a Q-switched-
Nd:YAG (Quality-switched Neodynium-doped Yttrium aluminium garnet) laser (Quanta-Ray 
PRO-270, Newport Spectra Physics), the output of which was used to pump a fibre-coupled 
optical  parametric  oscillator  (OPO,  GWU-Lasertechnik,  Germany).  This  creates  optical 
pulses of 8ns duration at a repetition frequency of 10Hz tuneable over the wavelength 
range 410-2100nm. The optical fibre produced a beam of 2cm diameter which was incident 
on the underside of the planar detection sensor and bathed the tissue of interest in broad-
field illumination. 
3.2.1.3 Planar sensor detection system 
The sensor used to detect generated PA signals was a Fabry-Perot interferometer (FPI), 
acoustically coupled to the tissue of interest via a droplet of water. The Fabry-Perot sensor 
head was created by vacuum deposition of a 38µm parylene C polymer film between two 
dichroic mirrors. The dichroic mirrors are highly reflective between 1500nm and 1650nm 
but transparent in the wavelength range 590nm-1200nm. This allows the laser excitation 
source to pass through the sensor head when it is between 590nm-1200nm and create PA 
signals that propagate backwards to the FPI and induce changes in its optical thickness, and 
therefore  the  reflected  power  intensity  of  the  interrogation  laser  (Figure  3.5)  (20).  A 
fundamental limit of the lateral resolution with this system is the spot size of the light from 
the interrogation laser incident on the FPI and the step size used for the point-to-point 
raster scanning of the FPI. A 100um interrogation laser step size will support a lateral 
frequency content up to 7.5 MHz The bandwidth of the FPI sensor must be able to detect 
this  frequency  content.  The  standard  FPI  sensor  is  40  microns  thick  which  allows  a 
bandwidth  of  22  MHz,  sufficient  to  detect  all  higher  frequency  content  in  the  lateral 
dimension induced by changes in the FPI sensor thickness. This permits a lateral resolution 59 
 
in the region of 100 microns. For the axial resolution, a sampling time of 10nS, which 
corresponds  roughly  to  axial  scan  step  size  of  15um,  was  used.  This  axial  resolution 
worsens  with  imaging  depth,  as  the  high  frequency  contents  of  the  PA  signal  gets 
attenuated more in tissue. Even if high frequency PA signals are generated in tissue at 
depth they will become attenuated as they travel through tissue to the sensor. 
 
 
 
 
 
 
 
   
Figure 3.5 Reflectance characteristics of the Fabry-Perot Interferometer sensor 
The graph shows the transmission through the Fabry-Perot interferometer sensor head for a range 
of  laser  wavelengths.  For  the  laser  excitation  source  at  600nm-1200nm  the  interferometer  is 
transparent, whilst for the sensor interrogation laser the interferometer is 95% reflective. 60 
 
3.2.1.4 Interrogation laser  
In order to detect the PA-induced changes in sensor optical thickness, a continuous wave 
focussed interrogation laser beam produced from an external laser (Thorlabs ECL5000DT), 
nominally at 1550nm, was raster scanned across the FPI using a galvanometer mirror-based 
x-y scanner. At 1550nm the dichroic mirrors are highly reflective (95%) to the laser light 
and  therefore  the  interrogation  laser  does  not  pass  through  into  the  tissue.  The 
interrogation laser is only nominally at 1550nm because in practice at each point of the x-y 
scan  the  polymer  film  spacer  of  the  sensor  has  a  different  optical  thickness,  so  the 
wavelength  is  set  to  that  which  provides  the  maximum  slope  on  the  interferometer 
transfer function, thus achieving the optimal sensitivity. This phase biasing is achieved by 
first scanning a range of wavelengths that is greater than the free spectral range  (FSR) of 
the  interferometer  (in  the  case  of  our  38µm  FPI  this  is  18.8nm),  which  provides  the 
wavelength  dependent  measure  of  reflectivity  R(λ).  This  measured  reflectance  is  then 
plotted as a function of phase  to get normalised interferometer transfer function (ITF), a 
derivative of which is normalised phase sensitivity S(λ). The interrogation laser can then be 
set to λopt,the value which will give the maximum sensitivity. The whole process of phase-
biasing takes ≈50ms for each point (20). 
 
 
 
 
   
Figure 3.6 Phase biasing of the Fabry-Perot interferometer 
The graph shows the interferometer transfer function for the Fabry-Perot sensor head. As each 
point  of  the  sensor  will  have  a  different  optical  thickness,  an  optimal  phase  is  selected  for 
maximum sensitivity to reflected power for each point. This is achieved by first scanning a range of 
excitation wavelengths that cover the free spectral range (FSR) of the sensor point. 
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3.2.2 Signal acquisition and processing/DSO 
The  acquisition  and  processing  of  the  PA  signal  is  performed  by  the  Digital  Storage 
Oscilloscope (DSO); once a specific point is selected the λopt is set and the excitation laser 
fired at the same time as the DSO is triggered to record the PA waveform. A photodiode-
transimpedance amplifier unit detects changes in the reflected power intensity and this is 
stored in the DSO. Once the waveform has been acquired the interrogation laser beam is 
moved to the next point and the procedure repeated, thereby recording the 2D (x and Y) 
pattern  of  acoustic  waves  incident  on  the  sensor  in  a  time  (t)  varying  manner.  The 
maximum scan size was 14mm by 14mm, with a usual scan comprising 20,000 waveforms 
and taking 8 minutes to acquire. Image reconstruction in 3D is therefore an inverse k-space 
method based on a Fourier transform of the x-y detected time-resolved photoacoustic 
signal, to recreate the initial pressure distribution caused by the absorbed energy. 
3.2.3 Physiological monitoring 
In vivo experiments were achieved by first anaesthetising the animals in an induction box at 
4% Isoflurane before transferring them on to a specifically designed 3D-printed holder that 
clipped straight in to position on top of the planar detection system. This incorporated a 
nose-cone for maintenance of anaesthesia at 1-2% Isoflurane. A rectal probe was used to 
determine body temperature with a heated chamber maintaining animal core temperature 
to a constant 37°C. This chamber was made of Perspex, allowing respiration rate to be 
monitored visually. A depiction of the system set-up and photoacoustic detection principle 
can be seen in figure 3.7.   62 
 
 
 
 
 
 
 
Figure 3.7 Depiction of PA scanner and photoacoustic detection principle 
Panel A shows the PA scanner with major parts described in section  3.2.1 indicated. Panel B 
shows the functioning of the Fabry-Perot sensor head; the excitation laser is able to pass both 
dichroic mirrors of the sensor and produce a PA effect in the tissue of interest. This causes a PA 
wave to propagate back to the sensor, changing the thickness of the polymer film spacer. This 
change in optical thickness causes the reflected power intensity to vary, which can be detected by 
raster scanning an interrogation beam across the surface of the sensor.  
DSO  Interrogation laser  Excitation laser 
Thermal chamber  Fabry-Perot interferometer  Scan in progress 
B 
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3.2.4 Experimental design 
3.2.4.1 Initial PA scanner imaging capabilities 
To compare the imaging ability of the UCL PA scanner to published data on absorption 
coefficient of haemoglobin, an initial ex vivo blood spectrum was acquired. Mouse blood 
obtained via cardiac puncture exsanguination (n=2, ≈1ml each) was put in a welled-slide 
and  placed  on  top  of  the  PA  scanner  sensor.  A  spectroscopic  experiment  was  then 
performed at a single excitation point of the sensor, starting at 600nm and proceeding in 
steps of 2nm up to a maximum of 1000nm. Two data series were acquired, with results 
plotted as absorption coefficient (µa cm
-1) at each wavelength, using published data for 
comparison (24). 
The ability of the scanner to image blood vessels in vivo was initially demonstrated by 
imaging the superficial vasculature of the palm of my hand. A suitable location was found 
and a single scan at 600nm excitation was acquired for reconstruction. 
A further exploratory experiment was performed to assess the effect of melanin on image 
acquisition  prior  to  the  main  aim  of  investigating  tumour  vascular  development  and 
subsequent  tumour  imaging  studies.  A  single  C57BL/6  female  25g  mouse  was 
anaesthetised and the fur on the flank removed with hair removal cream. The flank of the 
animal was then imaged at 590nm, 600nm, 620nm, 640nm, 660nm, 680nm and 700nm 
excitation wavelengths. 
3.2.4.2 Inhalational gas experiments 
To observe the effect of the inhalation gas, used to carry the anaesthetic, on systemic 
oxygen  status  of  animals  during  in  vivo  blood  vessel  imaging,  a  series  of  experiments 
measured the acquired PA signal intensity over time with both pure oxygen (100% O2, BOC 
Healthcare, UK) and medical air (20.9% ±0.5% O2, BOC Healthcare, UK) . For this study n=3 
mice  were  used  for  both  oxygen  and  medical  air  over  one  hour  of  1%  Isoflurane 
anaesthesia for each gas, during which 5 scans per gas were acquired. The reconstructed 
data were used to visually assess any potential structural changes due to increased oxygen. 
Measures  of  PA  signal  were  also  taken  from  the  data  and  an  ANOVA  two-factor  with 
replication  statistical  test  performed  to  check  for  any  variation  in  signal  between  the 
inspired gasses. This was then compared to an external measure of systemic oxygenation 
status measured via a PulseOx laser Doppler system. N=6 animals were anaesthetised and 
the  systemic  blood  oxygenation  measured  via  a  tail  vein  cuff.  Results  were plotted  as 
percentage oxygenation status over time, and compared to PA acquired data. 64 
 
3.2.4.3 In vivo imaging of tumours 
After initial experiments on scanner capability and reconstruction of acquired data sets, the 
system was used to characterise the in vivo pathophysiological appearance of tumours. 
N=6 SW1222 and n=6 LS174T tumours were established in the flank of nude mice. Caliper 
measurements were used to monitor growth of the tumours, and PA scans acquired when 
tumours were palpable (≈0.1cm
3 after 7 days). PA scans were continued every few days as 
the tumours developed until the animals were terminated via a schedule I method due to 
tumour size (maximum volume 1.5cm
3). In addition to the flank containing the tumour, in 
vivo images of selected normal tissues were acquired. Liver, kidney and spleen were all 
scanned both in vivo and ex vivo. PA images of tumour pathophysiology were compared 
with  known  immunohistological  fluorescence  images  of  hypoxia,  perfusion  and  blood 
vessels, and also to vascular casts of the tumour blood vessel network. Raw data of micro-
CT scanned tumour polymer casts were a kind gift from Dr Amos Folarin (25); this data was 
re-analysed, reconstructed and visualised with MatLab software alongside the acquired PA 
data sets.   65 
 
3.3 Results 
3.3.1 Ex vivo blood analysis 
Figure 3.8 shows the acquired absorption coefficient µa for whole mouse blood containing 
the  anti-coagulant  heparin  across  the  excitation  wavelength  spectrum  from  600nm  to 
1000nm using the in house system. The two acquired measurements are shown in yellow 
and  green,  whilst  the  known  absorption  coefficients  for  oxy-haemoglobin  and  deoxy-
haemoglobin  are  shown  in  red  and  blue  respectively.  The  acquired  measurements  lie 
initially between the oxy- and deoxy- haemoglobin spectra, between 600-675nm. After 
675nm and up to the maximum 1000nm the acquired measurements are higher than the 
known  haemoglobin  spectra.  The  pattern  of  acquired  data  closely  follows  that  of  oxy-
haemoglobin, albeit constantly 20-30 µa (cm -1) higher.  
 
 
 
   
Figure 3.8 Ex vivo PAT spectroscopy of whole blood  
Whole  mouse  blood  acquired  from  cardiac  puncture  was  used  to  obtain  absorption 
coefficient (µa cm-1) spectra of whole blood from the in-house PAT system (2 measurements 
taken, shown in yellow and green). This is compared to known absorption coefficients for 
oxy- and deoxy-haemoglobin (red and blue respectively)  66 
 
3.3.2 Typical reconstruction of normal tissue vasculature 
Represented in figure 3.9 is a typical superficial vascular network from the palm of my 
hand. Both panel A and B are Maximum Intensity Projections (MIPs) in the Z direction of a 
14mm by 14mm area in the X and Y direction. Resolution in the X and Y is 33.3µm, with 
resolution in the Z direction of 15.6µm. Panel A is of the entire Z-stack and shows a striated 
pattern  across  the  entire figure,  similar  to  that observed  in  finger  printing,  and  a  few 
tubular  structures  throughout  the  image.  The  striated  pattern  corresponds  to  the  skin 
surface of my hand, whilst the tubular structures arise from the haemoglobin within the 
blood vessels. This is clearly shown by panel B where the top 100µm of the Z-stack has 
been  removed;  the  majority  of  the  signal  from  the  skin  has  been  removed,  with  the 
vascular network much more clearly defined. The origin of the observed striations is not 
clear, and thought to be potentially caused by a number of factors; chromophores within 
the skin, such as pigmentation, may be a cause but are unlikely at this wavelength of 
600nm. As the signal is present within the striations of the skin it could be due to the lipids 
and  oily  nature  of  the  dermis,  or  some  chromophore  such  as  carbon  (e.g.  from  work 
surface dirt, etc) on the palm. Another possibility is that the contact achieved between the 
skin surface and the sensor is affected by the skin striations, resulting in the observed 
patterns. Whatever the cause the effect is easily removed from the acquired data, and not 
generally seen in subsequent imaging studies. 
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Figure 3.9 Typical reconstruction of PA vascular image 
Maximum intensity projections (MIPs) are shown for a typical in vivo PA image at 600nm. 
Both images depict a 14mm by 14mm section of human palm. Panel A shows the entire Z 
direction, with the image in panel B having the top 100µm section removed. PA signal from 
both skin pigmentation and haemoglobin is observed. 67 
 
3.3.3 In vivo effect of melanin 
The effect of melanin on imaging with the PAT system can be seen in figures 3.10 and 3.11. 
Panel  A  of  figure  3.10  shows  the  species  used  and  an  example  of  the  area  imaged 
demarked by the red rectangle. Although the melanin pigmentation of the hair is clear to 
see, the skin appears to be non-pigmented. This translates to an in vivo image of the flank 
at 590nm excitation wavelength seen in panel B, which shows a 14x14mm MIP in the X-Y 
direction. Superficial blood vessel networks are evident, as well as patches of small globular 
signal highlighted by the red arrows. The blood vessels are visible due to the haemoglobin 
content, with the small globular areas being caused by the melanin present in the hair 
follicles within the skin. The speckled nature of signal caused by the melanin is potentially 
due to distribution of hair follicles or glandular structures containing melanin within the 
skin. Panel C shows an MIP in the X and Z direction on the right hand side, depicting the 
depth capabilities of the acquired data. A measure of PA signal magnitude in arbitrary units 
has been drawn through this data set, and the peaks of signal related to the features of the 
PA  data  set  with  red  arrows.  Whilst  the  skin  surface  is  visible  there  are  also  many 
superficial vessels clearly defined within the image.  
Figure 3.11 represents a series of MIP images from the same mouse as in figure 3.10, 
acquired at increasing excitation wavelengths from 600nm up to 700nm. All panels are 
14x14mm X and Y with 33.3µm resolution, and have displayed next to them the same line 
of PA signal magnitude drawn through at the same point of the data set. All peaks on the 
PA signal amplitude graph correspond to features within the data set; the main skin peak 
has been highlighted in all graphs with the red arrow. Some blood vessels are still visible at 
600nm, as seen in the reconstructed image and also the signal peaks in the associated 
graph. At all excitation wavelengths above this the signal from the melanin in the skin 
dominates, and is the only thing visible in the reconstructed data. The graph of feature-
corresponding PA signal shows that below the level of the skin the ability to discern vessels 
decreases as the excitation wavelength increases. This has been depicted by the blue line 
which shows signal at the level of background noise, which increases with higher excitation 
wavelengths. 
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Figure 3.10 In vivo effect of melanin 
Panel A shows the imaged area (n=1) of a C57BL/6 mouse. Although the flank appears to 
have  no  pigmentation  present  the  MIP  image  at  590nm,  panel  B  clearly  shows  vessel 
structures and small globular regions of melanin deposition (examples highlighted by the red 
arrows). Panel C shows the magnitude of PA signal from the top of the Z-stack to the bottom 
of the acquired data, with peaks in the graph linked via red arrows to the anatomical feature 
they represent in the PA image. The skin surface is denoted by the dotted white line. 69 
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Figure 3.11 In vivo effect of melanin on PA imaging at increasing wavelength 
The  same  area  as  shown  in  Fig.  3.10  is  depicted  here  at  increasing  wavelengths.  As  the 
wavelengths increases above 600nm the signal from melanin is predominant and dominates the 
image. The corresponding graphs of Z-stack PA signals show that features below the level of the 
skin, shown by the peak highlighted by the red arrow,  are lost,  with an increasing  PA signal 
waveform that is the same as background highlighted by the increasing blue bar. 70 
 
3.3.4 Inhalation oxygen content effect on PA scanning 
The effect of using either medical air or pure oxygen for animal anaesthesia on PA imaging 
can be seen in Figure 3.12. Panel A and B are MIP images acquired at 680nm after 60 
minutes of breathing oxygen or medical air respectively. The structure and pattern of the 
observed vasculature is similar between the two images. An area of tissue, highlighted by 
the  red  discontinuous  circle,  does  appear  to  vary  in  signal  intensity  between  the  two 
images. A measure of PA signal amplitude was taken across a clear vessel at the point 
indicated by the red line. A graph of the n=5 measures during the 60 minutes for each 
mouse and each gas can be observed in panel C, where box plots of these values are given 
for oxygen 1-3 (O1, O2 and O3) and medical air 1-3 (A1, A2 and A3). This shows similar 
values when compared across gasses with no significant difference observed. A level of 
variance within the 60 minute time window is observed for each animal, demonstrating a 
degree of variability in measured PA signal amplitude. The systemic oxygenation levels 
from pulseOx measurement can be seen in panels D (oxygen) and E (medical air). Error bars 
denote  standard  deviation  of  the  mean,  with  the  plot  for  oxygen  being  much  more 
consistent and homogeneous through the group, with an average O2 saturation for the 
group over the 60 minute period of 98.5%. The graph for medical air shows much more 
variability between animals, with average O2 saturation being between 96 and 98%. 71 
 
 
   
Figure 3.12 Effect of inhalational oxygen on PA image acquisition 
Panel A and B show MIP PA images acquired at 680nm after 60 minutes of either oxygen or 
medical air respectively. The graph in panel C shows the PA signal amplitude measurements (n=5) 
for the same vessel over the 60min period for all animals (n=3, 1-3) for both oxygen (O) and 
medical air (A). No significant difference is observed between the two groups of measurements. 
Panels D and E show PulseOx measure systemic oxygenation status over 60min for n=6 animals. 
Error bars denote mean±SDM. 
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3.3.5 Three dimensional imaging of subcutaneous tumours 
Imaging  of  subcutaneous  tumours  was  achieved  in  all  n=6  SW1222  and  n=6  LS174T 
animals. Figure 3.13 panel A shows a reconstructed 3D representation of an LS174T tumour 
at day 7 post injection of cells at an excitation wavelength of 610nm. The tumour is located 
in the centre of the image and is highlighted with a white arrow. Non-tumour associated 
superficial blood vessels of the skin are visible either side of the central tumour. A large 
diffuse  PA  signal  is  located  beneath  both  the  blood  vessels  and  the  tumour;  this 
corresponds to the underlying muscle wall of the flank of the animal, highlighting that the 
tumour is in the subcutaneous space. As the data set is three dimensional, it is possible to 
optically section the data set at any point. This has been done for the present data set and 
can be seen in panel B. This shows that there is PA signal from every point of the 3D 
reconstruction. The image can be sectioned at any point through the tumour and provide 
information of the PA signal from that location. The image reconstructed here shows a 
maximum imaging depth of 6.5mm. 
 
 
 
 
 
 
Figure 3.13 3D PA imaging of subcutaneous tumours 
Panel A shows the three dimensional reconstruction of a subcutaneous LS174T tumour at 7 days 
after cell injection imaged at 610nm. The growing tumour is indicated by the white arrow. The 
data set can be optically sectioned, as is demonstrated in panel B; the data can be sectioned at 
any depth of the 6.5mm acquired and the PA signal information at that point observed. 
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3.3.6 Maximum depth imaged 
Over the course of imaging the growing tumours, various depths were achieved depending 
upon  signal  detection.  Figure  3.14  shows  the  maximum  depth  imaged  during  these 
acquisitions. The tumour depicted is an SW1222 at 17 days after cell injection acquired at 
793nm  excitation  wavelength.  The  high  excitation  wavelength  of  793nm  was  used  to 
increase  tissue  penetration  and  decrease  attenuation  effects,  thereby  allowing  greater 
depth imaging. A scan area of 12x12mm is shown in the X-Y MIP (panel A), with the tumour 
located in the centre of the image. In the Y-Z and X-Z MIP images (B and C respectively) the 
spherical tumour can be seen to a depth of 9mm as depicted by the dotted line. When 
reconstructed in 3D in panel D it is clear that the tumour occupies the entire acquired data 
set. 
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Figure 3.14 Maximum PA depth imaging  
Panel A, B and C shows the three dimensional reconstruction of a subcutaneous SW1222 tumour 
at 17 days after cell injection imaged at 793nm. The orientation in XYZ is indicated by the white 
arrow. 3D reconstruction of this data set can be observed in panel D. 74 
 
3.3.7 Comparative pathological features of tumour vasculature 
When  comparing  the  in  vivo  PA  images  of  the  two  tumour  types  various  pathological 
features  were  observed.  Figure  3.15  highlights  these,  and  compares  them  to  ex  vivo 
analysis by micro-CT imaging of vascular casts and immunohistological staining of tumour 
sections. In the PA images (A and B) the location of the tumour has been indicated by the 
dotted red circle. The PA signal from within SW1222 tumours (A) shows a fine distribution 
of small areas of signal, with a few areas of signal drop-out. In contrast LS174T tumours 
show large areas of no signal, with a few large invading vessels within the tumour. Both 
SW1222 and LS174T tumours show typical angiogenic ‘corkscrew’ shape vessels outside of 
the solid tumour, highlighted by the red arrows. Reconstruction of the micro-CT polymer 
cast raw data of these two tumour types shows a similar pattern for extent of tumour 
vasculature.  SW1222  tumours  (C)  show  a  homogeneous  spread  of  fine  tumour  micro-
vessels, with a few small areas of non-vascularised tissue. LS174T tumours on the other 
hand  (D)  have  a  heterogeneous  pattern  of  smaller  vessels  and  large  areas  of  non-
vascularised  tissue,  with  a  few  very  large  thick  invading  blood  vessels.  When  this  is 
compared to immunofluorescence of the same tumour types a similar pattern is observed. 
Whilst  this  was  observed  by  my  own  fluorescence  imaging,  the  quality  of  image  from 
experienced colleagues, such as Dr El Emir et al, allows greater comparison, and these are 
therefore  presented  in  panels  E  and  F.    The  images  in  panels  E  and  F show  CD31  for 
detection of blood vessels in red, perfusion by the injected marker Hoechst 33342 in blue, 
and anti-pimonidazole for the detection of hypoxia in green (data adapted from raw data 
acquired from El Emir et al (32)). SW1222 tumours (E) have a widespread expression of 
blood vessels, most of which is also perfused, shown by the co-localisation of the red and 
blue fluorescence. In the few areas of non-perfusion there is also hypoxia, shown by the 
green signal where no blue is apparent. LS174T tumours by contrast (F) have large hypoxic 
areas shown by the green, with only a few large intruding blood vessels that are perfused. 
These patterns of blood vessel expression are consistent across imaging modalities, and 
across the different tumour types imaged. The relative lack of spatial resolution for the PAT 
images when compared to images of CT casts and microscopy is outweighed by the fact 
that the process is completely non-invasive and carried out in situ. An example of this is the 
associated cork-screw vessels in the surrounding tissue, which is not imaged by the ex vivo 
modalities.  As  each  modality  is  imaging  the  same  associated  parameters  of  vascular 
function the similarity achieved is notable and shows PA can be used to image tumour 
vasculature. 75 
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Figure 3.15 Pathological features of tumours  
The top row A and B show in vivo images from PAI for SW1222 and LS174T tumours respectively. 
This is compared to ex vivo micro-CT imaged polymer casts of the microvasculature of these 
tumour  types  (C  and  D  respectively)  and  immunofluorescence  of  tumour  sections  (E  and  F) 
showing CD31 for blood vessels in red, perfusion by Hoechst 33342 in blue and hypoxia by anti-
pimonidazole in green. 76 
 
3.3.8 Development of tumours over time by PAT 
As tumours were imaged over a number of days it was possible to observe the progression 
of the developing tumour and the associated vasculature. Figure 3.16 shows an example of 
this for both LS174T and SW1222 tumours imaged at day 7, 8 and 12. Arrows in red or 
green  denote  similar  locations  between  scans  for  orientation  purposes.  The  exact 
wavelength used is denoted at the bottom left hand corner of each image. The images 
from day 7 and 8 are clearly of the same area of the flank, and show a diffuse pattern of PA 
signal at the location of the tumour for both tumour types, albeit more pronounced in the 
LS174T.  Images  from  day  12  show  identifiable  architecture  from  previous  days  in  the 
surrounding  non-tumour  associated  vasculature.  The  PA  signal  from  the  centre  of  the 
tumour and the angiogenic feeding vessels however is vastly changed, with a more defined 
location of signal. 
 
 
 
    Figure 3.16 Development of tumours over time by PAT  
The top row A depicts growth of an LS174T tumour by PAT, whilst the bottom row depicts the 
growth  of  an  SW1222  tumour.  Both  are  shown  at  day  7,  8  and  12,  with  exact  excitation 
wavelength shown in the bottom left of each image. Arrows in red and green depict architectural 
features that are identifiable throughout the imaging sequence. 77 
 
3.3.9 Spectroscopic analysis of tumours in vivo 
The ability to acquire spectroscopic data from tumours in vivo was also examined. Figure 
3.17 shows an example of an SW1222 tumour imaged at multiple excitation wavelengths, 
without moving the animal between scans, 8 days after cell injection. Four wavelengths are 
shown, 600nm (A), 620nm (B), 640nm (C) and 670nm (D), with three common features 
indicated in each; the red arrow highlights an angiogenic associated vessel outside of the 
tumour, the signal intensity of which appears to decrease as the wavelength increases. The 
centre of the tumour is highlighted by the interior of the red circle, with signal intensity 
from this area increasing as the wavelength increases. The third feature is a large deep-
lying vessel, indicated by the green arrow, that is not initially visible but that appears as the 
wavelength increases. Also of note is that many of the smaller superficial skin vasculature 
also disappears as the wavelength increases to 670nm. 
 
 
   
Figure 3.17 Spectroscopic analysis of tumours in vivo  
The  same  tumour  (SW1222  8  days  after  cell  injection)  is  imaged  increasing  PA  excitation 
wavelengths. The red arrow indicates an angiogenic feeding vessel, the red circle the centre of the 
tumour, and the green arrow a large deep-lying vessel, all of which vary in intensity depending on 
the excitation wavelength. 78 
 
3.3.10 PA imaging of other organs 
In order to assess the suitability of PAT for imaging internal tumours imaging of organs 
other  than  subcutaneous  tumours  by  PAT  was  also  performed.  Figure  3.18  shows  an 
example of some of the results achieved at 680nm. The top row is in vivo imaging, with 
panel A being of the flank of a mouse in the area of the spleen and panel B the abdomen of 
a mouse in the area of the liver. A feature in A, to the top left and indicated by the red 
arrow, is potentially the spleen, as it appears to have a unique pattern of PA signal and a 
rounded smooth edge. Visible in B are the major blood vessels running down the length of 
the abdomen from head (left hand side of the image) to tail (right hand side). A structure to 
the right of the vessels is presumed to be intestines (highlighted by the red arrow). The 
bottom row of panel C and D depict ex vivo PA images acquired from excised organs placed 
on the scanner sensor. Highlighted in C is a spleen, heart, lungs and kidney, whilst D is a 
section of excised liver. All organs in C appear homogeneous with regards to PA signal 
pattern and intensity. The excised liver section in D shows fine detail of the liver blood 
vessels that is unlike the in vivo setting. 
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Figure 3.18 PA imaging of other organs 
PA imaging at 680nm of mouse in vivo spleen (A), in vivo abdomen showing liver and intestines 
(B), ex vivo excised lung, heart, kidney and spleen (C), and ex vivo liver section (D) 79 
 
3.4 Discussion 
3.4.1 PA can image structural haemoglobin in vivo 
The natural contrast created for PA imaging in vivo is chromophores in biological tissue; 
within the optical imaging window of around 600nm to 800nm both haemoglobin and 
melanin are the main absorbers in tissue, so these were therefore the first to be assessed 
by the PA scanner system. Figure 3.8 shows the absorption coefficient spectrum in µa from 
a single point at the centre of the sensor. Information about the Z dimension is contained 
in the time series acquired at each scanned point of the sensor; knowing the speed of 
sound the Z distance can be calculated. The photoacoustic signal is proportional to the 
absorbed  energy,  as  it  is  the  time  derivative  of  the  energy.  For  a  one  dimensional 
acquisition such as this, and in a homogenous medium such as the blood samples used, the 
absorbed  energy  follows  an  exponential  decay  with  time.   The  constant  term  of  the 
exponential decay is the absorption coefficient µa, which can be calculated by fitting an 
exponential to the PA signal at different wavelengths to obtain the µa spectrum. Working 
out  the  chromophore  concentration  from  the  observed  absorption  coefficient  is 
challenging  (19);  relating  the  absorption  coefficient  to  the  concentration  of  the 
chromophores is possible, but only if their relative contributions within a composite image 
and  their  individual  absorption  profiles  are  known.  Within  the  blood  sample  used  a 
combination of oxyheamoglobin, deoxyheamoglobin, anticoagulant, and water was present 
in an unknown composition.  The spectra for pure oxyhaemoglobin and deoxyhaemoglobin 
were plotted against the experimental data from known published values (24). 
The ex vivo blood spectrum shown in figure 3.8 lies initially from 600nm to around 660nm 
between  the  expected  absorption  coefficients  for  oxygenated  and  deoxygenated 
haemoglobin,  for  both  of  the  measurements  taken.  This  would  suggest  that  the 
exsanguinated  blood  is  a  mixture  of  both  oxy-  and  deoxy-  haemoglobin.  Above  this 
wavelength however, from around 675nm to 1000nm, the signal is above the expected 
absorption coefficient, although it does track with oxy-haemoglobin, albeit 20-30µa (cm
-1) 
above  the  expected  value.  This  would  suggest  that  there  is  something  else within  the 
sample that is also acting as an optical absorber at these wavelengths. It is possible that 
either  the  anticoagulant  used,  heparin,  or  some  other  element  such  as  red  blood  cell 
aggregations within the sample, could cause an increase in the observed absorbance. It 
may also be an issue of comparing whole blood, with its component of water and plasma as 
well  as  haemoglobin,  to  measurements  of  pure  haemoglobin  that  confounds  the 
comparison. The results also demonstrate the difficulty in obtaining accurate quantitative 80 
 
measures  of  chromophore  concentration  even  from  a  simple  standardised  sample; 
quantitative  PA  imaging  (QPAI)  has  been  of  importance  and  desired  in  the  field  of  PA 
imaging for some time (26). The difficulty in normalising the energy applied to the tissue by 
the laser, and the scattering and absorption of the photons once in the tissue, coupled with 
not knowing how much conversion efficiency from light to heat has been achieved, i.e. the 
Grunesian coefficient, makes accurate measurements of chromophore concentration by PA 
imaging extremely challenging. This difficulty has been noted in the literature previously 
(27).  Straightforward  assumptions  about  PA  images  and  quantitative  measures  of 
absorption  coefficient,  like  presented  here  in  our  ex  vivo  blood  spectrum  assay,  will 
therefore always be an approximation and always semi-quantitative, as has already been 
shown experimentally (28). The observed measurements, however, are within a reasonable 
range of expected values, and given that the structure and architecture of healthy and 
pathological  blood  vessel  networks,  rather  than  any  intrinsically  flawed  measure  of 
functionality/quantitation, are the main interest of this research, it is realistic to assume 
that we have obtained an accurate assessment of the presence of haemoglobin. This is 
further  validated  by  the  in  vivo  measurements  obtained  from  the  palm,  where 
reconstruction  of  acquired  data  showed  a  33.3µm  high  resolution  image  of  superficial 
vascular networks. Of interest here is the finger-print type patterns created in the image 
due to signal in the striated grooves of the skin surface of the palm. The effect of melanin 
on image reconstruction is well known, as it is also a biological chromophore; even when 
no pigmentation is apparent the effect on image reconstruction was pronounced. This was 
either due to inherent small concentrations of melanin, or potentially some other absorber 
contained within the lipids of the skin microstructure. The imaging of melanin however was 
considered to be of further interest. 
3.4.2 Melanin is a strong in vivo optical absorber 
Melanin is known to be a strong optical absorber, and therefore useful as a PA contrast-
providing  agent.  The  effect  of  melanin  on  imaging  with  our  system  was  therefore 
warranted. As seen in fig. 3.10 A, even C57BL/6 mice, with significant amounts of melanin 
pigmentation present in their fur, have little apparent pigment in the skin, and therefore 
imaging of the superficial skin vasculature is possible at 590nm wavelength (fig. 3.10 B), 
where the contribution from haemoglobin is still relatively high (see fig. 3.3). It is even 
possible to  get  a  PA  signal  from  deeper structures  such  as  blood  vessels  (fig. 3.10  C). 
However, as the excitation wavelength increases this signal from melanin becomes too 
strong  to  be  able  to  detect  anything  else;  all  signal  is  generated  by  the  first  few 81 
 
micrometres of the skin layer, and no deeper haemoglobin signal was observed. Melanin is 
therefore very strongly picked up by the UCL PA system, which would not be useful to have 
melanin  present  when  studying  the  tumour  vasculature  as  it  would  provide  too  much 
contrast for the purposes of observing pathophysiology. As a reporter for PA scanning 
however, we have also shown that melanin is a strong optical absorber with this approach. 
This  could  therefore  be  used  to  study  inherent  cases  of  melanin  expression,  such  as 
attempted  by  others  in  the  field  for  melanoma  metastases  in  lymph  nodes  (29)  and 
detection  of  melanomas  via  photoacoustic  microscopy  (30).  The  problem  with  PA 
microscopy has already been discussed, and imaging of melanomas is interesting due to 
their inherent melanin. However, another approach taken at UCL is to use tyrosinase, the 
rate limiting step in melanin production, as a genetic reporter in order to be able to track 
any cell engineered to express the gene (31). As strong as this approach may be, it is not 
applicable to this study of the pathological environment of tumour vasculature in nude 
mice.  82 
 
3.4.3 Blood oxygenation does not affect PA structural images  
As both the tumour vascular environment and the acquired PA images are both susceptible 
to oxygenation status, the effect of the oxygen used during anaesthesia of the animals was 
evaluated. Fig. 3.12 shows no discernible difference in structure or vessel size between 
pure oxygen and medical air breathing even after 60 minutes. A small area highlighted does 
appear to increase slightly in PA contrast within the medical air image, however this is put 
down  to  inherent  variability  within  the  PA  system.  This  is  further  evidence  that  exact 
quantitation of signal is not entirely possible. However, a measure of PA signal amplitude of 
the same vessel throughout the hour acquisition in arbitrary units, taking in to account the 
caveat that the measurements are not fully quantitative, , shows no significant difference 
between inhalational gases. Using a systemic measure of blood oxygenation shows that 
when using oxygen as the inhalational gas for anaesthesia the results are much more stable 
and consistent across animals. It was therefore decided that oxygen would be used for all 
further studies as it did not affect the qualitative nature of the acquired data. 
3.4.4 Subcutaneous tumours can be resolved in vivo with PAT 
The  PAT  can  identify  solid  subcutaneous  tumours  in  vivo  based  on  the  detection  of 
haemoglobin. As can be seen in fig. 3.13 A, the location of the tumour between the skin 
vasculature and the underlying muscle wall clearly shows that it is in the subcutaneous 
space.  Fig.  3.13  B  also  shows  that  the  data  can  be  optically  sectioned  at  any  point, 
providing information on the presence of haemoglobin from the centre of the tumour. This 
is the first time that an all-optical photoacoustic tomography system has imaged tumours 
in  vivo  purely  based  on  the  haemoglobin  signal  from  the  blood  contained  within  the 
vasculature. What is more, as this is a tomography set up, and not a microscopy system 
that can only image a few hundred microns depth, this system was able to encompass the 
entire tumour. The deepest image acquired in this study can be seen in fig. 3.14 with the 
tumour clearly resolved to an imaging depth of 9mm which, considering it is an optical 
based system, is substantially better than other optical modalities. 83 
 
3.4.5 PAT can differentiate different tumour vascular 
pathophysiologies in vivo 
One of the aims of this research was to investigate the different architecture and extent of 
tumour vascularisation, its interaction with the surrounding microenvironment, and how 
this affects progression of the solid tumour. This study demonstrated that imaging with PA 
tomography can distinguish between two very different tumour vascular pathophysiologies 
through imaging of the haemoglobin content of the tumours. SW1222 and LS174T cell lines 
are both colorectal carcinomas, but they present very different states of vascularisation 
when grown as tumours in vivo. The SW1222 xenograft is well differentiated, and forms 
glandular structures when grown in vivo that reflect the colorectal origin of the initial cells. 
They  also  present  a  more  ‘normal’  tissue  organisation  pattern  and  greater  degree  of 
vascularisation.  The  vasculature  is  extensive  throughout  the  tumour,  with  little  or  no 
hypoxic regions or necrotic tissue. The LS174T cells on the other hand form a moderate to 
poorly differentiated xenograft with a disorganised structure, many avascular regions, and 
poor organisation of any existing vasculature (32, 33). Reconstructed PA images of SW1222 
tumours,  as  shown  in  fig.  3.15,  show  a  fine  resolution  of  signal  throughout  the  solid 
tumour, with few areas of non-signal; this would correspond to the tumour being fully 
vascularised  with  small  vessels,  as  the  signal  corresponds  directly  to  the  presence  of 
haemoglobin within the vasculature. In contrast, established LS174T tumours exhibit large 
areas of no signal, indicating large non-vascularised regions of the tumour, with a few large 
irregular vessels intruding in to the tumour mass. These images correspond well to ex vivo 
analysis of these tumour types with reconstructed data from other imaging sources; micro-
CT of SW1222 vascular polymer casts also show SW1222 tumours to have a smaller vessel 
size but more extensive coverage of vasculature, compared to LS174T tumours that have 
fewer and thicker vessels with large avascular regions between them. When compared to 
immunofluorescence  imaging,  the  in  vivo  PA  images  also  compare  favourably.  By 
pimonidazole, Hoechst 33342 and CD31 immunofluorescence, large areas of the LS174T 
tumours are shown to be hypoxic due to lack of blood vessels and perfusion, whilst the 
SW1222 tumours are more extensively covered with perfused blood vessels and have few 
hypoxic regions. This corresponds to the PA data, where areas of non-signal in the LS174T 
tumours are presumed to be avascular and therefore hypoxic or necrotic, whilst SW1222 
tumours have extensive PA contrast. This emphasises the ability of PAT to discriminate 
between two very different tumour vascular pathophysiologies with a simple non-invasive 
and non-ionising in vivo scan, which only requires anaesthetising of the animals during data 
acquisition.  What  is  also  advantageous  with  the  in  vivo  PA  scans  is  that  the 84 
 
microenvironment  surrounding  the  tumour  is  also  imaged.  This  allows  the  effect  of 
angiogenesis within the normal skin vasculature to be imaged, with highlighted vessels 
from the tumour periphery showing the characteristic ‘corkscrew-like’ appearance of co-
opted blood vessels. These are directed towards the growing tumours and are therefore 
tumour-associated,  being  affected  by  tumour  released  growth  factors.  The  ability  to 
longitudinally acquire data is also a major advantage, as the vasculature development can 
be imaged along with the tumour growth. Fig 3.16 demonstrates that the imaging between 
subsequent days is possible, and registration of similar features permits assessment of 
vascular change. Of interest here is how the appearance of the injected cells changes over 
time; at early time points of around a week after cell injection for both models the tumour 
appears  to  have  a  diffuse  pattern,  with  blood  vessels  of  the  normal  skin  vasculature 
showing  signs  of  angiogenic  attraction  towards  the  agglomeration  of  cells.  The  diffuse 
‘fuzzy’ signal from the haemoglobin within the tumour mass is thought to come from blood 
pooling within the nascent tumour that does not have an established vascular architecture. 
At 12 days after the injection of cells the tumours appear to have a completely different PA 
haemoglobin signal from the centre of the tumours; the ‘tumour-associated’ vessels are 
much closer to the edge of the growing solid tumour, and it is postulated that the internal 
structure of tumour vasculature is more developed and defined, and therefore more able 
to handle blood flow, leading to a change in PA pattern. This is somewhat substantiated by 
the appearance of a fine-mesh pattern in the SW1222 tumours and thick intruding vessels 
in the LS174T tumours at day 12. 
Imaging with PA tomography can therefore be used to assess the differing pathological 
vascular states of tumours in vivo, and it is shown to be ideally suited to imaging not only 
the developing tumour but also the vascular development in surrounding tissues. This lends 
itself  to  following  tumour  vascular  development,  differentiating  vascular  architecture 
between tumour types, and assessing therapies that exploit the interaction of the tumour 
vasculature with the surrounding microenvironment. It may also be used to assess tumour 
vascular states of patients and aid in therapy selection. 
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3.4.6 In vivo spectroscopy can provide qualitative data on tumour 
oxygenation 
When  looking  at  the  spectroscopic  ability  of  PA  imaging,  as  in  fig.  3.17,  valuable 
information  regarding  the  tumour  vascular  pathophysiology  can  also  be  acquired.  It  is 
worth restating the caveat that this data can only be semi-quantitative at the present 
moment due to the complex interaction of in vivo chromophores and the conversion of 
light into heat and therefore pressure distribution; however, qualitative data suggests that 
detection of vessel oxygenation status in vivo is possible. As the PA excitation wavelength is 
increased  the  relative  contribution  to  PA  signal  generation  of  oxyhaemoglobin  vs 
deoxyhaemoglobin goes down (fig. 3.3). It is therefore logical to assume that any decrease 
in vessel PA magnitude can be said to be predominantly oxygenated, whilst any increase 
can be assumed to be deoxygenated. In fig. 3.17 the vessels that decrease in signal are 
those tumour associated vessels that are directly linked to the tumour, or are the smallest 
vessels resolved which are assumed to be arterioles and capillaries. The areas that increase 
in signal as the wavelength is increased are the tumour core and a larger deeper lying 
vessel that is assumed to be a vein. Whilst spectrally un-mixing these two signals is difficult, 
the  qualitative  data  suggests  an  important  future  potential  for  PA  imaging  of  tumour 
oxygenation status. This application is further complicated however by the attenuation of 
different chromophores within the tissue at the different wavelengths and the difficulty in 
measuring their relative concentrations. 
3.4.7 Imaging of different organs and locations is difficult with PAT 
Imaging of different locations with PAT would enable a variety of different models to be 
employed, such as orthotopic models of cancer that more accurately reflect the clinical 
situation (34). Of interest to this work was imaging of the liver, as this would allow use of 
the more clinically relevant liver metastatic model of colorectal cancer. Results in fig. 3.18 
however show that PAT imaging of the liver in vivo was not achieved with this system. 
Whilst the surface of the spleen (fig. 3.18 A) can be seen, and also the vasculature of the 
abdomen and to some extent the intestines (fig. 3.18 B), the surface of the liver remained 
undetected. This was potentially due to motion artefacts from respiration or an issue of 
depth penetration of the photons into biological tissue, as the ex vivo data suggests that 
haemoglobin content within the lung, heart, kidney and spleen (fig. 3.18 C), and especially 
the liver (fig. 3.18 D), is sufficient to produce detailed images. However, at the current time 
PAT remains limited to imaging subcutaneous superficial tumours to a depth of ≈1cm.  
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3.5 Summary 
In  this  chapter  it  has  been  shown  that  photoacoustic  tomography  is  ideally  suited  to 
imaging tissue chromophores in vivo. I have demonstrated for the first time in vivo that PAT 
is able to visualise whole subcutaneous tumours with a simple non-invasive, non-ionising 
scan that detects tumour haemoglobin content. Imaging of tumour vasculature and the 
tumour-associated blood vessels in the surrounding microenvironment has been achieved. 
This  included  the  growth  of  typical  angiogenic  structures  from  co-opted  blood  vessels 
towards the tumour. Longitudinal monitoring of tumour progression and development of 
vascular state was also shown. Different vascular pathophysiologies can be detected using 
PAT, highlighting its potential in assisting vascular targeted therapy selection. The ability to 
assess oxygenation in vivo in a qualitative manner has also been demonstrated. All of these 
capabilities point to the use of PAT to evaluate vascular targeted therapies. Whilst PA 
imaging is not currently in clinical use, this will undoubtedly occur in the future, and it is an 
excellent  technique  for  investigating  preclinical  models  with  the  aim  of  increased 
translation of  novel  therapies.  The  subsequent  work  stemming  from  this  research  was 
therefore to evaluate the response to a tumour vasculature targeted drug in preclinical 
models, in order to demonstrate the utility of PAT for the translation of novel therapies. 
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Chapter 4 Photoacoustic imaging of 
vascular targeted therapy 
4.1 Introduction 
The ability of imaging modalities to provide information on the efficacy of drug action has 
been discussed at length in the introduction to this thesis. As established previously, the 
research  presented  in  this  thesis  is  focussed  on  assessing  the  reaction  of  the  tumour 
vascular microenvironment to therapy, so it was therefore decided to limit the scope of the 
work to concentrate on Vascular Disrupting Agents (VDAs), as this class of drug would 
potentially create the largest detectable difference in vascular function. Also previously 
discussed was the action of the combretastatin class of VDAs, and in particular OXi4503. 
Having shown in the previous chapter that PAT is capable of acquiring detailed images of 
the tumour vascular microenvironment and the interaction of this with the surrounding 
normal tissue, this chapter aims to demonstrate the ability of PAT to monitor the effects of 
vascular  targeted  therapy  with  OXi4503.  An  initial  recap  of  techniques  used  to  image 
tumour vasculature after VDA therapy will be described first, followed by a comparison 
with assessment via PAT. The methods used to demonstrate the ability of PAT to monitor 
response to vascular targeted therapy will then be set out and shown within the results 
section of this chapter.  
4.1.1 Assessing response of VDA drug efficacy  
Imaging modalities used to assess the tumour microenvironment were discussed in the 
introduction; what follows is a quick overview of those used to assess response to VDA 
therapy through directly imaging the tumour blood vessels. Other modalities that acquire 
quantitative  measurements  on  the  tumour  microenvironment  though  assessing 
parameters associated with tumour vasculature, such as MRI and bioluminescence, are 
described in the following chapters. 
4.1.1.1 Vessel Angiography with MRI 
Imaging  of  tumour  vasculature  with  MRI  is  possible  by  acquiring  Magnetic  Resonance 
Angiography (MRA) images. MRA can be used to resolve the large vessels of the tumour 
microenvironment  macroscopically,  allowing  visualisation  of  the  tumour-associated 
vasculature (1). This can be either based on ‘Time-of-flight’ MRA (TOF-MRA) to measure 
vessel  tortuosity  (2)  or  through  injection  of  exogenous  contrast  agents  (3,  4).  These 
approaches are able to image vascular morphology, but have disadvantages and certain 90 
 
limitations when imaging tumour microvasculature. With TOF-MRA small tumour blood 
vessels with a slow rate of blood perfusion will not be readily visualised, as TOF-MRA is a 
flow dependent technique that is insensitive to slow rates of blood flow  (5). Contrast- 
enhanced MRA has the added confounding factor of administration of a contrast agent. 
This is typically gadolinium, which quickly compartmentalises in the interstitial space due to 
a short intravascular half-life, making it ill-suited to high resolution MRA. Other contrast 
agents, such as iron oxide nanoparticles (6), can provide resolution of the microvasculature 
to around 100µm, but are still dependent on exogenous contrast and flow parameters of 
the tumour microenvironment. 
Based on MRA, parameters of the tumour microvasculature can be identified and classified, 
such  as  an  fractional  volume of  blood  content,  index  of vessel  size  (7),  tumour  vessel 
density (8), and vascular permeability (9, 10). These are generally considered to be vascular 
associated parameters however, and are discussed in more depth in the following chapter. 
The main disadvantage of these approaches is the lack of three-dimensional information 
regarding the architectural arrangement of tumour blood vessels. 
4.1.1.2 Computed Tomography Angiography 
Tumour blood vessel angiography can also be performed using Dynamic Contrast-Enhanced 
Computed Tomography (DCE-CT). As with MRA the microvascular structure of the tumour 
blood vessel network is not defined, but physiological parameters of regional tumour blood 
flow,  mean  blood  transit  time,  and  permeability  of  the  vessel  surface  area  can  all  be 
measured  using  DCE-CT  (11).  This  is  possible  due  to  analysis  of  the  temporal  changes 
observed in a succession of images acquired after administration of an exogenous contrast 
agent, typically an iodinated contrast material. DCE-CT has been shown to be reproducible 
in peripheral tumours, compared to various reference measures of blood flow, in both 
preclinical  models  and  human  studies  (12-14),  although  three-dimensional  vessel 
architecture of the tumour-associated vasculature is not observed. CT also requires the use 
of ionising radiation, so although DCE-CT can be used to assess vascular targeted therapy 
(15), the accumulation of radiation damage due to repeated measurements is a potential 
risk to the patient. The use of exogenous contrast agents also has the potential of causing 
nephrotoxicity. 
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4.1.1.3 Ultrasound  
Contrast  enhanced  US  (CEUS)  imaging,  using  microbubbles  as  a  contrast  agent,  is  a 
comparatively inexpensive imaging modality that can provide information on the vascular 
structure  of  tissues  and  potentially  angiogenesis  within  tumours  (16).  CEUS  has  been 
shown to provide quantitative estimation of tumour blood flow in response to treatment 
with  VDAs  (17,  18),  however  only  regional  enhancements  were  observed  with  no  link 
between structure and function of the vascular disruption. 
4.1.2 Potential of PAT for assessing vascular response to treatment 
The ability of PAT to assess the microvasculature of tumours in vivo was demonstrated in 
the previous chapter. It follows that PAT should be able to image the response of these 
tumours to vascular disruption with VDAs over time. Other modalities are able to image the 
tumour vascular microenvironment, as described above, but all have certain drawbacks 
that make them less than ideal for observing the effect of the tumour microvasculature and 
it’s interaction with the surrounding tissue following treatment. The main disadvantage of 
these modalities is a lack of resolution with regards to the vasculature and an inability to 
resolve  three-dimensional  tumour  vascular  networks  in  vivo  without  the  addition  of 
exogenous  contrast.  This  chapter  describes  the  use  of  PAT  to  assess  the  tumour 
microvasculature and associated feeding vessels following treatment with OXi4503, with 
the aim of providing greater detail on vessel response, and demonstrating the utility of this 
entirely non-invasive technique for assessing vascular targeted treatment. 
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4.2 Methods 
All PAT was performed on the system previously described in chapter 3. Experiments were 
performed  at  a  number  of  excitation  wavelengths,  however  those  represented  in  this 
chapter are all at 680nm, as this wavelength afforded the greatest tissue penetration for PA 
imaging. Female CD1 nu/nu mice were acquired through UCL BSU services, transferred to 
the CABI, and subcutaneous tumours established via injection of either SW1222 or LS174T 
colorectal cells. As these experiments were longitudinal in nature, animals were kept in 
IVCs within CABI for the duration of the experiments under the same monitored conditions 
as outlined in chapter 2.  
4.2.1 Drug treatment 
The VDA OXi4503 was a kind gift from Dr David Chaplin (OXiGENE, San Francisco, USA). For 
dosing, a stock concentration of 4mg/ml was prepared in sterile saline and vortexed for 2 
minutes. The drug was readily soluble, with no particulates present following preparation. 
Drug solutions were made fresh for each session, kept in the dark in light tight containers 
and used within an hour of preparation.  Animals were injected i.v. at a ratio of 10ml/kg for 
a total dose of 40mg/kg. If lower doses were required the stock concentration was diluted 
accordingly, with rate of i.v. dose kept at 10ml/kg and therefore an equivalent volume, 
dependent on animal weight, injected. Sham doses consisted of i.v. sterile saline injected at 
10ml/kg. For longitudinal experiments, where PAT data was acquired on subsequent days, 
animals were placed in a heated recovery box following dosing and monitored for adverse 
effects for 15 minutes before returning to IVCs. At the end of the experiment animals were 
terminated via a schedule I method and tumours excised for histological assessment as 
previously described. The experimental design for assessing response to VDA therapy can 
be found in the following subsections. 
4.2.2 Acute response to vascular disruption 
To observe with PAT the immediate effect on tumour blood perfusion due to vascular 
disruption with OXi4503, n=2 SW1222 and n=2 LS174T s.c. tumours were dosed i.v. with 
40mg/kg  of  the  VDA,  and  PA  images  acquired  at  1hr  post  dose.  Further  SW1222 
subcutaneous tumours (n=4) were also dosed in the same manner and imaged at 6hr post 
dose. Acquired PA data were reconstructed, and changes in signal and structure of tumour 
blood vessels analysed. 93 
 
 
4.2.3 Tumour blood vessel destruction 
In order to extend our observations on the effect of blood vessel destruction caused by 
VDA  treatment  a  longitudinal  experiment  following  the  same  tumours  was  devised. 
SW1222 s.c. tumours (n=4) and LS174T s.c. tumours (n=2) were used for this study. Animals 
were imaged at baseline and then dosed with 40mg/kg of OXi4503 (n=2 for both SW1222 
and LS174T tumours) or sham dosed with saline (n=2 SW1222). Subsequent PAT imaging 
was  performed  at  24hr  and  48hr  following  dosing.  Identification  of  blood  vessels  was 
achieved in a qualitative manner through interrogation of reconstructed data sets. Initial 
reconstruction of PA data was performed in order to ascertain that changes in induced 
signal had occurred, at which point (48hrs) the mice were killed and tumours excised. 
Histological assessment of tumour structure and viability via H&E staining was performed. 
Perfusion  and  distribution  of  tumour  blood  vessels  were  also  assessed  via 
immunofluorescence.  
4.2.4 Vessel regrowth following vascular disruption 
Having established the utility of PAT to assess initial vascular disruption in response to VDA 
treatment, the ability to monitor subsequent behaviour of the tumour blood vessels was 
then studied. N=4 SW1222 and n=4 LS174T s.c. tumours were dosed i.v. with 40mg/kg of 
OXi4503 and imaged by PAT every two to three days after dosing. PA data was acquired up 
to day 16 following the dose of VDA, with caliper measurements for tumour volume also 
acquired over the same time course. At day 16 animals were killed via a schedule I method 
and tumours excised for histology. Analysis of PA data was performed to include PA signal 
intensity on a voxel by voxel basis across the tumour region. The tumour was selected as a 
region of interest (ROI) through a combined manual and automated process. Broad tumour 
regions were first segmented using reconstruction software Amira 5.4.0, followed by a 
threshold limit of the data set. A background measure of signal intensity was acquired, with 
a subjective measure of 10% used to reject any voxels within the tumour ROI containing PA 
signal above this, thereby acquiring volume measurements of internal tumour areas of 
signal  void.  For  a  positive  measure  of PA  signal,  an  arbitrary  blood  vessel  outside  the 
tumour was selected in each image at a depth of 1-1.5mm. This provided a PA signal 
intensity measure for selection of tumour ROI voxels, which was then plotted against the 
total tumour volume as measured by caliper measurements and the extent of signal void 
within the tumour. 94 
 
4.2.5 PAT for dose response of VDAs 
The applicability of PAT to discern the effects of different doses of VDA on the level of 
vascular disruption following treatment was then investigated. For this, n=6 SW1222 and 
n=4  LS174T  s.c.  tumours  were  dosed  i.v.  with  10mg/kg  of  OXi4503  and  a  further  n=6 
SW1222 and n=4 LS174T were dosed i.v. with 1mg/kg. As with the study of vessel regrowth, 
these tumours were all imaged every two to three days until 16 days after treatment or 
until schedule I termination due to licence regulations. This data was compared to that 
previously acquired for 40mg/kg OXi4503. Caliper measurements of tumour volume, and 
PA analysis of voxel signal intensity, were also compared to the maximum dose of 40mg/kg. 
For histological assessment of vascular disruption, n=2 SW1222 s.c. tumours dosed with 
10mg/kg and n=2 dosed with 1mg/kg OXi4503 were excised at 48hr after dosing. These 
tumour samples were assessed for markers of perfusion and extent of remaining blood 
vessel  network  by  immunofluorescence,  and  tissue  morphology  by  H&E.  These  images 
were  then  compared  to  previously  acquired  analysis  of  48hr  post  dose  with  40mg/kg 
OXi4503 in SW1222 and LS174T, and with the sham dose of saline in SW1222 tumours 
(section 4.2.2). 
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4.3 Results 
4.3.1 Acute Assessment of vascular disruption 
Visualisation of the acute effects of vascular disruption with OXi4503 can be seen in Figure 
4.1. Each panel is 14mm x 14mm in the XY direction, with the Z direction being a maximum 
intensity projection (MIP) of the acquired data. The first row depicts the entire Z-stack 
within  the  MIP,  whilst  the  second  row  has  had  the  top  0.5mm  layer  removed  and  is 
therefore representative of PA signal from the centre of the tumour mass. The first column 
shows an LS174T tumour at 1hr post dose, the second shows an SW1222 at 1hr post dose, 
and the third shows the SW1222 at 6hr after dosing. All figures are representative of the 
specific tumour type and time point, as each effect was noted for all tumours imaged. All 
the images at 1hr post OXi4503 show typical PAT results with no obvious effect of vascular 
disruption, comparable to untreated tumours. At 6hr post treatment in the SW1222 there 
already  appears  to  be  an  area  with  some  loss  of  signal  at  the  centre  of  the  tumour, 
highlighted by the red arrow.  
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Figure 4.1 Acute effect of vascular disruption with OXi4503 by PAT  
Representative PAT images of LS174T (n=2) and SW1222 (n=6) s.c. tumours following 40mg/kg of 
the VDA OXi4503 i.v. Each panel is 14x14mm XY and MIP in the Z direction. The first row is of the 
entire Z-stack whilst the second row has had the first 0.5mm removed.  96 
 
4.3.2 Response to OXi4503 
The response to vascular disruption with 40mg/kg OXi4503 over 24hr-48hr, as assessed by 
PAT, can be seen in figure 4.2 (sham dose), fig. 4.3 (SW1222 tumours) and fig. 4.5 (LS174T 
tumours). Each panel is an MIP of the acquired and reconstructed PA data. The first row 
depicts a 14x14mm panel in the XY and 6mm in the Y direction at baseline, at 24 and 48 
hours after dosing. The large circular area of signal corresponds to the tumour mass, and is 
imaged  in  the  same  location  at  each  time  point  as  confirmed  by  the  similarity  of  the 
surrounding vascular features. No change in signal intensity or distribution is seen in figure 
4.2 (sham dose) over the 48 hour time-course. The second row is the same data set but 
with the initial 1.4mm of data removed, showing the PA signal corresponding to the blood 
vessels within the tumour. Again, no difference in appearance, either of signal intensity or 
distribution, is seen. The third row shows the tumour from the XZ direction in a 14x6mm 
panel, with the whole 14mm of the Y direction shown as an MIP. This angle clearly shows 
the depth imaging encompassing the whole subcutaneous tumour, which again shows no 
difference in signal across the 48hrs, confirming the presence of vessels throughout the 
tumour. Figure 4.3 (SW1222 tumours) shows the same layout as described for fig. 4.2, 
although in this case only a 1mm top slice of data has been removed in order to observe 
the internal tumour PA signal. At baseline acquisition the tumour is clearly visible in the X 
and Y directions as a spherical mass at the centre of the image, with surrounding superficial 
skin vasculature also clearly defined. In the Y direction the whole tumour in encompassed 
by the PAT image and can be seen to be protruding slightly from the level of the skin 
surface. The signal from the centre of the tumour is finely speckled and present across the 
entire tumour mass, as previously observed with this tumour type. At 24hr and 48hr post 
VDA  the  signal  from  the  centre  of  the  tumour  location,  corresponding  to  the  internal 
tumour blood vessels, is completely absent, as can be seen from the second row of images 
that have the top removed. Signal intensity in this region has changed from high and evenly 
spread across the tumour to a large area of no signal. The area around the tumour location 
has increased in PA signal, and shows a large band of diffuse signal for a few millimetres 
surrounding the tumour. This is also seen in the first row of images where the entire Z-
stack is depicted. Although the tumour location is visible, the appearance has changed from 
a fine speckle pattern to a diffuse patchy signal. This PA signal is from the remaining outer 
rim of the tumour, which inhibits clear visualisation of the more central, signal-void area. 
This is observed in the depth imaging in the third row, where the lack of PA signal can be 
seen in the centre of the tumour, but with PA signal present both above and beneath the 
tumour.  97 
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Figure 4.2 Initial response to saline sham dose  
Representative PAT images of SW1222 s.c. tumours following 10ml/kg of saline sham dose i.v.  
(n=2). The first and second rows are 14x14mm in the XY and 0-6mm and 1.4-6mm in the Y 
direction MIPs, whilst the third row is 14x6mm in the XZ with 14mm in the Y as an MIP. Each row 
shows baseline images followed by 24 and 48hr post dose.  98 
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Figure 4.3 Initial response to vascular disruption – SW1222  
Representative PAT images of SW1222 s.c. tumours following 40mg/kg of OXi4503 i.v. (n=4). The 
first and second rows are 14x14mm in the XY and 0-6mm and 1-6mm in the Y direction MIPs, 
whilst the third row is 14x6mm in the XZ with 14mm in the Y as an MIP. Each row shows baseline 
images followed by 24 and 48hr post dose.  99 
 
 
 
 
 
 
 
Histological  analysis  of  tumour  structure  by  Haematoxylin  and  Eosin  staining  at  48hr 
following treatment for these SW1222 tumours can be seen in Figure 4.4. Panel A shows a 
whole tumour cross section at 10x magnification. A darker edge can be seen around the 
tumour section, which when seen at 20x magnification (panel B) shows a rim of viable cells 
at the periphery of the tumour. The centre of the tumour section, also seen highlighted in 
panel C, shows cells that have rounded up, lost cell contact and typical glandular structure. 
Also present is evidence of cell breakdown and cellular debris in the form of non-specific 
protein staining in the intercellular spaces. Observed towards the edge of the tumour, 
either just inside or associated with the surviving rim of cells, are red blood cells either 
A  B 
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D 
Figure 4.4 Histology of initial response – SW1222 
Haematoxylin and Eosin staining of the n=4 SW1222 tumours used for initial response to vascular 
disruption by PAT was performed, an example cross section of which can be seen in panel A (10x 
magnification). A highlighted section of the surviving rim of tumour cells can be seen in panel B 
(20x). Panel C shows the central tumour necrosis and cellular debris present within the tumour 
core (20x). Panel D shows evidence of red blood cells within the tumour surviving rim and 
periphery of the tumour necrotic area. 100 
 
within vessels or pooled within the intercellular space. This can be seen mainly in the upper 
half of panel A and also highlighted in panel D. 
The PAT data for LS174T tumours can be seen in figure 4.5. The layout is as previously 
stated,  with  0.75mm  removed  from  the  surface  data  in  the  second  row.  At  baseline 
imaging the tumour is visible as the spherical mass of PA signal intensity at the centre of 
the  image.  Following  dosing  with  OXi4503  the  PA  signal  within  the  tumour  mass  is 
disrupted, with areas of no signal appearing at 24 and 48hours. This drop in signal is more 
pronounced  at 48  hours, where  a  ‘rim’  effect  can  be  observed,  with  diffuse  PA  signal 
appearing around the tumour location. This is not as marked an effect as seen in the 
SW1222 tumours, however, with some PA signal apparently still present within the centre 
of the tumour mass. The change in internal PA signal pattern is again obscured by signal 
from the surviving outer rim, and therefore although present it is not easily defined in the 
entire Z-stack MIP (first row) or depth imaging (third row) images. Also apparent is the 
survival of a few large feeding vessels close to the periphery of the tumour and surviving 
tumour rim. Histological analysis of tumour structure by Haematoxylin and Eosin staining at 
48hr following treatment for these LS174T tumours can be seen in Figure 4.6. Panel A 
shows a whole tumour cross section at 10x magnification. Certain areas appear unaffected 
by treatment with OXi4503, in that they appear well stained and organised, as highlighted 
in panel B. Other areas are lighter in staining, and upon closer inspection (panel C, 20x 
magnification) have lost structure and cell contact, cells have rounded up, and a necrotic 
appearance is apparent. This is similar to the observed effect in SW1222 tumours, however 
the extent of tumour necrosis is not the whole centre of the tumour, as with SW1222 
tumours, but more patchy and spread out across the tumour cross section. Once again, red 
blood cells can be seen, as highlighted in panel D, at the edge of these necrotic areas of 
tumour, within the surviving tumour tissue, or outside of the tumour within normal skin 
structures. 
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Figure 4.5 Initial response to vascular disruption – LS174T  
Representative PAT images of LS174T s.c. tumours following 40mg/kg of OXi4503 i.v. (n=4). The 
first and second rows are 14x14mm in the XY and 0-6mm and 1-6mm in the Y direction MIPs, 
whilst the third row is 14x6mm in the XZ with 14mm in the Y as an MIP. Each row shows baseline 
images followed by 24 and 48hr post dose.  102 
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Figure 4.6 Histology of initial response – LS174T 
Haematoxylin and Eosin staining of the n=4 LS174T tumours used for initial response to vascular 
disruption by PAT was performed, an example cross section of which can be seen in panel A (10x 
magnification). A highlighted section of surviving tumour tissue can be seen in panel B (20x). 
Panel C shows the necrosis and cellular debris that has occurred within areas of the tumour 
(20x). Panel D shows evidence of red blood cells within the tumour surviving tissue and 
periphery of the tumour necrotic area. 103 
 
4.3.3 Vessel regrowth following treatment 
Results  from  the  longitudinal  experiment  on  vessel  regrowth  can  be  observed  in  the 
representative  tumours  shown  in  figure  4.7  (SW1222)  and  figure  4.8  (LS174T).  These 
panels are 14x14mm MIP in the XY direction and 1-6mm and 0.75-6mm in the Z direction 
respectively, acquired at 680nm excitation wavelength, and at the time points indicated 
above each panel. The SW1222 tumours all initially exhibited the central lack of signal after 
dosing with 40mg/kg OXi4503. However, over the 16 days of the experiment this area of 
signal void became smaller, as signal returned to the centre of the tumour from the outside 
edge of the tumour mass. The tumour regrowth appeared similar to the baseline image, 
but with a small necrotic central area remaining. The response of the LS174T tumours 
appears similar to the initial results of dosing with OXi4503 over 48 hours; signal pattern is 
disrupted within the tumour interior, but with smaller areas devoid of signal compared 
with SW1222, and a lesser degree of tumour periphery enhancement. Tumour recovery 
over time is also not as clear as in the SW1222 tumours, with overall pattern of PA signal 
distribution within the LS174T tumours not returning to baseline-like appearance within 
the  16  days.  Signal  from  the  ‘void’  areas  does  return  to  some  extent,  albeit  with  an 
irregular distribution, and appears to have returned to most areas of the tumour at around 
10 days post dose, but with fewer vessels and a different pattern of distribution. This area 
of signal void, for both SW1222 and LS174T tumours, was plotted against measures of 
‘haemoglobin positive’ tumour voxels and tumour volume, as can be seen in figure 4.9. The 
blue line shows average total tumour volume and the red line shows average total area of 
internal tumour without signal, shown as a percentage of the baseline measurement at day 
0 measured on the left side Y axis, with error bars denoting standard error of the mean. 
Positive tumour voxels, as a measure of tumour haemoglobin within vessels, expressed as 
percentage of total tumour ROI voxels, can be seen in the black line measured on the right 
side Y axis. As can be seen, for the SW1222 tumours outward growth of the tumours does 
not occur whilst the area of internal signal void is still present. An initial decrease in tumour 
volume is accompanied by an increase in the internal areas of signal void and a decrease of 
percentage  positive  ‘haemoglobin’  voxels.  Towards  the  end  of  this  timeframe  all 
parameters appear to be returning to baseline values, with volume increasing and positive 
voxels returning to the tumour core. Areas of void remain high but appear to be on a 
downward trend. For the LS174T tumours growth of the tumours starts at around 10 days 
post dose, although the voxels of positive ‘haemoglobin’ signal are still below baseline 104 
 
values. Areas of PA signal void appear to initially decrease and stay at or below baseline 
values for the duration of the experiment.  
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Figure 4.7 Vessel regrowth following vascular disruption – SW1222  
Representative PAT images of SW1222 s.c. tumours following 40mg/kg of OXi4503 i.v. (n=6). 
Each panel is 14x14mm in the XY and 1-6mm in the Y direction MIPs reconstructed from PAT 
data acquisition. Time points are indicated above each panel, from baseline to 16 days after 
administration of dose. 105 
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Figure 4.8 Vessel regrowth following vascular disruption – LS174T  
Representative PAT images of LS174T s.c. tumours following 40mg/kg of OXi4503 i.v. (n=6). Each 
panel is 14x14mm in the XY and 0.75-6mm in the Y direction MIPs reconstructed from PAT data 
acquisition.  Time  points  are  indicated  above  each  panel,  from  baseline  to  16  days  after 
administration of dose. 106 
 
 
 
 
 
 
 
   
Figure 4.9 Comparison of tumour volume vs PA signal intensity 
Graph A shows data for the SW1222 tumours and graph B shows data for the LS174T tumours 
(n=4 respectively). Tumour volume assessed by caliper measurement is shown across the n=4 
tumours as percentage of baseline volume (Blue). The measure of PA signal intensity void within 
the tumour also as a measure of baseline is shown in red (left side axis). The percentage of 
tumour ROI at or above a reference PA signal measurement made in a superficial blood vessel is 
shown by the black line (right side axis). Error bars denote standard error of the mean.   
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4.3.4 Effect of different OXi4503 doses can be observed in vivo by 
PAT  
The  effect  of  different  degrees  of  vascular  disruption  on  the  signal  intensity  and 
distribution of PAT images caused by different concentrations of OXi4503, at 48hr post 
dose, can be seen in figure 4.10 for SW1222 tumours and figure 4.11 for LS174T tumours. 
The top row in each figure (A) shows an example PAT MIP images (14x14mm in the X and Y) 
for baseline, sham dose (for SW1222 only), and 1mg/kg, 10mg/kg, and 40mg/kg OXi4503. 
Each PAT image was acquired at 680nm and has had the top 1mm of the Z-stack removed. 
Voxel analysis of the tumour region was performed by manual segmentation, with intensity 
values for all voxels within this region displayed on a histogram of grey-scale intensity (0-
256). An example histogram for the PAT image shown is presented in the second row. This 
shows a marked reduction in range of values within the tumour region for the 40mg/kg 
group (C) when compared to sham dose values (B). Average percentage of the tumour ROI 
that  contained  voxels  of  an  intensity  equal  to  or  above  the  positive  ‘haemoglobin’ 
reference measurement across the whole groups can therefore be measured; this is shown 
by the graph D of figures 4.10 and 4.11, with the error bars denoting the standard error of 
the mean. These graphs show the average sham-dose value to be 8.5±0.8% for SW1222, 
which is consistent with baseline values measured of 8.3±1.25%. Baseline values for LS174T 
tumours were 10.25±1.75% All treated groups are lower in value in a dose dependent 
manner, with the 40mg/kg groups being 0.11±0.1%  and 0.15±0.3% for SW1222 and LS174T 
tumours respectively, the 10mg/kg groups being 2.5±0.5% and 2.89±0.6%, and the 1mg/kg 
groups being 8.17±1% and 8.65±0.95%.  
Histological analysis of these tumours for all dose levels in the SW1222 tumour can be seen 
in figure 4.12. The first column shows haematoxylin and eosin staining for basic tissue 
morphology.  The  sham  dose  tumour  is  composed  of  viable  tissue  which  has  a  highly 
nucleated  and  densely  packed  structure.  The  1mg/kg  tumour  consists  of  two  distinct 
tumour lobules that resemble the untreated tumour. The 10mg/kg and 40mg/kg groups  
resemble each other, both possessing a tumour core that has less nuclear staining from 
haematoxylin, typical of areas of induced necrosis, and an outer capsule of connective 
tissue. However, a thin rim of viable tumour tissue around the necrosis can be seen, which 
appears to be slightly thicker for the 10mg/kg than the 40mg/kg dose. The second column 
shows dual fluorescence microscopy, with perfusion in blue (Hoechst 33342) and blood 
vessels  in  red  (CD31).  These  channels  are  depicted  separately  in  the  subsequent  two 
columns respectively. Within the tumour region in the sham and 1mg/kg groups both blood 108 
 
vessels and perfusion are present across the tumour, indicating the presence of  viable 
tissue and corresponding well with the H&E stain. In the 10mg/kg and 40mg/kg groups the 
central tumour region appears as a void of signal, indicating a lack of blood vessels and 
perfusion in the core, albeit with perfused blood vessels around the tumour periphery and 
in the connective tissue. 
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Figure 4.12 Histological assessment of different doses of OXi4503 
Assessment of the tumour microenvironment by histological staining and immunofluorescence; 
the first column shows haematoxylin and eosin staining for tissue morphology representative of 
SW1222 tumours after dosing with saline control or 1mg/kg, 10mg/kg and 40mg/kg of OXi4503. 
The same tumours can be seen in column 2, which shows combined immunofluorescence for 
perfusion by Hoechst 33342 in blue, and blood vessel by CD31 in red. These channels are shown 
separately in columns 3 and respectively. 
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4.3.5 PA signal intensity corresponds to regrowth of tumours 
Measurement of tumour volume across the dose response groups can be seen in figure 
4.13. Graph A shows the tumour growth data for the SW1222 tumours and graph B the 
growth data for the LS174T tumours. Volume is expressed as the average percentage of 
baseline  volume,  with  error  bars  denoting  standard  error.  In  each  graph  the  40mg/kg 
OXi4503 is depicted by the blue line, the 10mg/kg group by the red line, the 1mg/kg group 
by the green line, and a control group, measured from n = 8 size matched tumours of each 
type over the same time frame, shown in purple. A typical dose response curve can be seen 
in both tumour types, with the 40mg/kg dose having the greatest effect on tumour volume, 
followed by the 10mg/kg and finally the 1mg/kg groups. The 1mg/kg group for both SW122 
and LS174T tumours is similar to the control group. Using 200% of initial tumour volume as 
a measure of doubling time (so as to be confident of actual tumour growth as opposed to 
measurement inaccuracy or tumour swelling/blood pooling due to treatment) the graph 
shows that the SW1222 40mg/kg group does not double within the 16 day timeframe, the 
10mg/kg group takes 13.9 days and the 1mg/kg group takes 3.8 days. Doubling time for the 
SW1222 control group was measured as 3.9 days. For the LS174T tumours doubling time 
was calculated as 12.2 days for the 40mg/kg group, 6.7 days for the 10mg/kg group, 3.5 
days for the 1mg/kg group, and 4.3 days for the control group. Using the PA images to 
calculate return of increased signal intensity to tumour voxels, as shown in figure 4.10 and 
4.11,  the  time  taken  for  tumours  to  return  to  a  ‘normal’  proportion  of  ‘haemoglobin 
positive’ PA signal across the tumour can be determined. This was calculated as 65% of 
baseline  values  for  the  SW1222  10mg/kg  group  at  day  13,  a  time  point  at  which  the 
tumours are re-growing by caliper measurement. For the 1mg/kg group the values at 48 
hours  post  VDA  are  98.3%  of  baseline  values,  with  the  growth  of  the  tumour  almost 
matching control volumes. For the LS174T tumours, at time points where the tumours 
appear to be re-growing, this is 51.9% at day 10 for the 40mg/kg group, 70.8% at day 10 for 
the 10mg/kg group, and 84.4% at 48 hours for the 1mg/kg group. 
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Figure 4.13 Dose response to OXi4503 compared to PA signal 
Tumour  volume  calculated  by  caliper  measurement  is  shown  for  control  (n=6,  purple)  and 
40mg/kg (blue), 10mg/kg (red) and 1mg/kg (green) of OXi4503 for both SW1222 (A) and LS174T 
(B) (n=4 for each group). Using PA signal intensity as a measure of internal tumour blood vessel 
structure, the point at which tumour return to a ‘normal’ growth can be linked to the PA tumour 
expression, as highlighted by the star above each group. 
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4.4 Discussion  
4.4.1 Destruction of tumour associated vasculature can be assessed 
by PAT 
It is well known that OXi4503 causes tumour specific destruction of blood vessels (19, 20). 
Studies that have shown this pre-clinically however are invasive, may alter the tumour 
microenvironment  due  to  experimental  procedure,  and  may  not  accurately  reflect  the 
tumour  blood  vessel  three  dimensional  networks,  associated  feeding  vessels  and 
interaction with its surroundings. Invasive studies are unable to image developing tumours 
over a significant period of time, unlike PAT. In this study, cancer cells were subcutaneously 
injected and left to develop as solid primary tumours, a model of disease that is a well-
established animal representation of cancer. These models are often difficult to translate 
into clinical use, so correct interpretation of model data is crucial (21, 22). Another caveat 
is that this tumour location is ectopic, and therefore the tumour-surrounding milieu does 
not reflect the microenvironment in which the tumour would originally develop; however, 
the progression of neo-angiogenesis and the growth of the internal tumour vasculature is 
representative of the clinical situation. Previous work has shown that VDAs (23-26), and 
specifically  OXi4503  (27),  start  to  affect  the  structure  and  viability  of  tumour  vascular 
endothelial cells within 1-4 hours of treatment, and cause blood vessel destruction and 
tumour  necrosis  from  6-24  hours  onwards.  In  order  to  observe  this  with  PAT,  a  dose 
sufficient  to  cause  massive  central  destruction  of  tumour  blood  vessels  was  used.  At 
40mg/kg, the dose of OXi4503 is higher than the 25mg/kg required to cause a reduction of 
90% in tumour perfusion in KHT sarcomas (28), and greater than the ED50 for tumour 
vessel shutdown of 3mg/kg in MDA-MB-231 adenocarcinomas and MHEC5-T hemangio-
endotheliomas (29). This dose of 40mg/kg was also close to the dose of 50mg/kg shown to 
be effective at reducing functional vascular volume by over 80% (19), and was therefore 
deemed sufficient to cause maximum effect within the colorectal tumours tested. Initial 
response to this dose at 1 hour for both SW1222 and LS174T, as seen in figure 4.1, did not 
appear to cause any change in PA signal or image quality. If the effect of OXi4503 within 
this hour was to slow and/or stop the flow of blood within the tumour blood vessels, as is 
the mechanism of action of VDAs (30), with no physical destruction of blood vessels, then 
the  haemoglobin  still  within  the  blood  located  in  the  vessels  would  be  sufficient  to 
maintain PA signal. A real-time video assessment of blood flow would be able to distinguish 
this; however, as currently each PA image requires around 8 minutes to acquire the full 
data  set,  any  changes  in  flow  are  not  detected  by  this  system.  Other  PA  imaging 114 
 
approaches using ultrasound detection arrays have recently reported real-time imaging 
capabilities (31) although, as is the case with piezoelectric detectors, the image quality and 
resolution is not sufficient for imaging subcutaneous tumours in great detail. The ability to 
image in real time on this all optical system would therefore be a major advantage, and 
studies are underway to improve this aspect of the UCL PA scanner in order to image blood 
flow within tissue (32).  
At 6 hours post dosing, when vessel destruction is expected, a slight change in PA signal 
was  noted  in  the  SW1222  tumours.  While  this  is  likely  to  indicate  the onset  of  vessel 
destruction, the effect was variable and not sufficient to confidently state it was the result 
of VDA action. However, at the later times of 24 and 48 hours post injection (figures 4.3 
and 4.5), the effect of vascular disruption with OXi4503 was clearly apparent; the signal 
from the internal section of the tumour has completely disappeared, compared to the 
saline sham dose that has maintained signal intensity. The effect was most pronounced in 
the  SW1222  tumours,  which  showed  a  complete  void  of  signal,  correlating  to  a  total 
destruction of tumour blood vessels. A high intensity signal from the tumour periphery is 
also present, which is thought to be due to a combination of factors: firstly, vessels in the 
remaining viable tumour rim; secondly, blood destined for the tumour no longer having a 
vascular structure through which to diffuse and simply pooling at the tumour edge; and 
thirdly,  the  haemoglobin  from  the  destroyed  central  blood  vessels  being  pushed  out 
towards the rim of the necrotic area due to high intra-tumour pressure. This is verified by 
the histological assessment of these tumours in figures 4.4 and 4.6; in the SW1222 tumours 
a clear boundary is set by the rim of surviving cells around the tumour cross section. Inside 
of  this  the  tumour  is  necrotic,  with  a  loss  of  structure,  rounding  of  cells,  and  cellular 
breakdown products. Any red blood cells are either within vessels of the normal tissue or 
very close to the surviving rim. Of note is the fact that no PAT signal from the destroyed 
tumour blood vessels remains in the tumour core which is consistent with the histological 
analysis, and therefore the haemoglobin must have either been removed or shifted to the 
tumour edge, even though previous work (33) has shown remnants of endothelial cells to 
exist within the necrotic area. This increased presence of haemoglobin and supposed blood 
around  the  periphery  of  the  tumour  is  consistent  with  the  known  effect  of  a  viable 
surviving rim following treatment with OXi4503 (34).The change in PA signal within LS174T 
tumours also shows a decrease in signal from within the tumour and areas of signal void, 
however the effect is much less pronounced than in the SW1222 tumours. Histology shows 
that the necrotic areas appear in a patchy manner, and the obvious central necrosis in the 115 
 
SW1222 tumours is not replicated. Necrotic areas do appear however, and the red blood 
cell distribution around the periphery of these necrotic areas is similar to the SW1222 
tumours. A peripheral rim effect is however still present in the PAT data, demonstrating 
this destruction of internal blood vessels and the pooling of blood at the tumour edge. The 
difference in response also reflects the ability of PAT to distinguish between two tumours 
with differing vascular pathophysiologies, and also different levels of response within the 
same tumour, which may both be clinically translatable as prognostic factors for response 
to  vascular  targeted  therapies.  This  aspect of  research  would  need  to  be examined  in 
greater depth in future studies. 
4.4.2 Internal tumour vasculature is required for outward growth of 
the tumour 
Longitudinal studies following the regrowth of internal blood vessels, seen up to day 16 
following the highest dose of 40mg/kg in figures 4.7 and 4.8 for qualitative assessment of 
response in both SW1222 and LS174T respectively, and in figure 4.9 for a semi-quantitative 
assessment of lack of internal PA signal and return of high-signal voxels compared to actual 
tumour volume, provide novel insights in to the effect of targeting the tumour vasculature 
with VDA treatment. Firstly, the tumours are not completely eradicated by a single dose; 
whilst this is a known effect of VDA treatment, and the tumours regrow from a surviving 
viable  rim  of  cells  (35),  the  manner  in  which  this  occurs  has  not  been  previously 
demonstrated.  From  this  work  I  have  shown  that  the  avascular  areas  of  tumour  are 
repopulated  from  the surviving  rim,  with  angiogenic  vessels  growing  inwards  from  the 
tumour periphery. This is evident from qualitative assessment of the PAT images and the 
shrinkage of the internal areas of signal void. From the semi-quantitative assessment of 
tumour  voxels  the  return  of  high-signal  voxels,  comparable  to  haemoglobin  containing 
voxels outside of the tumour location and therefore assumed to be areas of haemoglobin 
containing vasculature, appears to have a greater significance than the detection of signal 
void voxels. For SW1222 tumours the void areas remain high at day 16 post dose, and 
whilst there is no outward growth of the tumours the content of vascular voxels within the 
tumour ROI is increasing, signalling return of a normal vascular distribution. The LS174T 
tumours by contrasts appear to have fewer or similar areas of signal void, equating to 
avascular and necrotic sections of the tumour, and a decreased percentage of vascular 
regions. The areas of vascular voxels, whilst not returning to baseline values, do appear to 
increase from around day 7 which is consistent with outward increase in tumour volume. 
Whilst the inward growth of tumour vasculature from the surviving rim may seem logical, it 116 
 
is nonetheless only demonstrable by longitudinal in vivo studies such as those presented 
here. Of importance is also the fact that for certain vascular pathophysiologies, such as the 
well organised SW1222 tumours, whilst this central avascular area remains outward growth 
of the solid tumour does not occur whilst the avascular tumour areas remain; figure 4.9 
clearly shows that the SW1222 tumours do not grow over this period of time and that the 
internal  PA  signal  is  only  just  returning  to  baseline  values.  For  other  types  of  tumour 
vasculature extent, such as the more chaotic LS174T tumours, an increase in haemoglobin 
containing  regions  appears  sufficient  to  allow  growth  of  the  tumour.  This  method  of 
assessing return of vasculature is a straightforward approach, but is thus shown to be 
effective. The structure of the new vasculature however is not observed; although the PA 
signal has returned, the appearance of the LS174T tumours is visually different to baseline 
images.  It  is  possible  that,  as  LS174T  tumours  are  more  chaotic  with  regards  to  neo-
angiogenesis and, having a less extensively organised vasculature to begin with (36), are 
used to conditions of low oxygenation, scarce nutrients and abnormal blood supply, that 
they are more predisposed to an aggressive survival phenotype and are able to regrow in 
micro-environmental conditions to which the SW1222 tumours are not suited. Qualitative 
assessment of the neo-angiogenesis of the SW1222 tumours suggests a regular pattern of 
PA signal as seen in baseline images. This difference in vascular pathophysiology, which 
affects outcome to treatment with VDAs, is observable with PAT and could potentially be a 
powerful  application  of  PAT  in  the  clinic,  used  to  assess  tumour  vascular  state,  and 
therefore expected outcome, in different patients. What is also useful for clinical practice is 
noting  the  pharmacodynamic  effect  of  VDA  action,  i.e.  when  the  tumour  has  re-
vascularised, and therefore the interval with which patients need to be re-dosed in order to 
inhibit tumour growth. Interpretation of the data would be improved however by further 
analysis, such as vessel detection algorithms and texture analysis of grey scale values. Even 
with the approach used here however, I have demonstrated that large avascular areas 
within the tumour need to be repopulated with tumour tissue before outward growth can 
occur. 
4.4.3 Efficacy of vascular targeted treatment can be observed with 
PAT 
Having shown that PAT can detect vascular disruption and inward regrowth of the tumour 
vessels following treatment with a high dose of OXi4503, it is valuable to note that PAT can 
also detect smaller changes in vascular disruption within the tumour, as demonstrated by 
reduced doses of the VDA. The shift in PA values within tumour voxels at 48 hours, seen in 117 
 
figures 4.10 and 4.11, show that lower doses of OXi4503 had a lesser effect than the 
highest 40mg/kg dose. Microscopy images at this time point (figure 4.12) show that the 
effect of vascular disruption was greatest in the 40mg/kg group and 10mg/kg group, with 
no blood vessels or perfusion present in the core of the tumours. Morphological staining by 
H&E shows these regions to be necrotic, with less densely packed nucleic staining. The 
lowest  treatment  group  of  1mg/kg  appears  to  be  similar  to  sham  dosed  tumours, 
suggesting a very minor response to treatment. These reflect the PA signal obtained in vivo, 
where the greatest changes are seen in the 40mg/kg and 10mg/kg groups, with a smaller 
reduction in the 1mg/kg group. A similar effect is noted by Hill et al, 2002, where 1mg/kg of 
OXi4503 causes a reduction of 50% of functional vascular volume compared to greater than 
80%  for  doses  above  10mg/kg  (19).  This  translates  in  vivo  to  a  retardation  of  tumour 
growth in a dose dependent manner, as can be seen in figure 4.13. The growth curves for 
40mg/kg, 10mg/kg, and 1mg/kg are separated on typical response curves seen in other 
models, what is shown here for the first time is that measures of PAT can distinguish, based 
on voxel comparison to baseline data, between effective and non-effective doses of the 
same vascular targeted drug. This again demonstrates the potential utility of PAT in the 
clinic  for  monitoring  response  to  vascular  targeted  treatment.  Also  of  interest  is  that, 
although  not  fully  back  to  baseline  values,  around  50%  ‘haemoglobin  positive’  voxels 
spread across the tumour ROI are needed for re-growth. Whilst this study has concentrated 
on the response to VDA treatment, other vascular targeted agents such as anti-angiogenic 
therapies using humanised antibodies (37), and small molecules that attempt to normalise 
the  tumour  vascular  microenvironment  (38),  would  also  be  prime  candidates  for 
investigation with PAT.  
4.5 Conclusion  
In this chapter I have shown that PAT can be used effectively for monitoring response to 
vascular disruption with OXi4503. The resultant change in PA signal can be used to assess 
initial state of vascularisation and likelihood of achieving efficacy, and also relapse of the 
halt that is placed on tumour growth. As such it could be translated to the clinic to be used 
as a marker of vascular targeted therapies in patients. Further work on other vascular 
targeted therapies is a future aim of this research. I have also shown that different vascular 
pathophysiologies will respond differently to the same dose of drug, and that PAT can 
image  these  different  vascular  states  in  a  longitudinal  manner.  Whilst  many  different 
vascular pathophysiologies will exist in patients, and the response to different vascular 118 
 
targeted drugs and treatment strategies will vary considerably, the future use of PAT in the 
clinic is potentially a very powerful tool for determining patient response.. Further work on 
the analysis of the acquired data, such as determining the exact structure of the effected 
vasculature,  is  ongoing.  However,  it  has  also  been  noted  that  the  internal  vasculature 
returns from the periphery of the tumour at the surviving rim with neo-angiogenesis from 
the surrounding normal skin vasculature. 
In order to further analyse the acquired data for this vasculature structure, more in depth 
studies correlating these PAT data with histology could be performed. For a quantitative 
measure  histological  staining  for  blood  vessels  could  be  accompanied  by  tissue  micro-
vessel density determination tissue slices and compared to PAT data sets. Two issues would 
arise  from  this  comparison  that  would  further  complicate  analysis;  the  first  is  that 
histological assessment of micro-vessel density would only be in two dimensions whilst the 
PAT is in three. The second problem would be that even if three-dimensional histology was 
not required, and the signal from only a section of the PAT data used to match the tissue 
section, the tissue deformation ex vivo would complicate correct alignment of both data 
sets. Fiducial markers would need to be implemented and shown to correlate precisely 
between data sets. 
Whilst initial studies are promising, and the future potential of the use of PAT in the clinic is 
to some degree demonstrated, this research also shows some problematic areas that need 
addressing.  Real  time  imaging  is  not  currently  possible  with  optical  PAT.  The  imaging 
window, whilst large for in vivo optical studies, is small when compared to clinical used 
systems such as CT, MRI, SPECT and PET. Whole body imaging is not possible with this 
system, making difficult the assessment of deep sited or widespread disease. Models of 
cancer that are orthotopically located, such as within the liver to reflect metastasis, are 
therefore hard to image. As orthotopic locations have a tumour microenvironment that 
better imitates the clinical situation the response to therapy may be different to that which 
occurs in the subcutaneous location. 
For all these reasons this research in to the pathological vascular microenvironment of 
tumours was next assessed by MRI parameters associated with blood supply to the tumour, 
both  in  subcutaneous  and  liver  metastasis orthotopic  models.  This  is  presented  in  the 
following chapters. 
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Chapter 5 Magnetic resonance 
imaging parameters associated with 
tumour vascular pathophysiology  
5.1 Introduction 
As described in the concluding remarks of the previous chapter, this research in to the 
pathological  vascular  microenvironment  will  now  concentrate  on  MRI  parameters 
associated  with  tumour  development,  and  especially  those  that  provide  a  functional 
response marker to therapeutic tumour vascular disruption. The advantage of this is a 
more immediate translational possibility, given that MRI scanners are widespread within 
hospitals and routinely used to assess patients. In addition, a larger area can be imaged 
compared to PAT, which opens up the possibility of using more relevant orthotopically 
sited tumour models. Given the importance of the pre-clinical model for translation to the 
clinic (1) and the ability to measure functional responses from imaging studies (2), it is 
envisaged that MRI will provide additional insights in to the response of tumours to VDAs 
that, when compared to PAT, is currently of increased translational relevance. The basic 
description  of  how  MRI  is  used  to  visualise  biological  function  was  discussed  in  the 
Introduction to this thesis; this chapter will therefore introduce in more detail the specific 
vascular-associated parameters affected by VDA treatment, the MRI sequences developed 
to quantify them, and an initial demonstration of feasibility in subcutaneous tumours. An 
initial review will highlight the current work published in this area, and where advances can 
be made in understanding VDA mechanism of action and patient response to treatment. 
5.1.1 MRI of tumour vasculature 
Imaging of blood vessels using MRI angiography was noted in the previous chapter; it was 
established that certain vascular associated parameters, such as vessel size (3), density (4) 
and permeability (5, 6), could be determined using MRI angiography, however the use of an 
external  contrast  agent  is  a  confounding  factor  when  assessing  tumour  response  to 
therapy. Endogenous contrast that is inherent to the tumour microenvironment provides a 
more direct assessment that eliminates the potential errors introduced through use of 
exogenous  agents.  A  number  of  MRI  techniques  have  been  previously  used  to  assess 
tumour response to therapy; measurement of acute response to VDA therapy in particular 
has mainly been assessed by intrinsic susceptibility contrast MRI (7) and diffusion MRI (8). 124 
 
Another parameter than can be used to assess function is perfusion in biological tissue 
using arterial spin labelling (ASL) MRI (9). This has mainly been used for imaging the brain 
and cerebral blood flow (10), with little application to tumours outside of the head. These 
three  functional  parameters,  perfusion  using  ASL,  intrinsic  susceptibility  and  diffusion 
weighted MRI, are described in the following sections. 
5.1.1 Arterial spin labelling  
ASL is an MRI technique developed primarily to quantitatively measure cerebral blood flow, 
using the water in blood as an endogenous tracer (11-13). A pulsed ASL sequence called 
FAIR (Flow-sensitive alternating inversion recovery) has been designed to acquire pairs of 
images  after  global  and  slice  selective  inversion  pulses  (14,  15),  thereby  magnetically 
‘tagging’ blood outside of the area of interest and generating an image of the flow of this 
blood into the tissue. This can then be used to generate quantitative maps of perfusion 
based on the inflow of blood (9). Assessment of vascular perfusion in solid tumours with 
ASL has received some interest, but generally only within the brain; ASL has been used to 
measure perfusion of brain metastases in patients (16-18) and in animal models (19, 20), as 
motion artefacts can  be accounted  for.  In  other  locations outside  of  the  brain  motion 
artefacts, susceptibility differences caused by magnetic field inhomogeneity and visceral 
fat, coupled with a generally low rate of tumour perfusion, have made ASL challenging. One 
reported application of ASL in mouse xenograft models showed that it can be used to 
assess response to the anti-angiogenic agent Sorafenib, with significant reduction in blood 
flow seen at day 3 post-treatment (21). Another recent study looked at early response to 
anti-angiogenic treatment with Bevacizumab, also in subcutaneous tumour models, and 
found significant reduction in flow at 24 hours when compared to baseline measurements 
of perfusion (22). Response to vascular therapy is therefore possible with ASL, and should 
be suited to imaging response to vascular disruption with OXi4503. The time-course of 
action  of  OXi4503  may  also  provide  a  better  model  in  which  to  study  tumour 
haemodynamics with ASL, as blood flow will be affected at a much earlier point. Coupled to 
this is the ability of ASL to assess baseline measures of tumour blood flow, and therefore 
extent of tumour vasculature, with potentially improved predictive markers of therapy. ASL 
will therefore be developed as a marker of tumour perfusion first in the subcutaneous 
setting, before potentially being used in the colorectal liver metastasis model. 
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5.2.2 Intrinsic susceptibility MRI 
IS-MRI is based on measuring the nuclear magnetic resonance transverse relaxation rate 
R2* (R2* = 1/T2*) (23). Transverse magnetisation is produced by applying a radiofrequency 
pulse to flip the longitudinal magnetisation into the transverse plane; this induces an MR 
signal in the receiver radiofrequency coil as all the protons are in phase. As the protons 
dephase the transverse magnetisation decreases, giving a measure of relaxation time T2, 
which represents 1/e signal decay. Dephasing purely of spin-spin interactions is denoted as 
T2, but field inhomogeneities caused by susceptibility differences between different tissues 
also dephase the proton spin. This causes a faster relaxation of the transverse relaxation 
known as T2*. The rate of this, 1/T2*, is known as R2* and, in water molecules within 
blood at high magnetic field strengths, is predominantly determined by the oxygenation 
state  of  haemoglobin  (24).  This  is  because  deoxyhaemoglobin  is  paramagnetic,  which 
affects R2*, whilst oxyhaemoglobin is diamagnetic, which does not affect the MR signal 
(25). R2* can therefore be used to quantify deoxyhaemoglobin build-up via assessment of 
the  transverse  relaxation  rate  R2*.  Physiological  interpretation  of  variations  in  such 
measurements can be challenging however, due to its potential dependence on numerous 
physiological  processes.  A  strong  relationship  between  deoxyhaemoglobin  and  R2*  has 
been demonstrated in animal models under different inspired oxygen concentrations (26), 
although the correlation between R2* and oxygen pressure within solid tumours is harder 
to interpret, with poor relationships reported  (27, 28). Interpretation of R2* is further 
complicated by the observation that less hypoxic tumours, as assessed by pimonidazole 
adduct formation, have higher R2* values (29). Prognostic ability of R2* however has been 
shown for outcome to radiotherapy, based on different baseline values of R2* (30). R2* has 
also been shown to respond to vascular disruption with the research compound ZD6126 
where,  35  minutes  following  dosing,  the  measured  R2*  had  increased  by  16±4%  from 
baseline values, with a significant decrease at 24 hours after dosing (7). This is consistent 
with vascular collapse due to therapy, and could provide prognostic markers for response 
to treatment. Initial phase I clinical trials with OXi4503 have been conducted (31), and 
although  R2*  was  performed  on  the  patients  the  main  parameter  used  for  reporting 
response  was  DCE-MRI,  with  R2*  values  not  reported.  As  the  interpretation  of  R2* 
measurements is difficult, it is thought the combination with other markers, such as ASL 
and ADC described below, will further elucidate the reaction to dosing with VDAs and in 
particular OXi4503, and further validate the use of R2* as a biomarker of response. 
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5.1.3 Diffusion weighted MRI 
An MRI sequence that is weighted towards diffusion of water molecules can be created and 
used to assess tissue abnormalities that are not yet apparent on morphological imaging 
sequences.  These  sequences  measure  the  Brownian  motion  of  water  molecules  in  the 
extracellular, intracellular, and intravascular space where movement is not restricted (32). 
This gives a measure of apparent diffusion coefficient (ADC), which is inversely related to 
the cellularity and integrity of tissue structure due to the restriction of space for water 
diffusion (33, 34). ADC can therefore be used as a measure of cellularity of the tissue and 
associated microstructural characteristics, such as fluid viscosity, membrane permeability, 
blood flow and tumour necrosis in response to therapy, as the structural integrity of the 
tissue is broken down. The sequence differentiates water movement by imaging paired 
diffusion gradients and changing a parameter known as ‘b-value’ multiple times; b-values 
are  proportional  to  the  gradient  amplitude  applied,  the  duration  of  this  and  the  time 
interval between successive gradients. For static molecules the second diffusion gradient 
will rephase the protons without substantial loss of signal when compared to the first 
gradient; however, molecules that have moved will show different phase information for 
the  second  diffusion  gradient  when  compared  to  the  first.  This  attenuation  in  signal 
intensity is proportional to the degree of water motion. Diffusion weighted imaging (DWI) 
typically uses multiple b-values in the range of 0 to 1000 s/mm
2, with the larger b-values 
providing the greatest signal attenuation, and is therefore biased towards slower water 
diffusion movements. By plotting the logarithm of the relative signal intensity measured 
against the b-values used, the slope of the resultant line describes the ADC value for that 
specific region. This is independent of scanner field strength and therefore comparable 
across systems, and results in a map of values across the region of interest. When using 
ADC  to  assess  response  to  vascular  disruption,  necrosis  is  the  main  influence  on  ADC 
change, and studies have shown an increase due to CA4P therapy (8, 35, 36). Clinical use of 
ADC as a marker for VDA-induced necrosis, however, is restricted by a lack of consensus on 
data acquisition and processing (37). The combination of ADC measurements with both ASL 
and  R2*  should  provide  insight  into  the  tumour  response  to  vascular  disruption  with 
OXi4503, as all parameters should be interlinked, thereby providing an overall picture of 
related responses. Also of interest would be acute measures of ADC in addition to just 
using the movement of water molecules as a marker of necrosis, as tumour blood vessel 
obstruction caused by VDA treatment should also have an effect on tumour ADC values.  
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5.1.4 Hypothesis of vascular functional parameters in response to 
OXi4503  
 
The above mentioned functional parameters associated with tumour vascular function, ASL 
for tumour blood vessel perfusion, R2* as a measure of deoxyhaemoglobin build-up as 
blood flow ceases, and ADC as an initial measure of vessel obstruction and tumour cell 
structure swelling, and subsequently as a measure of induced tumour necrosis, should all 
be interrelated in response to vascular disruption with OXi4503. Although all have to some 
extent  been  used  to  assess  tumour  response  already,  the  combination  of  all  three  in 
response to the second generation VDA OXi4503 should provide greater understanding of 
the  tumour  microvasculature.  It  is  envisaged  that biomarkers,  not  only  of  response to 
treatment  but  also  for  prognosis  of  potential  efficacy,  will  be  forthcoming  due  to  this 
increased understanding of the tumour vascular capability. These parameters will therefore 
be first established in subcutaneous models of colorectal carcinoma before progressing to 
the  more  clinically  useful  liver  metastatic  model,  and  always  with  a  view  to  clinical 
translation of the assessment technique. The pulse sequences used to achieve this, and the 
experimental set-up employed, is described in the next section. 
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5.2 Methods 
All  CD1  nu/nu  animals  were  acquired  through  UCL  BSU  and  subcutaneous  tumours 
established as previously described. All MRI imaging was performed at the UCL Centre for 
Advanced  Biomedical  Imaging  on  a  dedicated  small  animal  9.4T  Agilent  VNMRS  20cm 
horizontal bore system (Agilent Technologies, Santa Clara, USA). Small gradients were used 
in conjunction with a 39mm birdcage coil (RAPID Biomed, Rimpar, Germany). Anaesthesia 
was induced with 4% Isoflurane in oxygen within the designated preparatory room before 
transfer to the MRI cradle for imaging. Anaesthesia was maintained at 1-2% Isoflurane via 
nose-cone,  and  a  rectal  temperature  probe  and  respiration  pillow  put  in  place  for 
physiological monitoring.  In order to limit motion of the tumour, the flank of the animal 
was fixed in place using a fixative paste and tape. The MRI cradle was then placed in the 
centre of the bore of the magnet and animal temperature maintained at 36.8°C via a core 
body temperature-linked warm air blower (SA Instruments, USA). Monitoring of animal 
core temperature and respiration rate during image acquisition was performed via remote 
software within the MRI console room. For administration of substances, a heparin coated 
i.v. cannula line was placed in the tail vein of the mouse and a remote line placed outside 
the scanner bore. Baseline images were acquired before injection of either saline control or 
40mg/kg of freshly made-up OXi4503 solution. For longitudinal studies the animals were 
placed in a heated recovery box after the imaging session, and returned to IVCs kept at the 
BSU holding room within CABI. 
5.2.1 MRI pulse sequences 
All MRI scan parameters were developed in conjunction with Dr Walker-Samuel (UCL CABI). 
In addition, the arterial spin labelling sequence used for perfusion was further modified in 
conjunction with Mr Ramasawmy (UCL CABI).  A description of each sequence can be found 
below. 
5.2.1.1 High resolution morphological sequence 
A  multiple  slice  Fast-Spin  Echo  (FSE)  sequence  was  used  to  obtain  morphological 
information on the animal being imaged. This structural information was then used to plan 
subsequent data acquisition with other scans. This initial sequence was T2-weighted and 
respiratory-gated in order to obtain the best resolution possible. Sequence parameters 
included a field of view 35x35mm
2 with a matrix size of 256x256. The repetition time 
between  excitation  pulses  was  set  to  TR  =  1500ms,  with  n=4  180°  refocussing  pulses 
applied (Echo train length=4) per TR. Effective echo time was TE=26ms. To cover the whole 
tumour area n=30 contiguous 0.5mm slices were acquired with n=2 dummy scans and n=4 129 
 
averages per acquisition. For data planning, scans were visualised using the MRI scanner 
software VNMRJ (Agilent Technologies, Santa Clara, USA); for presentation of scans, the 
data was analysed with MATLAB (MathWorks, USA) and images visualised using Amira 
5.4.0 software. 
5.2.1.2 Arterial spin labelling sequence  
Data for tissue perfusion was acquired by an arterial spin labelling sequence using a flow-
sensitive alternating inversion recovery (FAIR) Look-Locker sequence (38). The sequence 
was single slice with 1mm thickness and a field of view of 30x30mm. Scan parameters 
included a matrix size of 128x128, a TE of 1.18ms, a time to inversion of the Look-Locker 
TILook-Locker of 110ms with a repetition of the inversion TRI of 13s, a TRRF of 2.3ms, an angle 
αRF of 8°, 50 inversion recovery readouts, and 4 lines per segmented acquisition. A selective 
local inversion of 6mm thickness was performed across the area of interest of the tumour 
ROI, followed by a global inversion. Total scan time for each acquisition was around 14 
minutes in duration. Maps of perfusion were calculated using the model suggested by Belle 
(39).  Longitudinal  relaxation  time  T1  of  intravascular  blood  was  based  on  previously 
measured value of 1900ms (40), which was acquired in the ventricular blood pool of the 
mouse  heart.  A  blood-tissue  partition  coefficient  of  λ=0.95mlg
-1  was  used  based  on 
previously reported measurements from 
85Krypton gas clearance experiments (41). A three 
parameter fit of the inversion recovery was therefore calculated which was corrected for 
the  signal  saturation  caused  by  the  FAIR  acquisition  sequence.  Values  of  ASL  were 
calculated per voxel of acquired data using MATLAB, with three dimensional visualisation of 
R2* values across the tumour performed in Amira 5.4.0. 
5.2.1.3 Intrinsic susceptibility sequence 
Values of the MRI transverse relaxation rate (R2*) were acquired from a respiratory-gated, 
multiple-echo,  multiple-slice  gradient  echo  sequence  (MGEMS).  Sequence  parameters 
included 8 echoes with a spacing of 2ms, a 30x30mm
2 field of view, and 128x128 matrix 
size. Time to the first echo, TE1, was 2ms, with a TR set to 280ms. A total of 15 slices of 
1mm thickness were used to encompass the tumour region. R2* was estimated using a 
maximum likelihood approach that took in to account the Rician distribution of the data 
(42). The tumour ROI was selected in Amira 5.4.0 and analysis performed with an in-house 
designed IDL programme. Values of R2* were calculated per voxel of acquired data, with 
three dimensional visualisation of R2* values across the tumour performed in Amira 5.4.0. 130 
 
5.2.1.4 Diffusion weighted imaging sequence 
To estimate the apparent diffusion coefficient of water molecule movement within the 
tumours, a diffusion weighted fast spin echo sequence (FSEdif) was established. Using the 
geometry  from  the  FSE  sequence,  a  40x40mm  field  of  view  was  placed  covering  the 
location  of  the  tumour.  A  slice  thickness  of  1mm  was  used,  with  20  contiguous  slices 
acquired. The matrix size was 128x128 with TR set at 1500ms and TE set to 22ms. Diffusion 
gradients were set in the slice direction with b values of 2.5, 214, 413, 609, 805 and 1000 
s/mm
2. Analysis of acquired data was performed using a tumour selected ROI in Amira 
5.4.0, and an in-house designed IDL programme to extract ADC parameters for each voxel 
of acquired data, with data fitted to a single exponential model on a pixel by pixel basis 
using a Bayesian maximum a posteriori approach. Three dimensional visualisation of ADC 
values across the tumour performed in Amira 5.4.0. 
 
5.2.2 In vivo procedure  
Animals  were  used  for  MRI  experiments  once  tumour  volume,  as  assessed  by  caliper 
measurement, had reached approximately 0.6cm
3. Each imaging session was limited to 
three  hours  total  anaesthesia  time  per  mouse  due  to  licence  restrictions;  imaging  of 
cohorts of mice was therefore staggered over subsequent days. Initial studies of saline-
dosed sham controls were acquired in order to gain experimental set-up experience and to 
demonstrate no change of measured parameters from baseline in n=2 SW1222 tumours. 
Studies of response to OXi4503 treatment were then performed in n=4 LS174T and n=6 
SW1222 tumour bearing mice. Imaging sessions consisted of baseline acquisitions of R2*, 
ASL and ADC followed by dosing via the remote i.v. line. The animal was then left within the 
scanner bore and acquisitions of R2* and ADC acquired consecutively until 90 minutes 
post-dose, at which point a final measure of ASL was acquired and the animals returned to 
IVCs. The LS174T tumour bearing mice were terminated at this point. The SW1222 tumour 
bearing mice were imaged subsequently for longitudinal response to OXi4503 at days 1, 3 
and 5 post-dose. One mouse was sacrificed on day 1 post-dose, one mouse at day 3 post-
dose, and the remaining n=4 at day 5 post-dose. All tumours were excised at termination 
and fixed in 10% formalin for histological assessment.  
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5.3 Results 
5.3.1 High resolution and segmentation 
Imaging  of  the  sham-dosed  animals  demonstrated  the  feasibility  of  work  flow,  data 
acquisition,  correct  sequence  set-up  and  analysis  of  data.  No  significant  changes  from 
baseline were observed. In figure 5.1 an example of the high resolution morphological scan 
raw data can be seen in panel A. The subcutaneous tumour is evident due to its location on 
the top of the animal’s flank above the internal abdominal section. This spherical region is 
hypo-intense in signal, and is indicated here by the red arrow. An example of the Amira 
5.4.0 workflow to segment the tumour region can be seen in panel B. The work area to the 
left of the image is a Amira 5.4.0 showing the different possible methods of segmenting 
materials based on voxel values; the area to the right highlighted in red shows the voxels 
designated as a region of interest. This can then be represented separately as in panel C, 
which shows the tumour volume rendered in orange above the high resolution MRI image 
slice.  This  tumour  segmented  area  was  then  used  to  calculate  values  for  functional 
parameter measurements.  
  
 
   
A 
Figure 5.1 High resolution morphological MRI images & segmentation  
Representative MRI image from a morphological FSE sequence of a subcutaneous tumour, with 
subcutaneous tumour highlighted by the red arrow (A), the segmentation of the tumour ROI 
using Amira 5.4.2 (B), and the three dimensional rendering of the tumour volume within Amira 
5.4.0 (C) (n=2 animals used for development). 
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5.3.2 ASL acute 
Measurements of tumour perfusion using arterial spin labelling in SW1222 tumours was 
unsuccessful and yielded corrupted data acquisition with no information. This data is not 
shown, as it was not possible to reconstruct any images or three dimensional volumes. It is 
possible that the low blood flow within the region of interest was not sufficient to produce 
the necessary contrast for ASL in subcutaneous SW1222 tumours. With LS174T tumour the 
results were similar, and although the data was not corrupted it none-the-less showed no 
change in values across the tumour and from baseline to post-dose imaging. An example of 
the LS174T data can be seen in figure 5.2. Each section from left to right shows a single 
1mm slice through the tumour. The first row is from baseline values, with the second and 
third corresponding to 90 minutes after OXi4503. Each voxel shows the measured ASL in 
ml/g/min  as  per  the  colour  bar  included  in  the  figure;  no  change  is  noted  across  the 
tumour.  It  is  thought  that  the  small  area  of the  tumour  leads  to  low  perfusion  which 
compromised correct ASL measurements, and that increased sequence acquisitions and 
averaging of data would allow this small ASL value to be obtained.  
 
 
 
   
Figure 5.2 Tumour perfusion maps   
Representative perfusion maps from an ASL sequence of a subcutaneous LS174T tumour (n=4). 
The top row indicates voxel perfusion measurements acquired at baseline, with the second and 
third rows showing the same tumour at 90min post 40mg/kg of OXi4503. Each row depicts 7 x 
1mm slices that encompass the whole tumour from top to bottom. 
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5.3.3 R2* acute 
Data  acquisition  for  values  of  R2*  across  the  tumour  were  attained  and  mapped.  An 
example of this can be seen in figure 5.3 for both SW1222 and LS174T tumours. The top 
row  shows  R2*  mapped  across  the  tumour  at  baseline  (A)  and  90  minutes  following 
administration of OXi4503 (B) in a representative tumour ROI (SW1222). A histogram of the 
values for all voxels from the example in A and B can be seen below each tumour R2* map 
(C and D). The median value for baseline images is shown on the histogram by the T50 
value, which is used to demonstrate shift in the values at 90 minutes; a threshold at this T50 
value has been drawn and shows the percentage of voxels now above this value. In the 
example,  an  increase  in  values  from  baseline,  expressed  as  a  shift  to  the  right  of  the 
distribution within the histogram, can be seen, with 52% of tumour voxels now above the 
median baseline value. From this whole tumour voxel-data the increase in median values 
and standard deviation from the mean across the whole cohort can be calculated for both 
tumour types; a continuous representation of this over the 90 minutes post-dose time 
period is shown in panel E, which depicts n=13 acquisitions of median R2* value, with error 
bars denoting standard deviation, for SW1222 in blue and LS174T in red. SW1222 tumours 
show  an  initial  decrease  in  value  at  the  5  minute  time-point,  followed  by  a  sustained 
increase to 4.5% over baseline values at 90 minutes; LS174T tumours also show an initial 
decrease followed by an increase, however both are not as pronounced as the SW1222 
tumours. At 90 minute no significant increase is noted, with the R2* value being only 0.5% 
above baseline.  
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Figure 5.3 Acute measurement of R2*   
Panel A and B show 3D representations of R2* (S
-1) mapped across tumour voxels at baseline and 
90min  after  40mg/kg  OXi4503  i.v..  The  change  in  signal  intensity  can  be  shown  by  voxel 
histograms as in panel C and D and used to assess percentage of tumour voxels above median 
baseline values. A graph of these values as percentage of baseline can then be constructed 
(panel E) for the n=6 SW1222 (blue line) and n=4 LS174T (red line) tumours. 
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5.3.4 ADC acute 
Data acquisition for values of ADC across the tumour were mapped across the tumour 
region as previously shown for the R2* measurements. An example of this can be seen in 
figure 5.4 for both SW1222 and LS174T tumours. The top row shows ADC mapped across 
the  tumour  at  baseline  (A)  and 90 minutes  following  administration of OXi4503  (B).  A 
histogram of the values for all voxels can be seen below each tumour ADC map (C and D). 
No apparent change in ADC values is noted from baseline to 90 minutes post-dose. Median 
values and standard deviation from the mean over the 90 minute experiment are shown in 
panel  E,  with  SW1222  tumours  in  blue  and  LS174T  in  red.  As  can  be  seen  there  is  a 
reduction for both SW1222 and LS174T at the 90 minute time point, with values being 82% 
and 92% of baseline values respectively. 
 
    Figure 5.4 Acute measurement of ADC  
Panel A and B show 3D representations of ADC mapped across tumour voxels at baseline and 
90min  after  40mg/kg  OXi4503  i.v..  The  change  in  signal  intensity  can  be  shown  by  voxel 
histograms as in panel C and D and used to assess percentage of tumour voxels below median 
baseline values. A graph of these values as percentage of baseline can then be constructed 
(panel E) for the n=6 SW1222 (blue line) and n=4 LS174T (red line) tumours. 
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5.3.5 Baseline vs 90min response 
Measurements of both R2* and ADC can be linked spatially within the same tumour, an 
example of which, performed in one SW1222 tumour, is shown in figure 5.5 A (R2*), B 
(ADC) and C (combination of R2* and ADC). This allows regional comparison of tumour 
voxels over time, linking baseline values to values acquired post dose. Graph D of figure 5.6 
shows an example of this, where initial R2* values from an SW1222 tumour have been 
categorised into deciles and linked to the percentage change of ADC at 90minutes post 
dose with each decile. From this is can be seen that those voxels with the lowest R2*values 
at baseline (deciles 1 to 5) will generally respond with a decrease in ADC at 90minutes, 
those with an above average baseline R2* value (deciles 6 and 7) will show an increase in 
ADC, and those with the highest R2* values (deciles 8 to 10) show only a slight reduction in 
ADC.  Whilst  this  may  be  indicative  of  an  association  between  R2*  and  ADC  values, 
comparisons across different tumours are complicated, and no definitive correlation was 
found across the group (n=6 SW1222) over the time frame imaged. 
 
 
   
Figure 5.5 Spatial correlation of R2* and ADC values  
Panel A and B show 3D representations of R2* at baseline and ADC at 90min post 40mg/kg 
OXi4503 i.v. mapped across the same tumour (n=1 shown, n=6 total). Panel C shows both R2* 
and ADC mapped within the same image. Quantifying baseline R2* in to deciles and plotting the 
change in ADC at 90min shows variation in results across the tumour, as seen in panel D (error 
bars denote mean±SDM). 
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5.3.6 Longitudinal MRI assessment of response 
Values for R2* and ADC were acquired for the SW1222 tumours at 90 minutes, 1, 3 and 5 
days post dose. As an example of value mapping across the tumour, values of ADC at 
baseline and at 24 hours post OXi4503 in an example SW1222 tumour can be seen in figure 
5.6 A and B respectively. Histological assessment by H&E staining can also be seen for 
baseline and 24 hours in panels C and D of the same figure. Values of ADC show a marked 
increase from baseline values with more ‘hot’ areas of high ADC values. Morphological 
staining confirms the typical necrotic centre of OXi4503 treated tumours at 24 hours, with 
a rim of surviving cells, when compared to baseline. Values across the cohort of tumours 
over the 5 day longitudinal study are depicted by the box and whisker plots in figure 5.7 
that show median values across the tumour voxels. Graph A shows the results for R2*, 
which show a slight increase in values from baseline to 90 minutes post dose, a widening of 
results but still within the same value range at 24 hours, and a significant decrease (p≤0.05) 
from baseline values at 3 and 5 days post dose. Graph B shows the same layout for results 
of  ADC.  At  90  minutes  post  treatment  there  was  a  slight  reduction  in  values  and  a 
narrowing  in  the  range  of  results.  All  time  points  after  this  (days  1,  3  and  5),  show 
significantly higher (p≤0.05) ADC values. For both graphs, error bars denote maximum and 
minimum measurements, with boxes denoting the interquartile range and median values. 
 
 
 
 
 
 
D  C 
B  A 
Figure 5.6 Confirmation of longitudinal MRI feasibility  
Panel A and B show 3D representations of ADC in an SW1222 tumour at baseline and 24 hours 
after  40mg/kg  OXi4503  i.v.  mapped  across  the  same  tumour.  Panel  C  and  D  represent 
morphological H&E images of baseline and 24 hours post drug respectively. 
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A 
B 
Figure 5.7 Longitudinal R2* and ADC measurements  
Graph A shows median values for R2* and graph B median values for ADC across n=6 SW1222 
tumours at baseline, 90 minutes, 1, 3 and 5 days post 40mg/kg OXi4503 i.v. Error bars show 
maximum and minimum values, with boxes showing interquartile range and median values. 
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5.4 Discussion 
5.4.1 MRI Sequences function as predicted 
Arterial  spin  labelling  for  tissue  perfusion,  intrinsic  susceptibility  measures  of  R2*  and 
diffusion weighted measures of ADC have all been previously used to assess response to 
therapy,  as  discussed  in  the  introduction  to  this  chapter.  Different  MRI  acquisition 
sequences  can  be  employed  to  achieve  each  functional  measurement,  however,  and 
sequences must be fully tested to ensure they achieve accurate results for each different 
MRI scanner used and with each new model tested. The aim of this chapter was therefore 
to  assess  the  developed  MRI  sequences  for  ASL,  R2*  and  ADC  in  two  subcutaneous 
colorectal  models  with  different  pathophysiologies,  before  progressing  to  the  more 
clinically relevant liver metastatic model. The results shown in this chapter demonstrate 
that values for each sequence can be achieved in both these models. Values of R2* and 
ADC in particular could be acquired and mapped across the 3D rendering of the tumour 
ROI. Perfusion as measured by ASL was more challenging, with results acquired for LS174T 
and sham-dosed tumours showing little change, and results from SW1222 tumours being 
corrupted to the point of being unusable. The sequence worked correctly on larger cross 
sections of mouse anatomy, however the small size of the tumour area and the low level of 
perfusion in subcutaneous tumours meant no functional perfusion measurement could be 
acquired  with  this  model.  The  sequence  was  adapted  by  incorporating  a  MATLAB 
programme to reject severely corrupted data acquired in the Look-Locker train sequence, 
thereby eliminating ‘ghost’ artefacts and motion corruption, with the remaining images 
fitted by a non-linear least-squares method to generate T1 maps. It is thought that this, 
coupled with the larger cross section and increased blood flow in liver tissue, will provide 
non-corrupted and significant functional ASL measurements for the liver orthotopic model. 
Having determined that the developed MRI sequences work with the scanner and model 
used, there are a number of observations that can be drawn from the experimental studies 
conducted. These are discussed below. 
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5.4.2 Vascular shutdown can be observed using R2* and ADC 
The interaction of R2* and ADC should show the effect of dosing with OXi4503 and the 
resultant vascular destruction.   From  the  literature,  the  vascular  shutdown  caused  by 
OXi4503 will start to take effect from around 1 hour post dose, with around 50% reduction 
in actual blood flow, and maximum effects noted from around 6 hours to 24 hours post 
dose (43). With the related VDA compound CA4P (44) a significant reduction in blood flow 
can be seen at 5 minutes after dosing, with complete shutdown noted at 20 minutes (45). 
During the acute phase of vascular shutdown it is thought that the morphological and 
functional alterations to the endothelial cytoskeleton caused by VDAs, such as cell shape 
(46), are the main source of cessation of blood flow. With regards to R2* this slowing of 
blood flow would have the effect of increasing the deoxygenated content of the blood 
within the tumour; the slow flow rate would provide more time for tumour cells to use up 
the available oxygen, with a resulting increase in paramagnetic deoxyhaemoglobin. This in 
turn would lead to an increase in the measured R2* as the tumour blood flow eventually 
stops entirely. Over the 90 minutes measured, the R2* for SW1222 tumours increases to 
around 4.5% over baseline, whilst in LS174T tumours only a modest 0.5% is observed. This 
potentially illustrates a more rapid slowing in vascular flow in the SW1222 tumours. This 
also fits in with reported literature that less hypoxic tumours have a higher R2* value (29). 
This is probably due to the overall content of blood within the tumour vasculature, where 
SW1222 tumours, with a greater blood vessel network, subsequently have an increased 
percentage of deoxygenated blood affecting the R2* measurement. This also links back to 
PAT  and  corrosion  cast  measurements  that  showed  a  greater  vascular  network  within 
SW1222 tumours when compared to LS174T. This change in R2* could also potentially be a 
product of altered blood volume within tumours following treatment. With values of ADC 
the acute measurements are unlikely to measure tumour cell necrosis, as it is presumed 
little tumour breakdown is occurring at this point. However, with blood flow stagnating 
within tumours and endothelial cell morphology becoming more rigid, it is possible that 
ADC  would  reflect  the  more  restricted  water  movement  by  showing  values  that  are 
reduced from baseline values. This is observed with the acquired data, where values have 
dropped to 82% and 92% of initial values for SW1222 and LS174T tumours. This shows that 
the initial effects of vascular shutdown can be assessed by R2* and ADC. It is possible that 
the main effect of blood vessel occlusion was not noted however, as it was only possible to 
image up to 90 minutes after dosing due to the time required for experimental set-up and 
licence restrictions. Measurements at 6 hours would have potentially shown greater effect, 
however imaging of the animals within the same 24 hour period was not possible. The 141 
 
opposing reactions of R2* and ADC over the time frame imaged, however, show that both 
are linked in relation to mechanism of drug action. Spatially linking R2* and ADC, as in 
figure 5.5, could demonstrate further the connection between voxels that show increased 
deoxyhaemoglobin (increased R2*) and occluded vessels (a decrease in water diffusion by 
ADC). No direct correlation was observed, but it is interesting to note that the greatest 
reduction in ADC occurred in those voxels that had the lowest baseline values of R2*, i.e. 
most oxygenated, whilst those with the highest baseline levels of R2*, i.e. the areas most 
deoxygenated initially, either showed little effect, which is presumably due to no reduction 
in blood flow, or an increased ADC, which is either related to increased water motion 
caused by the onset of necrosis or the breakdown of the tumour vasculature. Even though 
regional analysis proved no correlation, median values did reflect overall change in tumour 
functional parameters. 
5.4.3 Longitudinal analysis 
The action of OXi4503 was monitored longitudinally by imaging SW1222 tumours over a 5 
day period, as seen in figure 5.7. Whilst it was originally planned to also image the LS174T 
tumours over this time frame, logistical issues in relation to scanner time and coordination 
with in vivo studies meant that this was not possible. Correlation of exact changes in both 
R2* and ADC was also an initial aim of this study, but the deformation in the tumour 3D 
map over the course of time did not allow exact overlay of baseline and subsequent data 
sets.  Micro-regional  maps  of  values  are  therefore  not  shown  due  to  co-registration 
problems. Measurement of R2* also has the added difficulty in that scan parameters, such 
as  shim  values  acquired,  mean  that  direct  comparison  is  not  straightforward.  Median 
values were therefore used to assess response to OXi4503 treatment over time, as they 
proved to be the most consistent in terms of reliability. Response to treatment should lead 
to a central necrotic core with little remaining vasculature, as shown by PAI; necrosis was 
observed through H&E staining. This in turn should lead to an increase in ADC values across 
the tumour, and a drop in R2* as the haemoglobin is removed from the tumour core and 
cellular breakdown products become dispersed. This would be consistent with observed 
effects in PAT studies and other MRI experiments. These effects were indeed observed 
across  the  tumour  cohort,  with  the  expected  increase  in  water  diffusion  shown  by  an 
increase in tumour ADC, and the tumour blood vessel destruction and removal shown by 
the drop in R2* values. Whilst an increase in R2* has been described previously using MRI 
following  vascular  disruption,  this  is  in  the  acute  phase  of  vessel  shutdown  where 
deoxygenated blood accumulates within the tumour blood vessels. In this study that time-142 
 
frame is extended to cover the subsequent days of recovery for the first time, with a 
subsequent drop in R2* observed. The study therefore proved that the MRI sequences 
employed are capable of imaging not only the acute effects of vascular disruption with 
OXi4503, but also the longitudinal response. 
5.5 Conclusion 
The aim of this chapter was to determine and evaluate MRI sequences that would be 
capable of imaging tumour vasculature parameters associated with vascular disruption by 
the  VDA  OXi4503,  using  two  colorectal  cancer  models.  This  was  achieved  by  imaging 
subcutaneous tumours over an acute 90 minute period and follow-up of the same tumours 
at 24 hours and 3 and 5 days post dose. Although results of tumour perfusion by ASL were 
unsatisfactory  in  this  setting,  the  experimental  approach  proved  useful  in  that  the 
sequence was seen to acquire data, but required modifying for further use. Sequences 
were modified and provided successful perfusion imaging in later experiments. Measures 
of R2* and ADC were acquired with OXi4503 that reflected the known action of other 
VDAs.  The  response  was  consistent  with  the  literature,  and  demonstrated  a  complex 
interaction between the two parameters. A combination of MRI functional measures of 
tumour response with PAT morphological response of the tumour vascular network would 
be  extremely  advantageous  to  the  understanding  of  this  complex  interaction  between 
cessation of blood flow, increase in deoxyhaemoglobin, blood vessel occlusion and onset of 
necrosis. Preliminary  studies  were  carried out  to  check  the  feasibility of  this,  however 
coordinating two separate scanner schedules and timing in vivo study proved difficult, and 
the  little  data  achieved  (n=1  subcutaneous  tumour)  was  hard  to  co-register  accurately 
between  the  two  modalities.  Dual  imaging  would  obviously  be  a  powerful  tool  in  this 
context,  and  further  work  will  be  conducted  to  achieve  this  aim;  however  the  most 
immediate  translational  concern  was  to  demonstrate  that  these  functional  parameters 
could be used in a more clinically relevant setting. The next chapter will therefore show the 
development of a model of colorectal liver metastases and the monitoring of response to 
OXi4503.  
 
   143 
 
5.6 Reference List 
 
  (1)   Cook N, Jodrell DI, Tuveson DA. Predictive in vivo animal models and translation to 
clinical trials. Drug Discov Today 2012;17:253-60. 
  (2)   Brindle K. New approaches for imaging tumour responses to treatment. Nat Rev 
Cancer 2008;8:94-107. 
  (3)   Valable S, Lemasson B, Farion R, Beaumont M, Segebarth C, Remy C, et al. 
Assessment of blood volume, vessel size, and the expression of angiogenic factors 
in two rat glioma models: a longitudinal in vivo and ex vivo study. NMR Biomed 
2008;21:1043-56. 
  (4)   Lemasson B, Valable S, Farion R, Krainik A, Remy C, Barbier EL. In vivo imaging of 
vessel diameter, size, and density: a comparative study between MRI and histology. 
Magn Reson Med 2013;69:18-26. 
  (5)   Peng SL, Chen CF, Liu HL, Lui CC, Huang YJ, Lee TH, et al. Analysis of parametric 
histogram from dynamic contrast-enhanced MRI: application in evaluating brain 
tumor response to radiotherapy. NMR Biomed 2012. 
  (6)   Coenegrachts K, Bols A, Haspeslagh M, Rigauts H. Prediction and monitoring of 
treatment effect using T1-weighted dynamic contrast-enhanced magnetic 
resonance imaging in colorectal liver metastases: potential of whole tumour ROI 
and selective ROI analysis. Eur J Radiol 2012;81:3870-6. 
  (7)   Robinson SP, Kalber TL, Howe FA, McIntyre DJ, Griffiths JR, Blakey DC, et al. Acute 
tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance 
imaging. Neoplasia 2005;7:466-74. 
  (8)   Thoeny HC, De KF, Chen F, Vandecaveye V, Verbeken EK, Ahmed B, et al. Diffusion-
weighted magnetic resonance imaging allows noninvasive in vivo monitoring of the 
effects of combretastatin a-4 phosphate after repeated administration. Neoplasia 
2005;7:779-87. 
  (9)   Wells JA, Siow B, Lythgoe MF, Thomas DL. Measuring biexponential transverse 
relaxation of the ASL signal at 9.4 T to estimate arterial oxygen saturation and the 
time of exchange of labeled blood water into cortical brain tissue. J Cereb Blood 
Flow Metab 2013;33:215-24. 
  (10)   Zhou H, Chen M, Zhao D. Longitudinal MRI evaluation of intracranial development 
and vascular characteristics of breast cancer brain metastases in a mouse model. 
PLoS One 2013;8:e62238. 
  (11)   Morse OC, Singer JR. Blood velocity measurements in intact subjects. Science 
1970;170:440-1. 
  (12)   Detre JA, Leigh JS, Williams DS, Koretsky AP. Perfusion imaging. Magn Reson Med 
1992;23:37-45. 144 
 
  (13)   Detre JA, Subramanian VH, Mitchell MD, Smith DS, Kobayashi A, Zaman A, et al. 
Measurement of regional cerebral blood flow in cat brain using intracarotid 2H2O 
and 2H NMR imaging. Magn Reson Med 1990;14:389-95. 
  (14)   Kwong KK, Belliveau JW, Chesler DA, Goldberg IE, Weisskoff RM, Poncelet BP, et al. 
Dynamic magnetic resonance imaging of human brain activity during primary 
sensory stimulation. Proc Natl Acad Sci U S A 1992;89:5675-9. 
  (15)   Kim SG. Quantification of relative cerebral blood flow change by flow-sensitive 
alternating inversion recovery (FAIR) technique: application to functional mapping. 
Magn Reson Med 1995;34:293-301. 
  (16)   Hirai T, Kitajima M, Nakamura H, Okuda T, Sasao A, Shigematsu Y, et al. 
Quantitative blood flow measurements in gliomas using arterial spin-labeling at 3T: 
intermodality agreement and inter- and intraobserver reproducibility study. AJNR 
Am J Neuroradiol 2011;32:2073-9. 
  (17)   Knutsson L, van WD, Petersen ET, Bloch KM, Holtas S, Stahlberg F, et al. Absolute 
quantification of cerebral blood flow: correlation between dynamic susceptibility 
contrast MRI and model-free arterial spin labeling. Magn Reson Imaging 2010;28:1-
7. 
  (18)   Canale S, Rodrigo S, Tourdias T, Mellerio C, Perrin M, Souillard R, et al. [Grading of 
adults primitive glial neoplasms using arterial spin-labeled perfusion MR imaging]. J 
Neuroradiol 2011;38:207-13. 
  (19)   Silva AC, Kim SG, Garwood M. Imaging blood flow in brain tumors using arterial 
spin labeling. Magn Reson Med 2000;44:169-73. 
  (20)   Moffat BA, Chen M, Kariaapper MS, Hamstra DA, Hall DE, Stojanovska J, et al. 
Inhibition of vascular endothelial growth factor (VEGF)-A causes a paradoxical 
increase in tumor blood flow and up-regulation of VEGF-D. Clin Cancer Res 
2006;12:1525-32. 
  (21)   Schor-Bardach R, Alsop DC, Pedrosa I, Solazzo SA, Wang X, Marquis RP, et al. Does 
arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal 
cell cancer response to antiangiogenic therapy in a mouse model? Radiology 
2009;251:731-42. 
  (22)   Rajendran R, Huang W, Tang AM, Liang JM, Choo S, Reese T, et al. Early detection 
of antiangiogenic treatment responses in a mouse xenograft tumor model using 
quantitative perfusion MRI. Cancer Med 2014;3:47-60. 
  (23)   Chavhan GB, Babyn PS, Thomas B, Shroff MM, Haacke EM. Principles, techniques, 
and applications of T2*-based MR imaging and its special applications. 
Radiographics 2009;29:1433-49. 
  (24)   Thulborn KR, Waterton JC, Matthews PM, Radda GK. Oxygenation dependence of 
the transverse relaxation time of water protons in whole blood at high field. 
Biochim Biophys Acta 1982;714:265-70. 145 
 
  (25)   Christen T, Bolar DS, Zaharchuk G. Imaging brain oxygenation with MRI using blood 
oxygenation approaches: methods, validation, and clinical applications. AJNR Am J 
Neuroradiol 2013;34:1113-23. 
  (26)   Punwani S, Ordidge RJ, Cooper CE, Amess P, Clemence M. MRI measurements of 
cerebral deoxyhaemoglobin concentration [dHb]--correlation with near infrared 
spectroscopy (NIRS). NMR Biomed 1998;11:281-9. 
  (27)   Baudelet C, Gallez B. How does blood oxygen level-dependent (BOLD) contrast 
correlate with oxygen partial pressure (pO2) inside tumors? Magn Reson Med 
2002;48:980-6. 
  (28)   Chopra S, Foltz WD, Milosevic MF, Toi A, Bristow RG, Menard C, et al. Comparing 
oxygen-sensitive MRI (BOLD R2*) with oxygen electrode measurements: a pilot 
study in men with prostate cancer. Int J Radiat Biol 2009;85:805-13. 
  (29)   McPhail LD, Robinson SP. Intrinsic susceptibility MR imaging of chemically induced 
rat mammary tumors: relationship to histologic assessment of hypoxia and fibrosis. 
Radiology 2010;254:110-8. 
  (30)   Rodrigues LM, Howe FA, Griffiths JR, Robinson SP. Tumor R2* is a prognostic 
indicator of acute radiotherapeutic response in rodent tumors. J Magn Reson 
Imaging 2004;19:482-8. 
  (31)   Patterson DM, Zweifel M, Middleton MR, Price PM, Folkes LK, Stratford MR, et al. 
Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent 
OXi4503 in patients with advanced solid tumors. Clin Cancer Res 2012;18:1415-25. 
  (32)   Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and 
challenges in oncology. AJR Am J Roentgenol 2007;188:1622-35. 
  (33)   Guo Y, Cai YQ, Cai ZL, Gao YG, An NY, Ma L, et al. Differentiation of clinically benign 
and malignant breast lesions using diffusion-weighted imaging. J Magn Reson 
Imaging 2002;16:172-8. 
  (34)   Gauvain KM, McKinstry RC, Mukherjee P, Perry A, Neil JJ, Kaufman BA, et al. 
Evaluating pediatric brain tumor cellularity with diffusion-tensor imaging. AJR Am J 
Roentgenol 2001;177:449-54. 
  (35)   Thoeny HC, De KF, Vandecaveye V, Chen F, Sun X, Bosmans H, et al. Effect of 
vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus 
diffusion-weighted MR imaging. Radiology 2005;237:492-9. 
  (36)   Bohndiek SE, Kettunen MI, Hu DE, Witney TH, Kennedy BW, Gallagher FA, et al. 
Detection of tumor response to a vascular disrupting agent by hyperpolarized 13C 
magnetic resonance spectroscopy. Mol Cancer Ther 2010;9:3278-88. 
  (37)   Hamstra DA, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: a 
biomarker for treatment response in oncology. J Clin Oncol 2007;25:4104-9. 
  (38)   Campbell-Washburn AE, Price AN, Wells JA, Thomas DL, Ordidge RJ, Lythgoe MF. 
Cardiac arterial spin labeling using segmented ECG-gated Look-Locker FAIR: 146 
 
variability and repeatability in preclinical studies. Magn Reson Med 2013;69:238-
47. 
  (39)   Belle V, Kahler E, Waller C, Rommel E, Voll S, Hiller KH, et al. In vivo quantitative 
mapping of cardiac perfusion in rats using a noninvasive MR spin-labeling method. J 
Magn Reson Imaging 1998;8:1240-5. 
  (40)   Campbell-Washburn AE, Zhang H, Siow BM, Price AN, Lythgoe MF, Ordidge RJ, et al. 
Multislice cardiac arterial spin labeling using improved myocardial perfusion 
quantification with simultaneously measured blood pool input function. Magn 
Reson Med 2013;70:1125-36. 
  (41)   Rice GC, Leiberman DP, Mathie RT, Ryan CJ, Harper AM, Blumgart LH. Liver tissue 
blood flow measured by 85Kr clearance in the anaesthetized rat before and after 
partial hepatectomy. Br J Exp Pathol 1977;58:243-50. 
  (42)   Walker-Samuel S, Orton M, McPhail LD, Boult JK, Box G, Eccles SA, et al. Bayesian 
estimation of changes in transverse relaxation rates. Magn Reson Med 
2010;64:914-21. 
  (43)   Sheng Y, Hua J, Pinney KG, Garner CM, Kane RR, Prezioso JA, et al. Combretastatin 
family member OXI4503 induces tumor vascular collapse through the induction of 
endothelial apoptosis. Int J Cancer 2004;111:604-10. 
  (44)   El-Emir E, Boxer GM, Petrie IA, Boden RW, Dearling JL, Begent RH, et al. Tumour 
parameters affected by combretastatin A-4 phosphate therapy in a human 
colorectal xenograft model in nude mice. Eur J Cancer 2005;41:799-806. 
  (45)   Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, et al. Mechanisms 
associated with tumor vascular shut-down induced by combretastatin A-4 
phosphate: intravital microscopy and measurement of vascular permeability. 
Cancer Res 2001;61:6413-22. 
  (46)   Galbraith SM, Chaplin DJ, Lee F, Stratford MR, Locke RJ, Vojnovic B, et al. Effects of 
combretastatin A4 phosphate on endothelial cell morphology in vitro and 
relationship to tumour vascular targeting activity in vivo. Anticancer Res 
2001;21:93-102. 
 
 
 
   147 
 
Chapter 6 Functional MRI 
biomarkers of vascular disruption 
in a liver metastatic model of cancer 
6.1 Introduction 
In the previous chapter I have shown the development of three functional parameters 
associated  with  vascular  function  that  can  be  assessed  by  non-invasive  MR  imaging. 
Subcutaneous  models  of  cancer  however  only  offer  limited  translational  potential; 
orthotopic models of disease, in which the tumour grows at the correct anatomical location 
in which it would be found in patients, are generally considered to better reflect the clinical 
situation due to a more relevant microenvironment in which the tumours develop (1). This 
then provides a more reliable insight into the translational ability of the novel therapeutic 
tested or the preclinical imaging modalities used (2). As discussed in the introduction to this 
thesis, although there may be many different underlying causes of colorectal disease, one 
common factor is the high incidence of metastatic spread of the cancer cells to the liver; 
around a third of patients at diagnosis will present with detectable metastatic spread to the 
liver,  with  a  further  50%  of  those  with  undetectable  liver  disease  at  presentation 
progressing to develop metastasis (3). This late stage of colorectal cancer is difficult to treat 
effectively,  with  metastatic  spread  being  ultimately  the  main  cause  of  mortality  (4). 
Preclinical  models  of  liver  metastasis  that  mimic  this  clinical  situation  are  therefore 
necessary for effective translation of therapies and imaging techniques. Many different 
models have emerged (5, 6); the most reproducible model that combines relative ease of 
set-up and spread through blood vessels to the liver parenchyma is direct injection of 
cancer cells in to the spleen of the animals (7). Following the subsequent development of 
the solid tumour deposits however can be difficult, as access to MRI scanners is both time-
consuming and expensive. Bioluminescence has emerged as a useful way of following cells 
in vivo that is inexpensive, easy to use and has a high throughput (8).Transduction of cell 
lines  with  the  luciferase  gene  is  necessary,  but  allows  longitudinal  imaging  of  tumour 
progression. This chapter therefore aims to develop a model of colorectal liver metastasis 
by direct intrasplenic injection of luciferase transduced SW1222 and LS174T cells lines. This 
model will then be used to image the response to vascular disruption with OXi4503 using 
the functional vascular-associated MRI biomarkers described in the previous chapter.  148 
 
6.2 Method 
6.2.1 Validation of luciferase transduction 
In  order  to  image  cells  by  bioluminescent  imaging  the  colorectal  carcinoma  cell  lines 
SW1222 and LS174T were first stably transduced via a viral vector with the firefly luciferase 
reporter gene. Transduction has the advantage that the reporter is constitutively active and 
longitudinally viable with no decrease in gene expression. This procedure was carried out 
by the laboratory of Dr Martin Pule at the UCL Cancer Institute. The firefly luciferase gene 
was co-induced with the cellular marker CD34, allowing analysis of transduction efficiency 
via fluorescence activated cell sorting (FACS).  Analysis of non-transduced and luciferase 
transduced SW1222 and LS174T cell lines was performed on a CyAn ADP flow cytometer 
(Beckman Coulter), with measures of forward and side scatter used to identify viable single 
cell populations. This viable cell population was then measured for fluorescence to identify 
correct transduction of the luciferase gene in to the cell line. Quantitation of transduction 
efficiency  by  means  of  cell  population  was  performed  on  the  Summit  software  v4.3 
(Beckman Coulter). Transduced cell lines were frozen for storage at passage 5 (SW1222) 
and passage 8 (LS174T). Further in vitro validation of successful gene transduction was 
performed using the PhotonImager (Biospace) to conduct assays of cell growth kinetics in 
comparison  with  parental  cell  lines,  kinetics  of  luciferase  bioluminescent  activity,  cell 
number to luminescence correlation, and lower limit of cell detection by bioluminescence. 
In  vivo  characterisation  included  the  viability  of  transduced  cells  to  form  solid 
subcutaneous tumours with correct morphology, as assessed by H&E staining, and tumour 
growth curve kinetics compared to non-transduced cells.  
6.2.2 Characterisation of liver metastasis model 
In order to observe growth of the model in a longitudinal manner n=8 mice were injected 
intrasplenically  with  luciferase-transduced  SW1222  cells  under  recovery  surgery,  as 
established in the methods section of this thesis. Animal were allowed to recover for 48 
hours before imaging progression of the tumours commenced. Imaging by bioluminescence 
was achieved by injecting 30mg/kg i.p. luciferin and imaging at 15 minutes post dose. This 
was done every week up to four weeks after surgery. During this time imaging sessions on 
the 9.4T MRI scanner were also performed, with high-resolution T2-weighted sequences, as 
described in the previous chapter, used to acquire morphological scans that would enable 
volume  measurements.  During  these  scans,  working  up  of  diffusion,  perfusion  and 
deoxyhaemoglobin sensitive intrinsic susceptibility sequences was also performed. Liver 149 
 
sections containing tumour deposits were excised at termination at 4 weeks post-surgery 
for histological analysis. 
6.2.3 Functional assessment of response to vascular disruption 
For assessment of response to vascular disruption with the VDA OXi4503, n=12 mice were 
used to establish models of liver metastasis; n=6 with SW1222 cells and n=6 LS174T cells. A 
further n=5 were injected with SW1222 cells in order to be used as sham controls dosed 
with saline solution. Animals were monitored for tumour growth as described above. At 
around  three  weeks,  when  clearly  defined  individual  tumours  were  distinguishable  by 
bioluminescence  imaging,  animals were  used  for  therapy  response studies. Due  to  the 
time-intensive nature of this MRI scanning, it was performed over a number of consecutive 
days. Animals were positioned within the scanner and an i.v. line catheter placed in the tail 
vein and held in place with moulding paste and surgical tape. The line was left in place 
during localisation scans of the mouse abdomen to correctly place the image slice. Baseline 
measurements of ADC, ASL and R2* were acquired using the sequences described in the 
previous chapter. Dosing of the mice was then performed remotely, and scans of ADC and 
R2* acquired consecutively up until 90 minutes post dose, after which a final ASL perfusion 
scan  was  performed.  Animals  were  then  removed  from  the  scanner  and  the  tail  vein 
catheter  removed  and  checked  for  signs  of  an  unsuccessful  dose  (i.e.  a  subcutaneous 
injection, pooled liquid outside the cannula, etc). SW1222 tumours were the re-scanned at 
days 1, 3 and 5 post dose to observe longitudinal changes in functional parameters. Sham-
dosed  controls  and  LS174T  tumours  were  scanned  for  the  acute  90  minutes  only.  At 
experiment termination tumours were excised for histological assessment. 
6.2.4 Analysis of results 
Measures  of  ADC,  ASL  and  R2*  were  analysed  in  Matlab  and  reconstructed  in  Amira 
software. The acquired data-sets were searched for acute (90 minutes) and longitudinal (up 
to 5 days) change in value; data-sets were also analysed for markers of response, both 
inter- and intra-parameter. Analyses based on size of tumour deposit and location was also 
performed, with results from all tumour voxels considered for potential significance. 
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6.3 Results 
6.3.1 Expression of luciferase activity 
Results from the flow cytometry of the SW1222 cell line can be seen in figure 6.1. The top 
section shows results for SW1222 cells and the lower section for LS174T cells. Panels A and 
B in each show acquired data for the parental non-transduced cells, with statistics of total 
count and percentage of total gated cells shown on the right of the row. Panel A shows the 
entire cell suspension plotted as forward scatter vs side scatter. From this a region R1 is 
drawn  around  a  healthy  cell  population.  Panel  B  then  shows  the  fluorescence  of  this 
population of healthy cells; for SW1222 cells 99% are within region R4 of panel B, and for 
LS174T  cells  98.65%  are  within  region  R4,  showing  that  they  are  not  fluorescent  and 
therefore do not express the cell surface marker CD34. 
Panels C and D show the same metrics for the luciferase transduced cell lines. The total 
events  registered  is  maintained  in  a  similar  way  to  the  non-transduced  cells,  with  the 
percentage of total cells selected in the region R1 also maintained to around 35% of total 
cells. The population of SW1222 and LS174T cells in the region R4, however, has decreased 
to 6.46%  and  5.13%  respectively,  with  93.02%  and  94.84% of this  sub-population  now 
within the region R2 of panel B. This shows the cells to be positive for fluorescence and 
therefore expressing the cell surface marker CD34, which correlates to expression of the 
luciferase gene. 
Following this, full characterisation of transduced cell lines was performed, including in 
vitro  cell  growth  kinetics,  time  profile  of  cellular  luciferase  activity,  correlation  of 
bioluminescent signal to cell number, lower limit of detection, and in vivo comparison of 
subcutaneous growth between parental and transduced cell lines. No difference between 
transduced  and  parental  lines  was  noted,  and  experiments  proceeded  to  in  vivo 
bioluminescent  charaterisation  of  the  liver  metastasis  model  (in  vitro    characterisation 
results can be found in appendix I of this thesis).  
The n=8 mice injected intrasplenically with SW1222-Luc were imaged over the 4 week 
period by bioluminescence, an example of which can be seen in figure 6.2. Panel A shows a 
composite image of the whole group of mice at each time point, with the photon flux 
acquired superimposed over the photo of the animals in the scanner. As can be seen, the 
photon  flux  produced  by  the  luciferase-expressing  cells  can  be  detected  from  day  2 
onwards, and always located in the region of the abdomen and liver. Quantification of this 
photon flux is shown in panel B individually, with the growth of signal over time expressed 151 
 
as log10 of photon per second per cm
2 per steradian. As can be seen in panel B, the signal in 
all animals increases over the 4 weeks. Panel C shows the average photon flux across the 
group of animals, with error bars denoting standard deviation of the mean. 
 
 
 
 
 
 
 
SW1222 
Figure 6.1 Fluorescence activated cell sorting analysis of luciferase gene transduction  
SW1222 cell line (first panel) and LS174T cell line (second panel): FACS analysis of parental (A 
and B) and luciferase-transduced cells (C and D). A and C depict healthy cell population selection, 
B and D depict sub-population fluorescence expression. Total cell count and % of total is shown 
to the right of each row. 
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Figure 6.2 Bioluminescence monitoring of liver metastatic burden  
Panel A shows n=8 mice following intrasplenic injection of SW1222 cells at day 2, 9, 19 and 23. 
Images show bioluminescent photon flux superimposed on a photo background. Panel B shows 
calculation of log10 of photon flux in ph/s/cm
2/sr for all animals across all time points. Panel C 
shows the average with standard deviation of the mean denoted by error bars for the group. 
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6.3.2 Development of orthotopic model 
High resolution T2-weighted scans of the n=8 SW1222 mice were acquired over the 4 week 
imaging period, an example of which can be seen in figure 6.3. The day at which each 
image  was  acquired  is  below  the  MRI  section,  with  significant  abdominal  features 
highlighted by the arrows. Development of solid tumours within the liver is seen as  areas 
of hyper-intense ‘white’ signal as opposed to normal uniform grey signal that is from liver 
tissue; tumour deposits are first seen as small spherical objects in one lobe of the example 
liver at day 14 following surgery. Tumour deposits increase in size until at day 27 the 
majority of  liver  area  is  taken  over  with  tumour  tissue.  This  can  be  segmented  and  a 
volume of total tumour burden calculated. An example of this is shown in figure 6.4, in 
which tumour deposits at weeks 2, 3 and 4 have been pseudo-coloured in orange. Tumour 
total  burden  across  the  group  of  mice  can  therefore  be  calculated,  and  is  shown  as 
percentage tumour burden within the liver in the lower right hand panel of figure 6.4. 
 
 
 
 
 
 
 
Day 8 
Day 20  Day 27 
Day 14 
Figure 6.3 Magnetic resonance monitoring of liver metastatic deposits  
High resolution T2-weighted MRI images of progression of the liver metastatic model shown 
over a 4 week imaging period (n=8 total); abdominal features such as organs are highlighted by 
the arrows.  Tumours are  seen as hyper-intense  spherical regions  within the liver lobes that 
increase in size over the time frame imaged. 154 
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Figure 6.4 Segmentation of tumour deposits and total tumour burden  
Images show orange pseudo-colouring of segmented tumour deposits from high resolution T2-
weighted MRI images at weeks 2, 3 and 4 following surgery. Total liver burden can be calculated 
as percentage of the liver that is occupied by tumour tissue, a graph of which across the whole 
group can be seen in the lower right panel (n=8, error bars denote mean±SDM). 155 
 
6.3.3 Monitoring of functional response within tumour deposits 
 
In order to demonstrate the applicability of the MRI sequences developed in the previous 
chapter to study of the liver metastatic model used here, an example of the mapping ability 
is shown in figure 6.5. This shows results from the ASL sequence (A) and IS sequence (B) 
from within the same liver mapped across 4 distinct tumour deposits both at baseline and 
90 minutes  post  40mg/kg  OXi4503.  For  clarity  these  have  been  superimposed  on  high 
resolution T2-weighted images, and one of the deposits has been enlarged so as to clearly 
show  the  varied  results mapped  across  the  tumour  voxels.  Panels  C and  D  show  H&E 
staining of liver sections containing tumour deposits at 24 hours after dosing with saline 
control (C) or 40mg/kg of OXi4503 (D), which clearly shows a necrotic core with rim of 
surviving cells following dosing with OXi4503 and ‘normal’ healthy tumour cells with the 
saline control, demonstrating the efficacy of the i.v. line employed in this set-up. Results for 
the  ADC  sequence  are  not  shown,  as  bulk  motion  within  the  imaging  section  due  to 
peristaltic motion of the intestines and any residual respiratory motion not correctly gated 
out meant coupled with the small volume of the tumour deposits produced corrupted data 
sets, giving no useful measurement. Because of this only results for ASL and R2* will be 
shown hereafter. 156 
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Figure 6.5 Mapping of functional MRI measurements on to tumour deposits 
Functional  measurements  of  perfusion  (A)  and  increase  in  R2*  (B)  using  ASL  and  intrinsic 
susceptibility sequences at baseline and 90 minutes after 40mg/kg OXi4503 mapped across 4 
distinct tumour deposits (n=1 shown, n=6 total for each of SW1222 and LS174T). Histological 
assessment of SW1222 response shows a sham dosed control liver section containing a viable 
tumour deposit (C) and a dosed liver section (D) at 24 hours post 40mg/kg OXi4503 157 
 
6.3.4 Response of metastases to vascular disruption 
Functional response to vascular disruption using OXi4503 in the liver metastatic model was 
performed in n=6 SW1222 and n=6 LS174T mice, with a further n=5 SW1222 animals sham 
dosed  with  saline.  Distinct  tumour  deposits  within  the  liver,  clearly  identified  by  high 
resolution T2-weighted imaging, were used to position the single slice ASL sequence; this 
was matched to the R2* acquired data, providing n=22 distinct OXi4503 treated SW1222 
tumours, n=12 LS174T tumours, and n=13 sham dosed SW1222 tumours. As seen in the 
previous chapter, use of the median functional value acquired from across the tumour 
voxels was used as indicative of response of the whole tumour. Figure 6.6 shows box plots 
for values of ASL (A) and R2* (B) in sham treated SW1222 tumours, with the central line 
denoting the median value, the boxes the inert-quartile range and the whiskers denoting 
minimum  and  maximum  values.  Two  tailed  paired  T-Tests  between  values  show  no 
significant  results  across  the  90  minute  time  frame  acquired.  The  same  box  plot 
configuration has been used for both ASL and R2* in SW1222 and LS174T, shown in panels 
A and B of figures 6.7 and 6.8 respectively. Panel C in each of these figures shows the 
percentage of baseline median value of ASL in blue and R2* in red plotted on the same 
graph, with error bars denoting standard error of the mean. As the SW1222 group was 
imaged for a longer time period, this is reflected in the graphs within figure 6.7. Perfusion 
of tumours, as measured by ASL, appears to decrease slightly at 90 minutes and 24 hours 
post dose, with a return to higher values seen at day 3 and 5. R2* appears to increase 
slightly at 90 minutes, followed by a decrease at day 3 and 5. T-Tests for significant results 
however show that only 90 minute ASL and day 3 R2* are significantly different from 
baseline values. All other time points show a non-significant spread of values. 
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Figure 6.6 Functional response of tumour deposits – Sham dose 
Graphs depict functional measurements of perfusion (A) and increase in R2* (B) using ASL and 
intrinsic susceptibility sequences from baseline up to 90 minutes after saline sham dose (n=5). 
Box plots show the median value, interquartile range, and maximum and minimum of n= 13 
distinct SW1222 tumour deposits.  158 
 
 
 
Figure 6.7 Functional response of tumour deposits – SW1222 
Graphs of perfusion (A) and increase in R2* (B) using ASL and intrinsic susceptibility sequences 
from baseline up to 5 days post 40mg/kg OXi4503 (n=6). Box plots show the median value, 
interquartile range, and maximum and minimum of n= 22 distinct SW1222 tumour deposits, 
with * showing significance. Graph C shows average percentage of baseline values for R2* in red 
and ASL in blue across the cohort, with error bars denoting standard error of the mean 
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Figure 6.8 Functional response of tumour deposits – LS174T 
Graphs depict functional measurements of perfusion (A) and increase in R2* (B) using ASL and 
intrinsic susceptibility sequences from baseline up to 90 minutes after 40mg/kg OXi4503 (n=6). 
Box plots show the median value, interquartile range, and maximum and minimum of n= 12 
distinct LS174T tumour deposits. Graph C shows average percentage of baseline values for R2* 
in red and ASL in blue across the cohort, with error bars denoting standard error of the mean 160 
 
Results for the LS174T tumours shown in figure 6.8 depict the acute 90 minute imaging 
period. Although there is some suggestion of an increase in R2* over the first 60 minutes of 
data acquisition the results demonstrate a range of values that show no significance when 
compared  to  baseline.  As  the  cohort  data  showed  no  change,  even  though  individual 
tumour deposits did alter functional readings of perfusion and increase of deoxygenated 
haemoglobin, correlations between the two parameters on an individual tumour deposit 
basis  was  examined.  The  scatter  plots  depicted  in  figure  6.9  show  the  measured  ASL 
perfusion value at baseline across the X axis against the change measured at 90 minutes 
post OXi4503 on the Y axis for both SW1222 (A) and LS174T (B). Both tumour types show a 
negative  correlation  with  R
2  values  of  0.65  and  0.78  respectively,  showing  that  those 
tumour deposits that show a change in perfusion levels are those that have the highest 
initial perfusion at baseline. The same graphs layout is reproduced for values of R2* in 
figure  6.10.  No  association  is  observed  in  the  SW1222  tumours,  whilst  in  the  LS174T 
tumours a negative correlation is observed with an R
2 of 0.79. LS174T tumours with a high 
baseline R2*appear to decrease in value at 90 minutes whilst those with a low initial value 
show an increase at 90 minutes. The third comparison in figure 6.11 shows the change in 
perfusion by ASL at 90 minutes on the X axis compared to the change in R2* at 90 minutes 
on the Y axis. Although there is a suggestion of correlation between an increase in R2* 
relating to a decrease in perfusion in the SW1222 tumours, the R
2 is only 0.34, whilst no 
association is noted in the LS174T tumours. 
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Figure 6.9 Baseline vs change correlation in perfusion 
Graphs depict functional measurements of perfusion in SW1222 (A) (n=6 animals) and LS174T 
(B) (n=6 animals) tumours using ASL sequences. Median values per tumour deposit are shown 
for baseline measurements on the X axis with the change in perfusion at 90min on the Y axis. 
Error bars for individual points represent standard error of the median value acquired  161 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Figure 6.10 Baseline vs change correlation in R2* 
Graphs depict functional measurements of R2* in SW1222 (A) (n=6 animals) and LS174T (B) (n=6 
animals) tumours using intrinsic susceptibility sequences. Median values per tumour deposit are 
shown for baseline measurements on the X axis with the change in perfusion at 90min on the Y 
axis. Error bars for individual points represent standard error of the median value acquired  
Figure 6.11 Change in R2* vs change in perfusion 
Graphs depict functional measurements of change in perfusion and R2* in SW1222 (A) (n=6 
animals) and LS174T (B) (n=6 animals) tumours using ASL and intrinsic susceptibility sequences. 
Median values per tumour deposit are shown for change in perfusion measurements on the X 
axis with the change in R2* on the Y axis. Error bars for individual points represent standard 
error of the median value acquired  
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6.3.5 Effect of tumour location 
Having  observed  differential  effect  of  functional  measurements  of  perfusion  and  R2* 
within different tumours deposits, even if they were within the same animal and lobe of 
liver, further analysis was performed to understand these differences. Histological analysis 
was  performed  on  larger  sections  to  encompass  more  than  one  solid  tumour  deposit. 
Results from this varied, however as can be seen in figure 6.12; certain liver sections did 
contain multiple tumour deposits at 24 hours post OXi4503 that had reacted differently to 
dosing. Highlighted by black arrows in panel A are two SW1222 tumour deposits that show 
typical signs of necrosis within the core of the tumour, with a healthy rim of surviving cells. 
A further two tumour deposits are highlighted by the red arrows that show no sign of 
necrosis, with densely nucleated tissue that is characteristic of healthy growing tumours. 
Panels B and C show enlarged examples of tumour deposits found to be non-responsive 
and responsive respectively, both in a similar position on the edge of the liver.  
 
 
 
 
 
 
 
Figure 6.12 Histological assessment of multiple tumours within a liver section 
Panels show H&E staining of a larger section of liver tissue containing multiple SW1222 tumour 
deposits. Highlighted in panel A by the black arrows are two deposits that have responded to 
40mg/kg of OXi4503, whilst highlighted by the red arrows are two tumour deposits that have 
not. Panels B and C show further examples of cases of non-response and response, respectively. 
Black bars within images denote 1000µm 
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Further categorisation of the functional MRI data based on tumour deposit size did not 
show  any  correlation  to observed effect.  Where  it  was  possible  to  categorise  tumours 
based on location this was implemented, with tumours designated as either close to a large 
blood vessel, close to a small blood vessel, or close to the periphery of the liver lobe. An 
example of the segmentation used to achieve this can be seen in  figure 6.13 panel A, 
where a three-dimensional liver area has been segmented in Amira and represented by the 
maroon coloured structure. The major blood vessel networks within the liver have also 
been segmented and are represented in blue. All tumour deposits have been segmented 
and  coloured  in  yellow,  with  three  coloured  differently  to  demonstrate  categorisation 
based on location; the tumour in red is proximal to a large vessel, the tumour in green is 
proximal to smaller vessels, and the tumour in light blue is at the periphery of the liver 
lobe. The resultant change at 90 minutes in perfusion and R2* can then be shown based on 
this grouping, with perfusion shown in blue and R2* in red, for both SW1222 (panel B) and 
LS174T (panel C). For SW1222 tumours not much difference is seen in changes in R2*, 
however there is a decrease of 48%±14% for tumours close to large vessels, a more varied 
but also large decrease for tumour located close to small vessels of 59±48%, and a small 
and varied decrease at the liver periphery of 17±28%. Baseline perfusion measurements for 
these  locations  showed  that  those  close  to  large  vessels  were  better  perfused  at 
1.5±0.8ml/g
-1 min
-1, compared to 1.3±0.7 ml/g
-1 min
-1 and 0.6±0.3 ml/g
-1 min
-1 respectively. 
However,  for  the  LS174T  tumours  there  was  no  difference  noted  in  perfusion 
measurements, although those located close to large vessels had a significantly different 
increase in measured R2* of 74.7±23% when compared to tumours located close to small 
vessels or the liver periphery. Initial values of R2* for these tumours were significantly 
lower,  at  0.05±0.01  s
-1,  when  compared  to  tumours  located  close  to  small  vessels 
(0.15±0.08 s
-1) and liver periphery (0.25±0.1 s
-1). 
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    Figure 6.13 Functional response of tumour deposits categorised by location  
Panel A shows a whole liver in 3D segmented for liver tissue (maroon), major blood vessels 
(blue) and tumour deposits (yellow). Three example tumours are shown in red for adjacent to 
‘large vessel’, green for ‘small vessel’, and light blue for ‘periphery’. Change from baseline value 
based on this categorisation can be seen in panel B for SW1222 (n=6 animals) and C for LS174T 
(n=6 animals), with ASL for perfusion in blue and R2* in red. 
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6.4 Discussion 
6.4.1 Correct transduction of cells lines was achieved  
Bioluminescence is a useful preclinical in vivo tool that allows highly sensitive tracking of 
cells that express an introduced gene in a rapid, inexpensive and relatively easy manner (9-
11); luciferase in particular, from the firefly Photinus Pyralis, has been extensively used in 
biomedical research (12, 13). In this chapter I have shown that the transduction of two 
colorectal carcinoma cell lines with the luciferase gene has been achieved, and that this 
does  not  affect  growth  characteristics  of  the  cells  in  vitro  or  the  progression  of  solid 
tumours in vivo. Luciferase expression was also not altered over time in the dividing cells or 
due to liquid nitrogen storage, as the cells were transduced with luciferase rather than 
transfected.  This  enabled  monitoring  of  the  developing  tumours  in  vivo  in  a  fast  and 
inexpensive  manner,  and  is  similar  to  previous  work  using  luciferase  to  monitor  liver 
models of cancer that have used for different cell lines (14, 15). Bioluminescence was used 
here  simply  as  a  tool  to  monitor  tumour  progression,  in  order  to  time  functional 
assessment of VDA treatment with MRI; translation to the clinic of bioluminescence is not a 
viable option, given that the cells need to be transduced externally to the patient in order 
to express the luciferase gene. However, previous work using bioluminescence as a marker 
of response to VDA treatment in its own right has shown that it may also be a useful 
translational tool for novel therapeutics that target tumour vasculature (16); Zhao et al 
have  shown  that  dynamic  response  to  CA4P  can  be  monitored  by  luciferase  activity, 
proving that correct transduction of cell lines, with no altered growth characteristics, may 
in the future prove a useful technique for assessing new vascular targeted therapies. 
6.4.2 Functional MRI biomarkers can be measured on individual 
tumour deposits 
Although  previous  work  has  shown  response  to  OXi4503  in  liver  metastatic  models  of 
cancer (17) this is the first time that non-invasive imaging of vascular parameters across the 
whole  liver  has  been  assessed.  Pre-treatment  tumours  showed  variable  baseline 
measurements  of  perfusion  and  R2*,  and  a  heterogeneous  response  to  OXi4503  was 
observed  in  both  ASL  and  IS-MRI  techniques.  Because  of  this  observed  heterogeneous 
response  each  metastasis  was  considered  as  an  individual  entity;  caution  is  therefore 
needed in the interpretation of the statistical changes, as some effects may be affected by 
systemic changes within the whole animal. However, the ability to map these values across 
the  tumour  voxels,  as  with  subcutaneous  tumours  shown  in  the  previous  chapter, 
demonstrates that these functional markers of response can be measured individually from 166 
 
one tumour deposit to the next. This is the first time that arterial spin labelling has been 
used to measure perfusion in tumours outside of the brain; the use of hepatic ASL to assess 
response to VDA therapy in this liver metastatic model is therefore a novel approach to 
monitor vascular changes. A significant reduction in perfusion was observed at 90 minutes 
following administration of 40 mg/kg of OXi4503 in SW1222 tumours, which is consistent 
with the proposed vascular targeting action of the agent (18), and relates well to previously 
published ex vivo histological data of a similar VDA (19). It is interesting to note that at 24hr 
the value of ASL for the SW1222 tumours (figure 6.7) appears to measure perfusion within 
the tumour that should be centrally necrotic; this is possibly an effect of heterogeneous 
response observed, in that whilst some tumours will have no flow due to a necrotic core 
others were not  affected at 24hr post-dose and therefore retain a flow measurement. 
Another possibility is that the area of tumour ROI is sufficient to include some of the 
tumour  periphery  and  normal  liver,  which  will  still  be  perfused.  Indeed,  from  the PAT 
experiments presented earlier in this thesis it appears that the remaining tumour periphery 
and  surrounding  normal  tissue  increases  in  haemoglobin  presence  following  OXi4503 
therapy. This flow to the periphery may explain some of the measured ASL in figure 6.7. A 
further possibility is of a potentially introduced bias for positive values during the post-
processing of the acquired data; any negative values were automatically assigned a value of 
zero, given that a negative flow was not possible, which may skew the data towards a 
higher average value. This on its own however is not sufficient to explain the measured 
perfusion with ASL, and it is thought likely that it is a combination of the above. 
An increase in R2* from IS-MRI was also measured at 90min, which is consistent with 
previous studies (20). However, measurements taken at subsequent time-points showed 
no  significant  difference  from  baseline.  The  same  was  found  for  LS174T  tumour 
measurements of ASL and R2*. It is possible that the 90 minute time frame is not sufficient 
to observe any induced effects, however the more likely explanation is a heterogeneous 
response to treatment on a tumour-to-tumour basis. As these measurements were based 
on  median  values  across  tumour  deposits  and  groups  the  range  in  values  masks  any 
potential biomarker effect of the measured parameters. In fact, when both SW1222 and 
LS174T tumour deposits are assessed individually it can be seen that high initial levels of 
perfusion  correspond  to  those  tumours  with  the  greatest  response  to  therapy;  this 
suggests that tumours with high initial vascularisation stand are potentially sensitive to the 
actions  of  VDAs  and  indicates  a  potential  prognostic  ability  of  ASL  measurement  in 
tumours,  i.e.  not  all  tumours  will  have  the  same degrees  of  perfusion,  but  those  that 167 
 
possess  high  perfusion  based  on  ASL  measurements  will  respond  effectively  to  VDA 
treatment. Tumour cell kill in response to therapy is also dependent on the absolute blood 
flow to the tumour and the length of time that this is shut down within the tumour. Further 
investigation of how these high-perfusion metastasis respond in this regard would be very 
informative. With R2* there is no correlation between baseline and subsequent change 
within SW1222 tumours, and an inverse relationship with LS174T tumours, reflecting the 
differing  vascular  pathophysiologies  between  the  two  tumours.  It  is  possible  that  the 
LS174T tumours with high initial R2* reflect tumours with an already impaired vascular 
supply,  leading  to  significant  levels  of  deoxyhaemoglobin  already  present  within  the 
tumours. Low initial levels of R2* would indicate a relatively well perfused tumour deposit 
to  begin  with  which,  when  treated  with  OXi4503,  actually  increases  the  content  of 
deoxygenated blood and therefore the measure of R2*. This could explain the differences 
in response observed, and essentially show tumours at different stages of progression of 
necrosis. Given that a decrease in perfusion would lead to an increase in R2* it is surprising 
that no correlation exists between the two parameters, even if there was a small indication 
of a negative correlation. This is potentially due to the timing of complete vascular shut 
down  within  the  tumour  vasculature  and  the  subsequent  consumption  of  the  oxygen 
within the stopped blood. This highlights the complex vascular pathophysiological changes 
induced by VDAs and the need for multiple markers of response. It was not possible to 
exactly correlate the different histological tumour sections with the corresponding MRI 
data, as differential response was not initially expected, and subsequent liver deformation 
during tissue processing meant the link between actual tumour and MRI data was lost. In 
order  to  address  this,  in  any  future  repeat  of  the  study  the  individual  solid  tumour 
metastasis would need to be identified on excision during dissection (i.e. which lobe of the 
liver, position within the liver, etc) and placed in to separate labelled containers. In this 
manner  any  changes  in  tumour  perfusion  by  a  reduction  in  Hoechst  33342  perfusion, 
reduction in tumour vasculature by CD34 staining, the presence or not of a necrotic core, 
and any further histological assessment, could be linked nack to the MRI data. Therefore 
responders  and  non-responders  could  be  identified  ex  vivo  and  linked  to  the  in  vivo 
functional data.  Current histology from 24 hours post dose however does indicate that 
different tumour deposits reacted differently to OXi4503. 
6.4.3 Effect of tumour location 
I have also shown within this chapter that tumour deposit location within the liver can 
affect  functional  response  to  dosing  with  OXi4503.  H&E  staining  showed  evidence  of 168 
 
different responses between metastases within the same liver; by categorising the location 
of tumour deposits within the liver relative to major blood vessels or the periphery, I have 
shown  that  for  SW1222  tumours  the  reduction  in  perfusion  was  greatest  and  most 
consistent in metastases close to large vessels, similar but less consistent in metastases 
close to smaller vessels, and was smallest in those at the periphery of the liver. With 
LS174T tumours this categorisation shows that metastases close to large vessels will show 
an  increase  in R2*  whilst  those  less  perfused,  i.e. close  to  smaller vessels or  the  liver 
periphery,  will  not.  This  suggests  that  the  pharmacokinetics  of  drug  action  may  be 
influenced  by  micro-environmental  factors  such  as  tumour  perfusion,  and  that  the 
underlying tumour pathophysiology also has a role to play in determining which functional 
marker will show a change. This range of responses between metastases, dependent upon 
location and extent of growth, has been previously observed in the LS174T model, albeit 
with the use of radiolabelled antibodies (21), further validating this theory.  
6.4.4 Further work on hepatic ASL 
Liver metastases are arguably less suited to IS-MRI than subcutaneous tumour models, 
particularly as shimming of the B0 field can be challenging due to susceptibility artefacts 
propagating  from  surrounding  lungs  and  gut,  in  addition  to  respiratory  and  peristaltic 
motion artefacts which can be difficult to control. As such, and given the mechanism of 
action of VDAs, ASL arguably provides a biomarker of therapeutic response that affords a 
less ambiguous interpretation than IS-MRI. Furthermore, I have shown that ASL can identify 
a heterogeneous response between tumour deposits within the same liver, and therefore 
has the potential to highlight those metastases that may respond positively to treatment 
versus those that will not. It can also identify a patient in which none of the tumours 
respond to the VDA, thus sparing them from unnecessary treatment. Targeting of different 
tumour pathophysiologies often requires a combination treatment approach for adequate 
response,  especially  with  regards  to  VDAs  (22).  With  optimisation  of  the  combined 
biomarker approach, however, the two measures could provide a deeper insight into the 
mechanics of tumour response to therapy in vivo, by relating changes in blood flow to 
those in blood oxygen saturation.  
A  limitation  of  this  study  was  the  use  of  a  single-slice  acquisition  for  the  arterial  spin 
labelling sequence. This meant that only partial coverage of the liver was possible, and 
hence  a  number  of  metastases  were  omitted  from  analysis.  Since  this  study  was 
completed,  a  multi-slice  adaption  of  the  Look-Locker  FAIR  ASL  sequence  has  been 
developed (23). Utilising the vessel-selective pseudo-continuous ASL sequences (24) could 169 
 
also provide a direct method for separating the arterial and venous contributions to the 
liver blood supply, from which response biomarkers such as the hepatic perfusion index, a 
measure of the relative contribution of the two supplies in individual metastases, could be 
evaluated to further probe tumour pathophysiology (25).  
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Chapter 7 Conclusion 
7.1 Vascular anatomy with photoacoustic tomography 
The vascular anatomy and pathophysiology of tumours is of great importance for growth, 
metastatic spread and overall malignancy of cancer. As such, it has emerged as an area of 
cancer research that promises significant advances for treatment and survival of patients, 
with  targeted  therapy  to  tumour  vasculature  becoming  ever  more  widespread  and 
sophisticated.  An  understanding  of  the  biology  of  this  abnormal  pathophysiological 
vascular state of tumours is required to fully appreciate the interaction of the tumour 
vasculature  with  its  surrounding  microenvironment,  and  to  optimise  therapies.  In  this 
thesis I have shown that the novel imaging modality of photoacoustic tomography can be 
used in vivo to accurately depict the localisation of haemoglobin within tumours, which 
corresponds  to  the  location  of  the  tumour  blood  vessels,  and  allows  high  resolution 
imaging of tumour vasculature in a non-invasive and non-ionising way. This is based on 
inherent measures of tissue haemoglobin, and is therefore possible without the use of 
exogenous contrast agents. By being able to clearly demonstrate the differences between 
two models of CRC, I have shown that this technique should be applicable to all types of 
solid  tumours.  I  was  able  to  show  different  vascular  pathophysiologies  in  vivo, 
demonstrating   that PAT is capable of detecting different levels of vascular abnormality. 
This has potential implications for accurately staging solid tumours, and following their 
growth and local tissue invasion, impacting on patient treatment strategies. What is more, 
the  effect  of  angiogenic  signalling  was  also  observed  in  the  surrounding  tissue 
microenvironment by longitudinal PAT studies, as normal skin vasculature was modified 
into corkscrew tumour feeding vessels, and the normal tissue blood vessels were co-opted 
into the tumour.  This ability to image baseline levels of vascularisation and degree of 
abnormality  should  have  a  great  impact  on  understanding  the  adaptation  of  tumour 
vasculature in patients over time. The ability to image levels of oxygenation in tumours is 
another advantage to PAT imaging, and was demonstrated in this thesis in a qualitative 
manner. I have also been able to demonstrate the effects of vascular-targeted therapies on 
tumour  blood  vessels over  time  by PAT,  using  the VDA  OXi4503,  which  has important 
implications  for  translation  into  improved  clinical  strategies.  The  effect  of  vascular 
disruption  was  clearly  noted,  with  a  difference  in  response  between  different  vascular 
architectures  also  noticed,  further  highlighting  the  potential  of  PAT  to  assess  inherent 173 
 
degree of vascularisation and predicted response to treatment. Regrowth of tumour blood 
vessels over time was observed for the first time, showing an inward growth of vasculature 
from the surviving rim of tumour cells towards the necrotic tumour core. The ability to 
monitor the effect of a single treatment shows that PAT can be used as response marker 
that is capable of determining the need for further therapeutic intervention. Currently the 
potential clinical utility of PAT remains as a superficial imaging modality, because of a 
maximum  imaging  depth  of  around  1cm,  motion  artefacts  from  internal  organ  (e.g. 
peristalsis from intestines) and relatively long scan times of around 8 minutes. However, 
PAT  does  already  have  clinical  potential,  as  well  as  preclinical  translational  use,  in  the 
assessment of melanoma, head & neck, and breast cancers and the system is being further 
developed for wider use. 
7.1.1 Future PAT work 
Advancements  in  PAT  system  hardware  are  currently  being  developed  at  UCL  Medical 
Physics. This includes smaller, more portable and patient friendly scanner design which 
would allow PAT imaging in humans, and further work on corroborating the translational 
research carried out in this thesis. The development of smaller systems also brings up the 
possibility  of  endoscopic  PAT  imaging,  which  would  allow  primary  colorectal  and 
oesophageal tumours to be investigated. Real-time imaging of blood flow within tissue is 
also  being  pursued..  From  a  basic  translational  science  point  of  view,  future  work  on 
imaging  vascular  targeted  therapies  other  than  OXi4503,  including  anti-angiogenic 
therapies  and  their  effect  on  vascular  normalisation,  would  provide  important  clinical 
information.  . Fully quantitative analysis of acquired data is also urgently needed and is 
currently under investigation. Further possibilities include the tagging of therapeutics with 
contrast agents in order to image their biodistribution within the tumour. This may be 
possible with, for example, a fluorescent marker visible on PAT conjugated to a therapeutic 
antibody, permitting visualisation of antibody distribution whilst still having the inherent 
PAT marker of tumour response. 
7.2 Translation of vascular associated MRI sequences 
Given that the use of PAT imaging is currently restricted to small animal preclinical studies, 
and that translation to clinical use will take some time to be fully applicable, it was decided 
to use MRI to assess vascular function. Whilst many MRI sequences exist that can image 
vascular function, most employ exogenous contrast agents. It was envisaged that vascular 174 
 
function  could  be  measured  by  MRI  without  contrast  agents,  based  on  inherent 
characteristics of the tumours, and that this would be complimentary to PAT imaging. As 
MRI is a system capable of acquiring whole body scans it was also thought that sequences 
could be designed that would be applicable to orthotopic models of disease, as this would 
give  greater  translational  relevance  due  to  the  more  physiological  normal 
microenvironment. A liver model of orthotopic metastasis was used in this thesis; however 
one  disadvantage  of  this  was  the  inability  to  monitor,  cheaply  and  efficiently,  the 
development  of  the  tumour  deposits.  Luciferase  was  therefore  transduced  in  to  the 
parental cell lines and shown to have no effect on tumour cell growth kinetics in vitro or in 
vivo.  This  permitted  the  use  of  bioluminescence  scanning  following  the  injection  of 
luciferin, to observe the growth of the tumour cells within the liver and accurately time the 
more time consuming and technically challenging MRI experiments. The MRI sequences 
were first developed in subcutaneous models; the primary measure of tumour perfusion 
was  initially  not  adequate,  as  the  size  of  the  voxel  of  interest  was  limited  to  the 
subcutaneous tumours, which was too small, and perfusion too low, to achieve reliable 
information. In the metastatic model the area of interest was increased to encompass the 
perfusion measurements from whole liver with subsequent areas of metastatic tumours 
defined  by  data  segmentation;  this,  coupled  with  increased  flow  within  the  liver 
microenvironment  allowed  adequate  measurements  of  tumour  blood  perfusion. 
Measurements of the apparent diffusion of water on the other hand, as an estimate of 
tumour  necrosis,  worked  for  relatively  stable  areas  of  interest  such  as  subcutaneous 
tumours, but suffered from motion artefacts when in the more dynamic environment of 
the liver. For further studies this could be accounted for by decreasing the acquisition 
during the gated respiration window, i.e. being stricter on acquisition during respiratory 
phases. However, the peristaltic motion from the intestines could not be addressed, and 
the scan time would increase enormously. As this measure of necrosis was not performed 
to be associated with vascular function, but rather as a measure of the effective response 
to treatment, this was not considered too detrimental: ADC can be measured in humans, as 
has already been established. The novel aspect of this research was the application of ASL 
measurements  coupled  with  R2*  for  the  vascular  response  of  tumours.  Although  R2*, 
measured by intrinsic susceptibility sequences, has been used in a different model and in 
response to a different agent, this was only over a very acute range. I have shown that R2* 
and  ASL  can  be  used  a  measures  in  longitudinal  studies  as  well  as  acute  response  to 
treatment, and that they can be used to map values across individual metastasis within the 175 
 
same subject. This is a novel use of hepatic ASL, especially when in conjunction with R2*. As 
with the PAT imaging studies, response to treatment varied according to the extent of 
vascular network within the tumour types. This was further demonstrated by the effect of 
tumour  location  within  livers;  given  that  a  varied  response  was  observed  between 
metastases, and that perfusion by ASL appeared to be the more consistent in response 
from baseline to post-dose, another classification based on tumour blood perfusion was 
devised. It was assumed that tumours close to large liver blood vessels would have the 
greatest perfusion, compared to those next to smaller vessels or the periphery of the liver. 
When classified by these parameters, tumours that were well perfused, such as SW1222 
tumours close to large vessels, showed the largest decrease in ASL. In contrast tumour 
types that were less well perfused to begin with, such as LS174T tumours, demonstrated an 
increase in the deoxyhaemoglobin within the tumour. For both CRC tumour types, SW1222 
and LS174T, areas away from large vessels show less of a response, ostensibly due to 
decreased blood flow from normal tissue to, and pharmacokinetic action of the drug at, 
these locations. The response is therefore highly dependent on vascular function of the 
tumours, and the time at which the ASL or R2* parameters are acquired. However I have 
demonstrated that both can be used to assess vascular function, and are probably best 
acquired  in  conjunction  in  order  to  fully  understand  the  changes  occurring  within  the 
tumour vasculature. 
7.2.1 Future MRI work 
The heterogeneous response to treatment by metastases within the same liver was not 
expected, and warrants further investigation. Exact labelling of individual tumours would 
allow  histological  analysis  to  accurately  corroborate,  ex  vivo,  the  changes  in  vascular 
parameters observed in vivo. It is possible that this is also simply a timing issue, with some 
metastases taking longer for vascular disruption and necrosis to be established.  In vivo 
studies  over  longer  consecutive  time  frames  could  potentially  answer  this  question; 
however imaging sessions are limited due to animal experimentation regulations, which 
would make this study difficult to plan effectively. Since this work was conducted, multiple 
slice  ASL  has  been  developed  which  allows  imaging  of  the  whole  liver,  dramatically 
increasing the number of metastasis measureable .For future studies, this would need to 
be included in the experimental design 176 
 
7.3 Concluding remarks 
One proposed area of research for this thesis was the combination of PAT and MRI imaging 
modalities. However, once both PAT and MRI sequences had been individually validated, it 
was not possible to achieve this to any degree of satisfaction. The combined information 
from PAT  and MRI would  provide measures of tumour  response  for  structural  tumour 
vascular network and cessation of blood flow, increase in deoxyhaemoglobin, blood vessel 
occlusion  and  onset  of  necrosis  by  PAT,  whilst  at  the  same  time  providing  functional 
measurements of the vascular component in tumour voxels by MRI. This would have the 
advantage  of  simultaneously  validating  the  functional  MRI  sequences,  giving  more 
emphasis to clinical utilisation, while also allowing further development of PAT as a clinical 
tool. Experiments were planned and performed, but a sufficient number of complete data 
sets were not obtained due to difficulty in performing these large multimodal experiments. 
Even with the limited amount of data acquired, co-registration proved difficult without the 
implantation of fiducial markers within the tissue, which needs to be addressed before 
future combined studies are performed. This would then prove to be a very powerful tool 
for  assessing  vascular  targeted  therapies,  and  is  therefore  planned  for  future  work. 
However,  even  when  used  as  individual  modalities  for  assessing  vascular  function  and 
response to treatment, this work demonstrates that both PAT and MRI vascular sequences 
are highly effective, with great potential within pre-clinical tumour vascular research, and 
also for translation into clinical trials. 
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I Appendix  
I.I Cell growth kinetics 
No differences in growth kinetics were noted through cell passages. Time to confluence 
and subcultivation ratio between the transduced and non-transduced cell lines were the 
same. Results from cell countess assessment of viability can be seen in table 6.1 for the 
SW1222 cell line and table 6.2 for the LS174T. As seen in these tables the viability of cells 
for each of the two lines was above 90% at each point evaluated, with average cell size 
between 9.8µm and 13.1µm. 
 
 
 
 
   
Table I.I Viability of parental (‘Non’) and luciferase 
transduced (‘Luc’) SW1222 cells at varying passage number 
Table I.II Viability of parental (‘Non’) and luciferase 
transduced (‘Luc’) LS174T cells at varying passage number 178 
 
I.II Kinetics of luciferase activity 
Average photon radiance in vitro following addition of luciferin to the cell lines can be seen 
in Figure I.I. As representative images for all time-points within the n=3 experiments for 
both cell lines, panel A and B depict the acquired image of SW1222 cells within a petri dish 
with an overlay of photon emission data both before (A) and one minute after (B) the 
addition of luciferin.  The first image serves as a baseline with no photon radiance, whilst 
subsequent  images  clearly  show  emission  of  photons  from  the  centre  of  the  sample. 
Regions of interest were drawn around the acquired data and quantification of the average 
photon radiance performed over the 30 minute time course. Graph C shows the average of 
the three experiments performed for the SW1222 luc cell line, with error bars denoting 
standard error of the mean. A peak photon radiance of 2.5x10
7 can be observed at around 
three minutes post luciferin, after which there is a decrease in average radiance to roughly 
1.5x10
7 at 30 minutes post luciferin. The graph in section D shows results for the in vitro 
kinetics  of  luciferase  activity  in  the  LS174T  cell  line.  Average  radiance  from  the  n=3 
experiments is shown with error bars denoting standard error of the mean. A peak of 
2.5x10
7  is  seen  at  around  three  minutes  after  addition  of  luciferin  with  a  long  steady 
decrease in radiance up to the 30minute mark, where radiance has dropped to around 
1.5x10
7.Therefore results are very similar for the two colorectal cell lines. 
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Figure I.I In vitro kinetics of luciferase activity. A shows an 
example of acquired data for SW1222 cells before addition of 
luciferin, B shows the same sample after addition of luciferin. 
Graph C (SW1222) and D (LS174T) show average radiance of 
cells up to 30min post luciferin with error bars denoting 
standard error of the mean 180 
 
I.III Luciferase correlation to cell number 
Results from the experiments for correlation of photon radiance and cell number can be 
found  in  Figure  I.II.  Panel  A  is  a  photograph  of  one  of  the  96-well  plates  used, 
superimposed with the photon data acquired at one minute after luciferin addition, with 
regions of interest drawn around the triplicate cell concentrations. Both 1 and 5 minute 
acquisitions showed similar radiance. Cumulative data for the n=3 SW1222 plates can be 
seen in graph B, where a linear trend with an R
2 of 0.98 was found between decreasing cell 
concentration and average radiance. Error bars denote standard error of the mean. All 
negative controls show no emission of photons. 
For the LS174T cell line a similar pattern can be seen in graph C, where the decrease in cell 
concentration shows a linear correlation with decrease in photon average radiance. The R
2 
value for this correlation across the n=3 plates is 0.91. The trend is not as linear as with the 
SW1222 cell line in graph B, with higher concentrations between 1x10
5 and 8x10
4 showing 
variability  in  photon  radiance,  with  a  plateau  effect  observed  at  these  concentrations. 
Negative controls show no emission of photons. 
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Figure I.II In vitro correlation between cell number and luciferase 
activity. A shows an example of acquired data for SW1222 with 
ROIs drawn around all concentrations. B shows cumulative 
photon radiance data for SW1222 cells, with graph C cumulative 
data for LS174T cells. Error bars denote show standard error 
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I.IV Lower limit of luciferase detection 
Figure I.III shows results for the lower limit of detection experiment for the SW1222 cell 
line. Panel A is an example of one of the n=3 plates at 1 minute after addition of luciferin 
with overlaid photon radiance data acquired. Both the 1 and 5 minute time points showed 
similar results for cell number detection with no significant difference in average photon 
radiance. Panel B shows the average photon radiance of the n=3 experiments in triplicate 
for  a  total  of  n=9  sample  concentrations  for  the  SW1222  cell  line.  Error  bars  denote 
standard error of the mean. This bar graph shows that bioluminescence can be detected 
from  as  little  as  ≈300  cells,  with  concentrations  below  this  being  similar  to  negative 
controls. 
The data for the LS174T cell line can be seen in panel C, which again shows cumulative 
quantification data for the bioluminescent signal from the different cell concentrations. 
This shows a slightly reduced sensitivity when compared to the SW1222 cell line, with the 
highest concentration of 10,000 cells giving an average radiance of ≈7x10
5  ph/s/cm
2/st 
compared to ≈1.8 ph/s/cm
2/st for the SW1222 cell line (Panel B), however the lower limit 
of detection is still in the region of 300-600 cells. 
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Figure I.III In vitro lower limits of cell detection. A shows an 
example of acquired data for SW1222 with ROIs drawn around 
all concentrations. B shows cumulative photon radiance data 
for SW1222 cells, with graph C cumulative data for LS174T cells. 
Error bars denote show standard error  
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I.V Subcutaneous growth comparison 
Figure I.IV shows in vivo subcutaneous tumour growth data from the luciferase transduced 
cell lines. Non-transduced cell lines showed no bioluminescence activity and are therefore 
not  shown.  Panel  A  (SW1222)  and  C  (LS174T)  show  acquired  data  for  the  three  mice 
expressing the luciferase gene, with the overlay of photon data clearly showing that the 
photon expression is only observed at the site of subcutaneous tumour formation. Graphs 
B (SW1222) and C (LS174T) show the kinetics of photon average radiance following i.p. 
injection of the substrate luciferin. Both graphs show a peak bioluminescence signal at 15 
minutes post injection with a subsequent drop off in activity up to the 30 minute time 
point. 
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Figure I.IV In vivo subcutaneous average photon radiance. Panels A (SW1222) and 
C (LS174T) show examples of acquired data with ROIs drawn around areas of 
photon emission, correspondent with the site of solid tumour growth. Graphs B 
and D show average photon radiance post i.p. injection of luciferin up to 30 
minutes post dose. Error bars denote show standard error of the mean. 185 
 
Figure I.V shows the comparison between tumour progression over time as assessed by 
caliper measurement. Graph A represents the SW1222 cell line and graph B the LS174T cell 
line, with luciferase transduced cells shown in red and the non-transduced shown in blue. A 
similar rate of tumour growth is observed between transduced and non-transduced cells 
for both tumour types, with students T-Test showing no significant differences between 
groups. 
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Figure I.V In vivo growth comparison. Caliper measurements of 
subcutaneous tumour growth comparing non-transduced (blue) and 
luciferase transduced (red) SW1222 (Graph A) and LS174T (Graph B) cell lines  
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Figure I.VI compares the average photon radiance emitted by the growing tumours versus 
the volume increase over time, with tumour volume in red and bioluminescence count in 
blue. Graph A depicts SW1222 luc tumours whilst graph B depicts LS174T luc tumours. 
Bioluminescence is able, in both tumour types, to detect tumour cells at day 2 post cell 
injection. By contrast, accurate measurement by calipers is only possible 7 day later, at day 
9 post cell injection. Whilst there is a general trend between increasing tumour volume and 
increased  generation  of  photons,  there  is  no  clear  correlation  between  the  two,  with 
scatter plots of the two values showing no association. The higher number of cells present 
in  a  larger  tumour  does  relate  to  an  increased  photon  count,  but  exact  estimation  of 
tumour size based on photon radiance is not possible with the data generated. 
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Figure I.VI In vivo growth comparison vs bioluminescence. Caliper 
measurements of subcutaneous tumour growth comparing non-transduced 
(blue) and luciferase transduced (red) SW1222 (Graph A) and LS174T (Graph 
B) cell lines  